Characteristics of the P2Y 11 nucleotide receptor : ligand binding characteristics and P2Y 11-P2Y 1 receptor by Ecke, Denise
Characteristics of the P2Y11 nucleotide receptor:      
Ligand binding characteristics and P2Y11-P2Y1 receptor 
interaction 
 
Dissertation 
 
zur Erlangung des akademischen Grades 
 
doctor rerum naturalium 
  (Dr. rer. nat.), 
 
 
genehmigt durch 
die Fakultät der Naturwissenschaften 
der Otto-von-Guericke Universität Magdeburg 
 
 
 
von Apothekerin Denise Ecke 
 
 
 
 
Gutachter: 
Prof. Dr. Georg Reiser 
Prof. Dr. Karen Nieber 
 
Eingereicht am: 
06.06.07 
 
Verteidigung am: 
16.11.2007 
 
 
 
geb. am 25. September 1978 in Halle/S. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rosemarie Geide, in ewiger Erinnerung 
  
Danksagung 
 
Mein Dank gilt Herrn Prof. Dr. G. Reiser, der diese Arbeit ermöglicht hat. Durch seine stete 
Diskussionsbereitschaft, seine Anregungen und seine Unterstützung während des gesamten 
Projektes hat er den erfolgreichen Fortgang dieser Arbeit mitgestaltet. 
 
Der Platz reicht leider nicht aus, um mich angemessen bei Herrn Dr. Rainer Schäfer für seine 
Hilfsbereitschaft, seine Anregungen und sein Verständnis zu bedanken. Dennoch möchte ich 
kurz zusammenfassen, dass ich ihm für das Wissen, das er mir vermittelt hat, und dafür dass 
er immer zur Stelle war sehr dankbar bin.  
 
Herrn Dr. Theodor Hanck, Frau Dr. Fariba Sedehizadeh und Herrn Dr. Rolf Stricker bin ich 
für die Einführung in die molekularbiologische Methodik sehr dankbar. Ohne die Hilfe dieser 
drei Personen wäre ich mit Sicherheit in den ‚Startblöcken’ stecken geblieben oder auf dem 
Weg zum Abschluß dieser Arbeit gestrauchelt. Besonders dankbar bin ich auch für die 
Bereitschaft von Dr. Theodor Hanck in allen Lebenslagen als wandelndes Lexikon zur 
Verfügung zu stehen. 
 
Die Arbeit im Team mit Herrn Mohan E. Tulapurkar war sehr wertvoll für diese Arbeit. Ich 
möchte mich bei ihm zuerst für die Unterweisung im Fluoreszenz-Imaging und der 
konfokalen Mikroskopie bedanken. Weiterhin hat er mir klar gemacht, dass man mit ein 
wenig mehr Gelassenheit meistens mehr erreicht. Für seine Unterstützung und unsere gute 
Zusammenarbeit bin ich sehr dankbar. 
 
Die Versuche zu dieser Dissertation wären noch längst nicht abgeschlossen, hätte ich nicht 
auf die exzellente, technische Unterstützung von Dorothee Terhardt zurückgreifen können. 
Ich möchte mich bei ihr für ihre Aufmerksamkeit, ihr Engagement und ihre freiwillige 
Übernahme der Funktion: ‚mein zweites Gedächtnis’ bedanken. 
 
Mein Dank gilt auch allen anderen Mitarbeitern und ehemaligen Mitarbeitern unserer 
Arbeitsgruppe, insbesondere Frau A. Schneider, P. Grüneberg, Frau K. Christoph und E. 
Busse für ihre technische Unterstützung. Dankbar bin ich auch für die gute Atmosphäre im 
Labor, die vor allem durch Sabine Hein, Dr. Stefan Kahlert, Dr. Gregor Zündorf, Dr. Mikhail 
Strokin, und Claudia Borrmann aufrecht erhalten wurde. Weibo Luo bin ich für seine 
Kooperationsbereitschaft dankbar. Für die Unterstützung in allen organisatorischen 
Angelegenheiten möchte ich mich bei Frau I. Klaes und Frau M. Dullin-Viehweg bedanken. 
Letzteren bin ich weiterhin dankbar, dass sie mich beim Bowling immer haben gewinnen 
lassen. Bei Herrn Peter Ehrbarth bedanke ich mich für die prompte Reparatur von etwaigen 
technischen Geräten und abstürzenden Computern. Mein herzlicher Dank gilt auch den 
Leuten vom Mobitz-Stammtisch: Dr. U. Schröder, Dr. T. Hecht, Dr. E. Wilhelmi, J. Ullrich, 
D. Albrecht und Dr. C. Sabelhaus für die interessanten Debatten über reale Forschung.  
 
Nicht zuletzt möchte ich mich bei meinen Eltern für ihr grenzenloses Verständnis und die 
Unterstützung während der gesamten Zeit der Promotion bedanken. Sie haben mir immer 
wieder Mut gemacht, wenn ich am Abschluß dieser Arbeit gezweifelt habe. Das gleiche gilt 
auch für Tanuja Rohatgi. Ich bin ihr dankbar, dass sie all meine Launen ertragen hat und 
trotzdem immer noch zu mir hält. 
 
  I
Table of content 
1 Introduction 1 
1.1 Receptor theory .........................................................................................................1 
1.2 Purinergic Signaling ..................................................................................................3 
1.3 Purinergic Receptor Family ......................................................................................3 
1.3.1 General properties of P2Y receptors 4 
1.3.2 Pharmacological characteristics of the P2Y1 and P2Y11 receptor 7 
1.3.3 Physiological roles of the P2Y11 receptor 9 
1.3.4 Ligand recognition at the P2Y receptor 11 
1.4 Oligomerization of GPCRs......................................................................................14 
1.5 Aims of the thesis project ........................................................................................17 
2 Materials and Methods 20 
2.1 Materials ..................................................................................................................20 
2.1.1 Cell lines 20 
2.1.2 Bacterial strains 20 
2.1.3 Plasmid vectors 20 
2.1.4 Enzymes 21 
2.1.5 Kits 21 
2.1.6 Laboratory instruments 22 
2.1.7 Chemicals and reagents 23 
2.1.8 Antibodies 24 
2.1.9 Molecular mass markers 24 
2.1.10 Buffers and solvents 24 
2.1.11 Oligonucleotides 27 
2.2 Methods....................................................................................................................30 
2.2.1 Methods in molecular biology 30 
2.2.2 Methods in Cell Biology 40 
2.2.3 Methods in Protein chemistry 43 
2.2.4 [Ca2+]i measurements 46 
2.2.5 Confocal imaging 47 
2.2.6 Flow cytometry 48 
2.2.7 Data analysis 48 
  II
3 Results 49 
3.1 Diastereoselectivity of the P2Y11 receptor: Pα substituted ATP analogues ...........49 
3.1.1 Heterologous expression of the P2Y11GFP receptor in 1321N1 cells 49 
3.1.2 Calcium measurements with pairs of different ATP diastereoisomers 50 
3.1.3 Adenosine-5’-O-(α-thiotriphosphate) diastereoisomers 54 
3.2 Ligand recognition at the P2Y11 receptor...............................................................57 
3.2.1 Selection of residues putatively involved in ligand recognition 57 
3.2.2 Introduction of point mutations into the P2Y11 receptor DNA sequence 58 
3.2.3 Expression of P2Y11 receptor mutants in 1321N1 cells 59 
3.2.4 Pharmacological characterisation of the P2Y11 receptor mutants 59 
3.3 Hetero-oligomerization of the P2Y1 and the P2Y11 receptor..................................66 
3.3.1 Agonist-induced internalization of the P2Y11GFP receptor in HEK293 cells 66 
3.3.2 Co-Internalization of the P2Y1 and P2Y11GFP receptor in HEK293 cells 69 
3.3.3 Co-internalization of the P2Y1 and P2Y11 receptor in 1321N1 cells 72 
3.3.4 Co-Pulldown Experiments 78 
3.3.5 Co-immunoprecipitation of P2Y1mycHis and P2Y11GST receptors 81 
3.3.6 Pharmacological characteristics of the receptor heterooligomer 83 
4 Discussion 87 
4.1 Diastereoselective activation is opposite for the P2Y1 receptor and the P2Y11 
receptor ....................................................................................................................87 
4.2 Ligand binding site characteristics of the P2Y11 receptor deduced from 
mutational analysis ..................................................................................................90 
4.3 Crosstalk between two P2Y receptors: the P2Y1 and P2Y11 receptor ...................95 
5 Zusammenfassung 102 
6 Abstract 105 
7 References 107 
8 Abbreviations 114 
 
 
 
 
 
 
  III
Table of Figures 
 
Figure 1: Principles of linkage models in receptor theory (Rang et al., 2003; Colquhoun, 2006).................................. 1 
Figure 2: Recent developments in receptor theory (Kenakin and Onaran, 2002; Kenakin, 2004) ................................. 2 
Figure 3: Structure of a Class A GPCR ..................................................................................................................... 5 
Figure 4: (A) Multiple Sequence alignment (Clustal X 1.83) and (B) key residues of the human P2Y1 receptor 
involved in ligand recognition, adapted from (Ivanov et al., 2006)............................................................. 13 
Figure 5: Schematic representation of mechanisms potentially involved in GPCR oligomer formation adapted from 
(Kroeger et al., 2003)............................................................................................................................... 17 
Figure 6: Non-functional expression of P2X and P2Y receptors in wild type 1321N1 cells ....................................... 49 
Figure 7: Western blot detection of the P2Y11GFP receptor in stably transfected 1321N1 cells ................................. 50 
Figure 8: Concentration-response curves for ATP-α-B analogues and parent compounds at the P2Y11 receptor......... 52 
Figure 9: Concentration-response curves for 2-Cl-ATP-α-B analogues at the P2Y1 receptor..................................... 53 
Figure 10: Concentration-response curves for ATP-α-S analogues and parent compounds at the P2Y11 receptor ......... 55 
Figure 11: Docked ATP and interacting residues in a molecular model of the P2Y11 receptor ..................................... 57 
Figure 12: Introduction of mutations into the DNA-Sequence of the P2Y11 receptor................................................... 58 
Figure 13: Concentration-response curves for ATPγS at the wild type and mutant P2Y11GFP receptor stably expressed 
in 1321N1 cells ....................................................................................................................................... 61 
Figure 14: Concentration-response curves for ATP at the wild type and mutant P2Y11GFP receptor stably expressed in 
1321N1 cells ........................................................................................................................................... 62 
Figure 15: Concentration-response curves for ATP-α-S (A) and (B) isomers at the wild type and mutant P2Y11GFP 
receptors stably expressed in 1321N1 cells ............................................................................................... 64 
Figure 16: Section of the molecular model of the P2Y11 receptor displaying a hydrophobic pocket ............................. 66 
Figure 17: Live imaging of agonist-induced internalization of the P2Y11GFP receptor stably expressed in HEK293 cells
............................................................................................................................................................... 67 
Figure 18: Intracellular calcium rise in stably transfected HEK293 cells .................................................................... 68 
Figure 19: Expression levels of mRNA of different GPCRs in HEK293 cells............................................................. 69 
Figure 20: Intracellular calcium rise in HEKP2Y11GFP cells ..................................................................................... 70 
Figure 21: GPCR crosstalk in agonist-induced P2Y11GFP receptor endocytosis ......................................................... 71 
Figure 22: Agonist-induced internalization of the P2Y1GFP and P2Y11GFP receptor in 1321N1 cells......................... 72 
Figure 23: Co-internalization of the P2Y1mycHis and P2Y11GFP receptor in 1321N1 cells ........................................ 73 
Figure 24: Live-imaging of the A268P2Y11GFP receptor in HEK293 cells ................................................................... 75 
Figure 25: Expression level of P2Y1 receptor mRNA in HEKP2Y11GFP cells after siRNA treatment.......................... 76 
Figure 26: Treatment with P2Y1-R siRNA reduces internalization of the P2Y11GFP receptor in HEK293 cells ........... 76 
Figure 27: Fluorescence intensities of the P2Y11GFP receptor in cytosol of siRNA transfected HEK293 cells upon 
agonist stimulation .................................................................................................................................. 77 
Figure 28: Co-pulldown of the P2Y1mycHis and P2Y11GST receptor from HEK 293 cells ......................................... 80 
Figure 29: Co-Pulldown of the P2Y1mycHis and A268P2Y11 receptor from HEK 293 cells .......................................... 81 
Figure 30: Co-Immunoprecipitation (IP) of the P2Y1mycHis and P2Y11GST receptors from HEK293 cells ................ 82 
Figure 31: Peak values of intracellular calcium rise induced by P2Y receptor stimulation........................................... 84 
Figure 32: Peak values of intracellular calcium rise induced by UDP in HEK293 cells ............................................... 85 
Figure 33: Stimulation of cAMP accumulation in HEKP2Y11GFP cells ..................................................................... 86 
Introduction 
 1
1 INTRODUCTION 
1.1 Receptor theory 
The word ‘receptor’ originates from the Latin word ‘recipere’ – to accept, receive. Thus, in 
biochemistry a receptor is known to be a protein that accepts or receives signals (ligands, 
drugs), which then initiate a cellular response. The first step in the generation of such a signal-
transduction cascade is the formation of a reversible drug-receptor complex (Paul Ehrlich: 
‘Corpora non agunt nisi fixata’ ~ ‘A drug will not work unless it is bound’), where the 
reactions are governed by the Law of Mass Action (Rang et al., 2003). In terms of the 
occupation theory (linkage model), a linear relationship between receptor occupancy and 
cellular response was assumed because the roughly hyperbolic shape of the dose-response 
curves in pharmacological measurements seemed to reflect ‘Langmuirean binding’ (Fig. 1). 
However, there is not necessarily a linear relationship between the proportion of occupied 
receptors and the response which makes the use of the dose-response curves for determination 
of agonist affinity at a receptor impossible.  
 
A + R
k+1
k
-1
AR
agonist receptor complex
[AR]
Rt
=
[A]
[A] + kA
[1]
[2]
 
Figure 1: Principles of linkage models in receptor theory (Rang et al., 2003; Colquhoun, 2006) 
[1] Schematic representation of the reaction of agonist (A) and receptor (R) in drug-receptor complex (AR) 
formation with a specific association (k+1) and dissociation (k-1) rate constant. Applying the Law of Mass 
Action to this reaction results in equation [2] which is known as the Hill-Langmuir equation. The proportion 
of receptors occupied (AR) is dependent on the total receptor density (Rt), agonist concentration (A) and the 
equilibrium constant (kA). The equilibrium constant (kA) is a characteristic of the agonist and the receptor. 
This knowledge revealed the limitation of defining receptors simply by the order of agonist 
occupancy in a single tissue (Limbird, 2004). In the operational model, more emphasis was 
put on the characteristics of the tissue (e.g. nature of the coupling between the receptor and 
response), as well as of the agonist itself, and the concept of intrinsic efficacy was more 
closely related to experimentally observed behavior of pharmacological systems by the 
transducer function (Kenakin, 2004). Thus, this model was able to explain how differences in 
the transducer function and receptor density in different tissues can result in the same agonist, 
acting on the same receptor, appearing as a full agonist in one tissue, and as a partial agonist 
in another one (Rang et al., 2003). 
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The discovery of constitutively active G protein-coupled receptors (GPCR) and inverse 
agonism has led to a renaissance in receptor theory and already existing models had to be 
extended to describe this new receptor behaviour (Kenakin, 2004). The extended ternary 
complex model describes the coupling of a receptor to an agonist and/or a trimeric G protein 
with selective affinities of agonist/ antagonists for the active (Ra) or inactive receptor (Ri) 
(Fig. 2, [1]). This allowed for the theoretical characterization of an inverse agonist. Such an 
agent stabilizes the inactive form of the receptor thereby reducing its ‘basal’ or constitutive 
activity, whereas a full agonist has a high preference for the activated state of the receptor. 
Moreover, an antagonist shows no preference and binds to both states of a receptor, thereby 
not changing the existing equilibrium between both states and not eliciting an observable 
cellular response (Limbird, 2004).  
However, the shortcoming of all linkage models is that they must pre-define the species 
present in a thermodynamic space. If there are more species than defined, these models fail. 
The probabilistic model of GPCRs assumes that a receptor possesses a particular distribution 
between different conformations in a resting state (Fig. 2, [2]). The binding of a ligand and/ or 
G protein changes this distribution by stabilizing specific conformations. Thus, agonists are 
ligands that shift the distribution of conformations towards those that activate G proteins. 
After all, GPCRs are now seen as interactive information processing units other than switches 
for G proteins (Kenakin, 2004).  
[1] [2]
 
Figure 2: Recent developments in receptor theory (Kenakin and Onaran, 2002; Kenakin, 2004) 
[1] The extended ternary complex model describes the coexistence of inactive (Ri) and active (Ra) receptor 
states according to the constant L. G proteins (G) that enter the system can bind to Ra in or without the 
presence of an agonist (A). The ligand can bind to both receptor states. Constitutive activity is the 
spontaneous formation of RaG complexes. Affinity of ligands is described by Ka and efficacy by the two 
terms α and γ. [2] Example of the distribution of different receptor conformations in the probabilistic model 
of GPCRs. The ‘reference’ ensemble represents the collection of receptor conformations in the resting state. 
The intersection between the ‘reference’ and ‘G protein coupling’ ensembles indicates constitutive activity. 
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1.2 Purinergic Signaling 
The term ‘purinergic’ was coined by Geoffrey Burnstock, who first introduced ATP as a 
signaling molecule to the scientific world (Burnstock, 1971). Since then ATP was already 
known to be involved in many biochemical processes, but the idea of such an universal 
molecule also acting as a signal transmitter was not well accepted in the beginning. 
Subsequently, as the existence of purinergic receptors became obvious, also sceptics became 
convinced (Burnstock, 1976). The idea evolved that two types of purinergic receptors can be 
distinguished, and they were recognized as P1 (adenosine/ nucleoside) and P2 (nucleotide) 
receptors. Simultaneously, the presence of ectoenzymes that metabolize ATP or ADP to 
produce AMP or adenosine were discovered (Cooper et al., 1979) and two different 
ectonucleotidases and a nucleoside diphosphate kinase were characterized (Pearson et al., 
1980). This made the purinergic signaling system complete.  
1.3 Purinergic Receptor Family 
The purinergic receptor family consists of two different subgroups, the P1 and P2 receptors. 
P1/adenosine receptors (Table 1, next page) have four known members (A1, A2A, A2B, A3) 
that have been cloned from a variety of species. The natural agonist is adenosine. 
Nonselective antagonists (but not universal) at the P1 receptors are xanthines and xanthine 
derivatives (e.g. caffeine, theophylline). Selective antagonists of the A2A receptor are 
currently under investigation as novel Anti-Parkinson-Therapeutics (Jenner, 2005) due to an 
observed reduced affinity of agonists binding to D2 dopamine receptors upon stimulation of 
A2A receptors (Ferre et al., 1997). P1 and P2 receptors are found to be opponents under many 
physiological or pathophysiological conditions, as they crossregulate their mutual function 
due to the degradation of ATP to adenosine by ectoenzymes or the phosphorylation of 
adenosine by ectokinases.  
In 1985 the existence of two P2 receptor types was proposed (P2X and P2Y) (Burnstock 
and Kennedy, 1985) and to date seven P2X subtypes and eight P2Y receptor subtypes have 
been discovered (Ralevic and Burnstock, 1998). The P2X receptors are ligand-gated ion 
channels that, like other ion channels, are oligomeric proteins consisting of several subunits 
(Khakh et al., 2001). However, they are ion channels whose molecular architecture is different 
from any other ion channel family (Khakh and North, 2006). They have two membrane-
spanning domains and most of the protein is located extracellularly. All P2X receptors are 
cation-selective with almost equal permeability for Na+ and K+ and a significant permeability 
for Ca2+ (Evans et al., 1996). 
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The receptors can exist either as homomeric or heteromeric proteins. So far eleven P2X 
subunit combinations are known. ATP is the natural ligand at all seven homomeric P2X 
receptor subtypes. Moreover, nearly all P2X receptors respond more or less to BzATP, except 
the P2X6 receptor (Burnstock and Knight, 2004). Antagonists at the P2X receptor include the 
universal P2 receptor antagonists suramin and PPADS and the more selective antagonist 
TNP-ATP (Gever et al., 2006). 
P2X receptor subunits are widely expressed in the nervous system, and at some central 
synapses ATP is a fast neurotransmitter eliciting small synaptic currents (Khakh and North, 
2006). Moreover, there is evidence that ATP is involved in the chronic nociceptive behavior 
following nerve injury or inflammation acting through P2X3 receptors (Burnstock, 2006). 
1.3.1 General properties of P2Y receptors 
The P2Y receptors are G protein-coupled receptors. They belong to the rhodopsin family of G 
protein-coupled receptors also called Class A GPCRs with seven predicted transmembrane 
(TM) domains. The N-terminus locates on the extracellular side and the C-terminus on the 
cytoplasmic side of the plasma membrane (Fig. 3). The TMs and extracellular loops are 
believed to form the ligand-binding pocket and the intracellular loops interact with the 
appropriate G protein to activate subsequent transduction mechanisms (Ralevic and 
Burnstock, 1998). 
Table 1: P1 receptor effects and ligands adapted from Ralevic et.al. 1998 
P1 receptor 
subtypes 
G protein 
coupling effects Selective Agonists Selective Antagonists 
A1 
Gi/o 
cAMP↓; IP3↑ 
N6-cyclopentyladenosine 
(CPA) 
1,3-dipropyl-8-
cyclopentylxanthine 
(DPCPX) 
A2A 
Gs 
cAMP↑ 
2-[p-(2-carbonyl-ethyl)-
phenylethylamino]-5’-N-
ethylcarboximidoadenosine 
(CGS21680) 
1,3-dipropyl-8-(3,4-
dimethoxystyryl)-7-
methylxanthine     
(KF17837) 
A2B 
Gs, Gq 
cAMP↑; IP3↑ 
- - 
A3 
Gi, Gq 
cAMP↓; IP3↑ 
N6-(3-iodo-benzyl)-5’-(N-
methylcarbamoyl)adenosine 
(IB-MECA) 
3,6-dichloro-2’-
isopropyloxy-4’-
isopropylflavone  
(MRS1067) 
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Figure 3: Structure of a Class A GPCR 
As all other GPCRs, P2Y receptors are constituted by a single polypeptide chain, which crosses the cell 
membrane seven times, forming seven TMs (α-helical structure) connected by three extracellular and three 
intracellular loops. The amino terminal region is located outside the cell, while the carboxyl terminal region 
is located in the cytoplasm where the G proteins are activated. 
To date eight different P2Y receptors have been cloned and are divided into two 
phylogenetically different subgroups. The P2Y1, 2, 4, 6, 11 receptors belong to the group that 
preferentially couples to Gq proteins, and the P2Y12, 13, 14 receptors form the second group that 
couples to Gi proteins (Costanzi et al., 2004). Of the first group, the P2Y11 receptor also 
couples to Gs proteins and is less closely related to the other group members.  
The natural ligands of P2Y receptors can be either adenine or uridine nucleotides. In both 
P2Y receptor subgroups adenine nucleotide preferring receptors (P2Y1, 11, 12, 13) as well as 
uridine nucleotide preferring receptors (P2Y4, 6) can be found. The P2Y2 receptor is equally 
activated by UTP or ATP. A summary of the principal agonists and antagonists at the 
different P2Y receptor subtypes can be found in Table 2. 
The expression of the P2Y receptors in several tissues brings along many physiological 
roles of these receptors. The P2Y1 receptor is probably the most extensively studied subtype. 
It has a conserved macroscopic localization in the mammalian brain (Moore et al., 2000) and 
can function as a presynaptic inhibitor of glutamate release (Rodrigues et al., 2005). The most 
established function of the P2Y1 receptor is its role in the platelet physiology next to the 
P2Y12 receptor. The selective activation of the P2Y1 receptor on platelets leads to cytosolic 
Ca2+ mobilization and shape change, followed by a rapidly reversible aggregation of the 
platelets. However, activation of the P2Y12 receptor mediates sustained platelet aggregation in 
the absence of shape change (Oury et al., 2006). 
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Moreover, the P2Y1 receptor also functions as an activator of bone resorption, regulator 
of the vascular tone in the placenta and together with the P2Y2 receptor as a postsynaptic gene 
activator in neuromuscular junctions (Tsim and Barnard, 2002; Gallagher, 2004; Buvinic et 
al., 2006). Agonists at the P2Y2 receptor, furthermore, are targets of clinical research on 
cystic fibrosis (CF). It is known that activation of the P2Y2 receptor partially compensates the 
impaired chloride secretion in CF patients and that genetic variants of the P2Y2 receptor 
contribute to phenotypic differences in the disease state of the patients (Buscher et al., 2006).  
Table 2: Human P2Y receptors: activities of agonists and affinities of antagonists                                   
(a selective agonist/antagonist) at the different receptor subtypes and their distribution in tissues 
summarized from (Burnstock and Knight, 2004; von Kugelgen, 2006) 
Receptor 
subtype 
Major tissue 
distribution Agonists Antagonists 
P2Y1 
wide including platelets, 
heart, skeletal muscle, 
neuronal tissues, 
digestive tract 
MRS2365a > 2-MeS-ADP > 
ADP = ADPβS = ATPβS >> 
ATP 
MRS2179, MRS2500a, 
Suramin, 
Reactive Blue 2 
P2Y2 
wide including lung, 
heart, skeletal muscle, 
spleen, kidney 
UTP = ATP = UTPγS > 
INS37217 > Ap4A > ATPγS 
Reactive Blue 2, 
Suramin 
P2Y4 
placenta, lung, vascular 
smooth muscle, brain, 
liver 
UTP PPADS, Reactive Blue 2 
P2Y6 
wide including lung 
heart, aorta, spleen, 
placenta, thymus, 
intestine, brain 
UDP = UDPβS = 5-Br-UDP > 
2-MeS-ADP > UTP 
MRS2567a, Reactive 
Blue2, PPADS 
P2Y11 
spleen, intestine, 
immune system, brain, 
pituitary 
ARC67085 = ATPγS = BzATP 
> dATP > ATP > 2-MeS-ATP 
NF157, Suramin, 
Reactive Blue 2 
P2Y12 platelets, neural tissue 2-MeS-ADP > ADP = ATPβS > 2-MeS-ATP 
Clopidogrela, 
ARC69931MX, 
Suramin, Reactive 
Blue 2 
P2Y13 
spleen, leucocytes, bone 
marrow, liver, brain 
2-MeS-ADP > ADP = 
2-MeS-ATP > ADPβS 
ARC69931MX, 
Reactive Blue 2, 
Suramin, PPADS 
P2Y14 
placenta, adipose tissue, 
spleen, intestine, brain UDP-glucose > UDP-galactose - 
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Likewise, activation of the P2Y4 receptor can also influence epithelial ion transport. In 
mice jejunum and colon, P2Y4 receptor activation induces epithelial chloride transport and K+ 
secretion, respectively (Robaye et al., 2003; Matos et al., 2005). The other pyrimidine-
selective receptor P2Y6 seems to play a role in bone resorption by enhancing osteoclast 
survival (Korcok et al., 2005).  
The phylogenetic subgroup of P2Y receptors that comprises the receptors coupled to Gi 
proteins has physiological functions in the human blood system. As already mentioned, the 
P2Y12 receptor is important for platelet aggregation and thus thrombus formation. Moreover, 
recently the P2Y12 receptor was shown to have a role in microglial activation at early stages 
after injury which suggests a physiological benefit in neuronal injury and disease if the 
receptor function is modulated by specific antagonists. The other ADP-preferring receptor of 
this subgroup is the P2Y13 receptor, which was found to activate a negative feedback pathway 
for ATP release in red blood cells (RBCs). RBCs release ATP in response to reduction in 
oxygen tension and pH. The released ATP then acts on P2Y receptors expressed by 
endothelial cells of the vessels and leads to vasodilatation. Right after hydrolysis to ADP 
further release of ATP is attenuated by activation of the P2Y13 receptor. Thus, the P2Y13 
receptor acts as a regulator of ATP-induced vascular tone adaptation (Wang et al., 2005).  
Moreover, the P2Y14 receptor is associated to haematopoietic stem cells, where it plays a 
direct role in stem cell phenotype and localization to the bone marrow compartment. Stem 
cells expressing the receptor are capable of undergoing multilineage differentiation (Lee et al., 
2003). 
1.3.2 Pharmacological characteristics of the P2Y1 and P2Y11 receptor 
Among the P2Y receptors, the P2Y1 and P2Y11 receptor are found to be closest homologues, 
sharing 33% identical amino acids (Communi et al., 1997). However, both receptors display 
differences in their pharmacological properties despite of being exclusively activated by 
adenine nucleotides. The most striking difference is the preference of the human P2Y1 
receptor for adenosine diphosphates over triphosphates, which is opposite at the human P2Y11 
receptor. Moreover, the P2Y1 receptor is characterized by the high potency of 2-MeS-ADP or 
2-MeS-ATP (Palmer et al., 1998), whereas at the P2Y11 receptor these agonists are only 
weakly potent (Communi et al., 1997).  
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Further changes of the phosphate chain and the ribose moiety increase the potency of the 
2-alkylthio-ATP derivatives for the P2Y11 receptor, as was observed for ARC-67085MX (2-
propylthio-beta,gamma-dichloromethylene-d-ATP) (Communi et al., 1999; Wilkin et al., 
2001; White et al., 2003). Furthermore, modified ribose as in d-ATP and BzATP results in 
potent ligands at the P2Y11 receptor (Burnstock and Knight, 2004), whereas at the P2Y1 
receptor BzATP shows antagonistic activity (Vigne et al., 1999). A selective agonist for the 
P2Y1 receptor is MRS2365 ((N)-methanocarba-2MeSADP), in which a pseudo-ribose, 
consisting of a bicyclic structure fused into the (N)-methanocarba modification, replaces the 
ribose moiety (Chhatriwala et al., 2004). The constrained northern conformation of the 
pseudo-ribose leads to increased potency at the P2Y1 receptor in general and to a preserved 
potency at the P2Y11 receptor, whereas the corresponding (S) isomers display greatly reduced 
potency at both receptors (Kim et al., 2002). 
Adenosine phosphorothioates (ATP-β-S, ATP-γ-S) are able to activate both receptors, 
with the P2Y11 receptor preferring the γ- and the P2Y1 receptor the β-phosphorothioates as 
ligands. The action of adenosine 5’-O-(1-thiotriphosphate) (ATP-α-S) was more closely 
investigated. Through substitution of one of the non-bridging oxygen atoms of Pα by sulfur a 
new chiral center in the ATP molecule is introduced. The resulting diastereoisomers were 
separated, and these ATP-α-S diastereoisomers were shown to display a diastereoselective 
activity at the P2Y1 receptor (Major et al., 2004). The recently synthesized chiral ATP-α-B 
analogues, where a borano group (BH3) substitutes a non-bridging oxygen at Pα, proved 
agonists at the P2Y1 receptor, As with the ATP-α-S isomers, one chiral isomer was clearly 
preferred at this receptor (Nahum et al., 2002).  
If receptor antagonists are considered, both the P2Y1 and P2Y11 receptors show an 
affinity for the broad-spectrum P2Y receptor antagonists Suramin and Reactive Blue 2 
(Burnstock and Knight, 2004). The recently developed P2Y11 receptor antagonist NF157 
represents a Suramin derivative and clearly prefers the P2Y11 over the P2Y1 receptor but is 
still non-selective (Ullmann et al., 2005). In contrast, there are already selective antagonists 
available for the P2Y1 receptor. MRS2500 has a nucleotide-like structure and also contains a 
pseudoribose locked in a northern conformation as described above for the selective P2Y1 
receptor agonist (Hechler et al., 2006). 
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The different pharmacology of the P2Y1 and P2Y11 receptors is important to consider if 
cells or tissues are investigated where both receptors are co-expressed. Here selective 
activation of one of the receptors can be important for interfering with pathophysiological 
conditions. Both receptors are present in large quantities in the human central nervous system. 
Co-expression is found in basal ganglia, hippocampus and the cerebellum (Moore et al., 
2001). Moreover, the P2Y1 and P2Y11 receptors are also found in vascular smooth muscle 
cells and seem to mediate smooth muscle relaxation in the gastrointestinal tract. In immune 
cells, both receptors are expressed in macrophages, eosinophils and lymphocytes (Abbracchio 
et al., 2006). So far no clear cross-talk or cross-regulation between both receptors has been 
observed in such tissues. However, dendritic cells express the P2Y1 as well as the P2Y11 
receptor (Berchtold et al., 1999). The function of the latter has already been studied (see 
below), whereas no specific function has been ascribed to the P2Y1 receptor in dendritic cells. 
However, a previously uncharacterized ADP receptor seems to be involved in ERK activation 
and calcium mobilization leading to inhibition of cytokine production in these cells (Marteau 
et al., 2004). It can be hypothesized that this uncharacterized receptor represents a crosstalk 
between the P2Y1 and P2Y11 receptor that shows a combination of both receptor 
pharmacologies. Moreover, the P2Y1 receptor was found to mediate the purinergic inhibitory 
neuromuscular transmission in the human colon (Gallego et al., 2006). However, the specific 
P2Y1 receptor antagonist MRS2179 was not able to completely block the actions of ADPβS, 
suggesting the involvement of another P2Y receptor which is thought to be the P2Y11 receptor 
(Abbracchio et al., 2006). In addition, the P2Y1 and P2Y11 receptors are thought to play a role 
in the marked proliferation of mesangial cells in renal diseases but again a cross-talk was not 
confirmed (Vonend et al., 2003). 
1.3.3 Physiological roles of the P2Y11 receptor 
The P2Y11 receptor is known to couple to two different G proteins (Gs and Gq), which allows 
for induction of intracellular calcium rise as well as stimulation of cAMP production after 
receptor activation. Moreover, the P2Y11 receptor can also induce the production of the 
signaling molecule cyclic adenosine diphosphate ribose (cADPR) via PKA and subsequent 
ADP-ribosylcyclase (ADPRC) activation leading to a sustained Ca2+ increase (Moreschi et al., 
2006).  
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A major role of the P2Y11 receptor in physiology is thought to be a control of the cellular 
immune system. Above all, its presence in several different dendritic cell (DC) types implies a 
function of the receptor in shaping an immune response. Activation of the P2Y11 receptor in 
monocyte- and dermal-derived dendritic cells inhibits their migration. As the receptor is 
stimulated only at rather high ATP concentrations, the DCs are trapped at the epicenter of 
inflammation where due to the accumulation of ATP its concentration reaches high values. 
Here, DCs can internalize antigens and are exposed to maturation-inducing factors for 
prolonged time periods (Schnurr et al., 2003). Moreover, exposure of monocyte-derived DCs 
to ATPγS and ADPβS inhibits the release of major monocyte-recruiting chemokines. At the 
site of inflammation, released nucleotides might regulate the activation of monocytes as well 
as the arrival of other immature DCs (Horckmans et al., 2006).  
Langerhans cells, which are immature DCs of the skin, show an enhanced ability to 
present antigen upon treatment with ATPγS, which is one of the most potent agonists at the 
P2Y11 receptor (Table 2). These immunostimulatory properties of ATP derivatives could be 
used for an adjuvant activity to enhance the efficacy of vaccines (Granstein et al., 2005). 
Furthermore, agonists of the P2Y11 receptor also influence the maturation state of monocyte 
derived DCs. The ATP-induced maturation of DCs represents an alternative state that rather 
leads to reduced inflammation and control of the immune response. Therefore, the P2Y11 
receptor is a preferential target to pharmacologically manipulate the immune tolerance at the 
DC level (Marteau et al., 2005). Additionally, in lymphocytes the P2Y11 receptor is also 
known to influence maturation by elevating cAMP levels, thereby controlling the immune 
response at the level of lymphocyte proliferation or apoptosis (Conigrave et al., 2001). In 
contrast, in human granulocytes the P2Y11 receptor was found to be involved in pro-
inflammatory processes. The discovery of β-NAD+e being an agonist at the P2Y11 receptor 
revealed the participation of the receptor in the cADPR/Ca2+ signaling system, which is 
causally related to enhanced chemotaxis of granulocytes at sites of inflammation (Moreschi et 
al., 2006). 
The P2Y11 receptor also seems to be involved in mast cell physiology. Known agonists of 
the P2Y11 receptor increase cAMP levels in human mast cells, thereby initiating cAMP-
dependent inhibitory signaling pathways. In the past, the function of mast cells has been 
understood only partially. Mast cells were thought to play a role in allergic inflammatory 
diseases only, but emerging evidence supports an additional role in myocardial ischemia. 
After cardiovascular events the plasma levels of tryptase and histamine are elevated, which 
are released by activated mast cells (Feng et al., 2004).  
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Selective P2Y11 receptor agonists could be used to interfere with the activation of mast 
cells in cardiovascular diseases. Moreover, such agonists could also be useful in the treatment 
of heart failure. Mouse cardiomyocytes were found to show a significant inotropic response to 
ATP and derivatives via P2Y11-like receptors. Unfortunately, the involvement of the P2Y11 
receptor could not be directly confirmed as the gene has not yet been cloned in mouse or rat 
(Balogh et al., 2005). However, a common dimorphism in the human gene of the receptor 
(Ala-87-Thr) has been associated with acute myocardial infarction probably by stimulating 
inflammation, underlining the role of the P2Y11 receptor as a promising drug target in the 
prevention of cardiovascular disease (Amisten et al., 2007). 
In fat tissue the function of a P2Y11-like receptor was found especially in white 
adipocytes of the rat. Here, stimulation of the receptor increases lipolysis and decreases leptin 
production via protein kinase A signaling pathways. This suggests selective P2Y11 receptor 
agonists for a new antiobesity strategy (Lee et al., 2005). 
1.3.4 Ligand recognition at the P2Y receptor 
All class A GPCRs for small molecule agonists are activated by binding of the agonist to a 
binding pocket located deep inside the upper part of the 7TM domain of the receptor molecule 
(Kristiansen, 2004). The actual knowledge about ligand recognition at P2Y receptors suggests 
that the key structure responsible for binding and activation of the receptors is the phosphate 
moiety of the nucleotides. The negatively charged phosphate chain is likely coordinated to 
basic amino acids in TM3, 6 and 7 (Jacobson et al., 2004). The first evidence supporting this 
suggestion was highlighted in a study focussing at the P2Y2 receptor. Neutralization of three 
positively charged amino acids in TM6 and 7 (His6.52, Arg6.55, Arg7.39, highlighted in Fig. 
4A) by substitution with leucine in each case caused a marked decrease in potency of ATP 
and UTP at the receptor (Erb et al., 1995).  
Later studies focusing on the P2Y1 receptor also showed the importance of basic residues 
in TM3, 6 and 7 (Arg3.29, Lys6.55, Arg7.39, highlighted in Fig. 4A+B) for receptor activity 
(Jiang et al., 1997; Moro et al., 1998). Moreover, docking of UDP in a molecular model of the 
P2Y6 receptor revealed the binding of the phosphate moiety to the same positively charged 
subpocket formed by the three cationic amino acids (Fig. 4A) (Costanzi et al., 2005). 
Interestingly, adenosine receptors seem to lack basic residues at these positions supporting 
their function in binding of the phosphate chain. 
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Interaction of the adenine/ uracil moiety with the P2Y receptors in agonist recognition has 
been explored by means of molecular modelling. Hydrogen bonds between the nitrogen atoms 
of the base and residues in TM7 (Fig. 4A) have been predicted. For the P2Y1 receptor Ser314 
(7.43) was found to donate a hydrogen bond to the N1 position of adenine (Jiang et al., 1997). 
This serine residue was highly conserved among the Gq coupled P2Y receptors except for the 
P2Y11 receptor, that displayed a proline residue at this position. The amino acid at position 
7.36 is also important for the stabilization of the base. For both adenine nucleotide preferring 
P2Y receptors of the first subgroup (P2Y1-R and P2Y11-R) a glutamine is present at this 
position, which can interact with the N6 position of adenine by accepting a hydrogen bond. 
The P2Y2, P2Y4 and P2Y6 receptors all display a lysine at position 7.36 that interacts with the 
uracil ring (Fig. 4A) (Costanzi et al., 2004). Moreover, the base moiety also seems to be 
coordinated by interaction with hydrophobic amino acids (Fig. 4A). In the P2Y1 and P2Y6 
receptor the conserved phenylalanine at position 3.32 was found to be in proximity to the 
adenine/ uracil ring and mutation of this Phe131 in the P2Y1 receptor caused a substantial loss 
in the potency of agonists (Jiang et al., 1997; Costanzi et al., 2005). 
All of the aforementioned studies did not detect any specific interactions of the P2Y 
receptors with the ribose ring. However, structure-activity analyses of ribose-modified 
nucleotide derivatives revealed the importance of the 2’-OH group for the potency of 
nucleotides at the P2Y2, P2Y4 and most critically at the P2Y6 receptor (Besada et al., 2006; 
Jacobson et al., 2006). Interestingly, at the P2Y11 receptor, 2’deoxy-ATP was found to be 
more potent than the natural agonist (Communi et al., 1999). Moreover, P2Y receptors 
belonging to the first subgroup except the P2Y6 receptor have been shown to prefer 
nucleotides with a pseudoribose locked in a Northern (N, 2’-exo) conformation (Ravi et al., 
2002). This indicates the adoption of a specific conformation of the ribose upon binding of the 
nucleotide to the receptor. 
In contrast to the principal binding side, coordination of the ribose moiety by specific 
residues seems to be present in the meta-binding sites of the P2Y1 receptor. Meta-binding 
sites are not involved in the activation of a receptor by the agonist, but allow the ligand to 
move from the extracellular space to the principal binding pocket in the TM cleft by reducing 
the energy barrier (Moro et al., 1999). The meta-binding sites of the P2Y1 receptor are 
predominantly formed by amino acids in the extracellular loops of the receptor (Fig. 4B). 
Besides being part of the meta-binding sites in the P2Y1 receptor, EL2 is also thought to build 
a cap over the bound ligand after its penetration into the principal binding site (Jacobson et 
al., 2004). 
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P2Y4/1-365  
P2Y2/1-
P2Y6/1-328
P2Y1/1-373   
P2Y12/1-342
P2Y13/1-333
P2Y14/1-338
P2Y11/1-374
WLVVAGCLVPNLFFVTTSNKGT-TVLCHDTTRP------- E 192
WVLVLACQAPVLYFVTTSARGG-RVTCHDTSAP----------E 190
WLAVTTQCLPTAIFAATGIQRN-RTVCYDLSPP----------A 184
WLIVVVAISPILFYSGTGVRKNKTITCYDTTSD----------E 209
WAFMFLLSLPNMILTNRQPRDKNVKKCSFLKS-----------E 181
WFFLFFISLPNMILSNKEATPSSVKKCASLKG-----------P 179
WMLMLLLAVPNIILTNQSVREVTQIKCIELKS-----------E 178
WVLAALLAMPTLSFSHLKRPQQGAGNCSVARPEACIKCLGTADH 197
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EL2
P2Y4/1-365  ---------------SSRLRSLRTIAVVLTVFAVCFVPFHITRTIYYLAR----------272
P2Y2/1-377  ---------------RAKRKSVRTIAVVLAVFALCFLPFHVTRTLYYSFR----------272
P2Y6/1-328  --------------QERRGKAARMAVVVAAAFAISFLPFHITKTAYLAVRS---------267
P2Y1/1-373  ----------------LRRKSIYLVIIVLTVFAVSYIPFHVMKTMNLRARLDF-------290
P2Y12/1-342 ---------------VPRKKVNVKVFIIIAVFFICFVPFHFARIPYTLSQT---------264
P2Y13/1-333 ---------------KNNKKLEGKVFVVVAVFFVCFAPFHFARVPYTHSQT---------262
P2Y14/1-338 ---------------SVKKKSSRNIFSIVFVFFVCFVPYHIARIPYTKSQT---------261
P2Y11/1-374 ----------------EKLRVAALVASGVALYASSYVPYHIMRVLNVDARRRWSTRCPS-284
TM6
6.50
P2Y4/1-365   --------LLEADCRVLNIVNVVYKVTRPLASANSCLDPVLYLLTGDKYRRQLRQLC- 321
P2Y2/1-377   --------SLDLSCHTLNAINMAYKVTRPLASANSCLDPVLYFLAGQRLVRFARDAK- 321
P2Y6/1-328   --------TPGVPCTVLEAFAAAYKGTRPFASANSVLDPILFYFTQKKFRRRPHELL- 316
P2Y1/1-373   --------QTPAMCAFNDRVYATYQVTRGLASLNSCVDPILYFLAGDTFRRRLSRAT- 339
P2Y12/1-342  --------RDVFDCTAENTLFYVKESTLWLTSLNACLDPFIYFFLCKSFRNSLISML- 313
P2Y13/1-333  --------NNKTDCRLQNQLFIAKETTLFLAATNICMDPLIYIFLCKKFTEKLPCMQ- 311
P2Y14/1-338  --------EAHYSCQSKEILRYMKEFTLLLSAANVCLDPIIYFFLCQPFREILCKKL- 310
P2Y11/1-374  -----FADIAQATAALELGPYVGYQVMRGLMPLAFCVHPLLYMAAVPSLGCCCRHCP- 336
7.50
TM7
A
B
E209 
(EL2)
 
Figure 4: (A) Multiple Sequence alignment (Clustal X 1.83) and (B) key residues of the human 
P2Y1 receptor involved in ligand recognition, adapted from (Ivanov et al., 2006) 
(A) Alignment of the protein sequence of P2Y receptors. Grey: transmembrane domains of b-rhodopsin. 
Blue: conserved pattern. Yellow: similarity. Red: conserved proline/glycine residues. Red letters: residues 
already known to be involved in ligand recognition. Blue letters: residues included in a mutagenic analysis 
of the P2Y11 receptor in this study. (B) Docked ATP in a molecular model of the hP2Y1 receptor. The 
residues involved in ligand binding are colored as follows: pink = polar, uncharged residues (Y2.53, Y203, 
Y7.35, Q7.36 and S7.43); blue = positively charged residues (R3.29, K6.55, R7.39); red = non-polar 
residues (F3.32); magenta = negatively charged residues (E209). The black dashed ellipse surrounding two 
of the residues (E209, K6.55) indicates their involvement in meta-binding sites of the receptor. 
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Unlike the first subgroup of P2Y receptors, limited information on ligand recognition is 
available about the Gi coupled P2Y receptors. Molecular modelling of the P2Y12 receptor 
revealed a similar binding mode of the ligand to that found for the members of the first 
subgroup. However, there was a difference in the position of the basic residues coordinating 
the phosphate chain. The only cationic residue in common was an arginine at position 6.55, 
whereas the other positively charged amino acids were located in EL2 and at position 7.35, 
opposed to 3.29 and 7.39 in the P2Y1 like receptors (Fig. 4A). These three basic residues were 
conserved among the second P2Y receptor subgroup (Costanzi et al., 2004). The arginine in 
TM6 was found to be critical for normal P2Y12 receptor function. A patient with a congenital 
bleeding disorder was found to have a point mutation in the P2Y12 receptor gene that changed 
the Arg6.55 (Arg256) to Q, resulting in a functionally impaired receptor (Cattaneo et al., 
2003).  
1.4 Oligomerization of GPCRs 
The currently accepted notion of GPCR organization in the plasma membrane includes the 
well established fact that they tend to oligomerize among each other in order to directly link 
distinct signalling pathways and to integrate receptor functions (Kroeger et al., 2003). Early 
evidence for GPCR oligomerization accumulated from ligand binding assays, where 
unexplained cooperativity was observed, and from SDS-PAGE analysis of GPCRs that 
showed multiple bands of different sizes, indicating higher-order complexes. A clear proof of 
GPCR oligomerization was obtained through the finding that the GABAB receptors exist as an 
obligatory heterodimer (Marshall et al., 1999). Actual visualization of GPCR oligomers has 
been achieved by transmission electron and atomic force microscopy of native murine disc 
membranes from retinal rod photoreceptors, demonstrating the existence of rhodopsin (light-
percepting GPCR) dimers and higher oligomers (Fotiadis et al., 2003).  
Hetero-dimerization among purinergic receptors has also been detected. The A1 receptor 
was found to exert P2Y receptor like agonistic effects when co-expressed with the P2Y1 
receptor in HEK293 cells. By means of a bioluminescence resonance energy transfer (BRET) 
approach and co-immunoprecipitation, the two receptors were clearly shown to 
heterodimerize after co-expression (Yoshioka et al., 2002). Moreover, the P2Y1 receptor 
could also be co-immunoprecipitated by an A1 receptor antibody from rat brain cortical 
neurons, bringing evidence for a role of the hetero-dimer in vivo as well (Yoshioka et al., 
2002).  
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Consequently, the question about GPCR oligomerization has recently changed from ‘Do 
GPCR oligomers really exist ?’ to ‘Why do GPCRs exist as dimers?’. One hypothesis for the 
role of oligomerization is that two receptor molecules might be necessary to satisfy the 
binding requirements of a single G protein. Furthermore, oligomerization might be a common 
requirement for GPCRs to pass ER quality control because it can mask specific retention 
signals or hydrophobic patches that would otherwise retain the proteins in the ER (Terrillon 
and Bouvier, 2004; Bulenger et al., 2005). For example, the GABAB1 receptor does only 
reach the cell surface when co-expressed with the GABAB2 receptor because the ER retention 
signal is masked by hetero-dimerization of the receptors (Hansen and Sheikh, 2004). The 
same is true for the α1D and α1B receptors, as their hetero-dimerization is necessary for proper 
trafficking of the α1D receptor to the plasma membrane (Bulenger et al., 2005). 
In the light of drug development, a more intriguing question in receptor oligomerization is 
‘what are the functional consequences?’. Hetero-oligomerization has been proposed to change 
the selectivity of some GPCRs towards distinct Gα subunits of the G protein family. This can 
result in the activation of different signaling cascades following activation of the receptor 
hetero-dimer or monomers (Terrillon and Bouvier, 2004). Furthermore, the internalization of 
receptors and therewith their desensitization can be modulated by hetero-oligomerization. For 
example the co-expression of the β2 receptor with either the β1 or β3 receptor reduces the 
internalization of the β2 receptor (Prinster et al., 2005; Milligan, 2006). In contrast, the 
endocytosis-resistant somatostatin receptor SSTR1 could be efficiently internalized upon 
agonist-stimulation when co-expressed with the SSTR5 receptor (Prinster et al., 2005).  
This cross-internalization phenomenon might be a very important consequence of GPCR 
hetero-dimerization in regulating the desensitization or resensitization of the receptor 
responses. In case of Parkinson’s disease the hetero-dimerization of D2 and A2A receptors 
seems to accelerate the developing tolerance against L-DOPA, as adenosine levels are 
increased in patients treated with L-DOPA, and therefore the chronic activation of both 
receptors leads to a greater extent of desensitization. Thus, simultaneous treatment with A2A 
antagonists could improve the activity range in the L-DOPA therapy (Kroeger et al., 2003).  
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Perhaps even more interesting in relation to drug development is the observation that co-
expression of two GPCRs can alter the potency of drugs in inducing a response. For the A1-
P2Y1 receptor hetero-dimer a ligand binding assay showed that the potent P2Y1 receptor 
antagonist MRS2179 (Table 2) failed to displace a bound A1 agonist, whereas the P2Y1 
agonist ADPβS was sufficient in displacing the ligands from the A1 binding site. Thus, 
providing an explanation for the theophylline-sensitive P2Y receptors observed in brain that 
are insensitive to known P2Y receptor antagonists (Yoshioka et al., 2001). More recently, 
interaction of the P2Y2 receptor with the A1 receptor was also shown to influence the A1 
receptor signaling. UTP was able to reduce A1 receptor radioligand binding and attenuated A1 
receptor mediated inhibition of cAMP production (Suzuki et al., 2006). However, the 
regulation of A1 receptor signaling by P2Y1 or P2Y2 receptor agonists is different. ADPβS 
seems to act like a real A1 receptor agonist in the A1-P2Y1 receptor hetero-dimer, whereas 
UTP is not able to mediate A1 receptor signaling but interferes with binding of specific A1 
receptor agonists in the A1-P2Y2 receptor hetero-dimer. 
The last but not the least important question in the receptor oligomerization remaining is 
‘how do GPCRs oligomerize?’. Experimental data implicate that all TMs of a receptor could 
be involved in oligomerization, and a conserved dimer interface may be less likely. For 
rhodopsin it seems to be clear that only a TM4-TM5 dimeric interaction is possible (Hansen 
and Sheikh, 2004). However, currently there are two theories how the TMs of rhodopsin-like 
GPCRs (Class A) interact to form dimers. The first is the ‘Contact dimerization (lateral 
packing)’ theory, which would enable the maintenance of the heptahelical bundle for each 
monomer, but requires additional interaction sites on the exterior of the receptor (Fig. 5a). 
The second theory is called ‘Domain swapping’ and would force the separation of two 
independent folding units, which then interact via the sites used in forming the monomers for 
dimerization (Fig. 5b) There is indication that different receptors are likely to utilize different 
oligomerization mechanisms because unique residues are involved in the formation of 
different dimers (Kroeger et al., 2003).  
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Figure 5:  Schematic representation of mechanisms potentially involved in GPCR oligomer 
formation adapted from (Kroeger et al., 2003) 
(a) In the contact dimer, GPCRs directly contact each other via exterior residues. (b) The domain swapping 
model requires the exchange of independently folded TM domains between monomeric units using the 
same interaction sites as for the formation of monomers. 
1.5 Aims of the thesis project 
The main focus of the thesis project was to characterize a metabotropic nucleotide receptor, 
namely the P2Y11 receptor. We were interested in the P2Y11 receptor subtype because limited 
work has been done on the receptor pharmacology and function despite of being a promising 
drug target. Therefore, we undertook the present study to characterize this little explored 
member of the P2Y receptor family in terms of pharmacology, ligand recognition and 
interaction with other P2Y receptor subtypes. 
Aim 1: To study the pharmacological properties of a receptor, it is necessary that the 
receptor is heterologously expressed in an expression system that is devoid of endogenous 
nucleotide receptors to exclude contaminating signals during the pharmacological 
measurements. Towards this end, the 1321N1 astrocytoma cell line was selected because it 
does not express any P2Y receptor subtypes endogenously (Lazarowski et al., 1995). The 
P2Y11 receptor with a C-terminal green fluorescent protein (GFP) tag was stably expressed in 
the 1321N1 cells and used for the pharmacological characterization.  
Aim 2: Most of the agonists acting on the P2Y11 receptor are also potent P2Y1 receptor 
agonists, since the P2Y11 receptor is most closely related to the P2Y1 receptor (Costanzi et al., 
2004). Also, earlier studies have shown that knowledge about stereoselective preferences of 
P2Y receptors can be of great help in establishing new lead compounds for the development 
of specific ligands (Kim et al., 2002; Costanzi et al., 2005). Hence, we decided to concentrate 
on the stereochemic differences in the ligands that are preferred by the P2Y11 or the P2Y1 
receptor.  
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The P2Y1 receptor was shown to prefer one chiral isomer of Pα substituted ATP 
derivatives (Nahum et al., 2002; Major et al., 2004). Thus, it was interesting to know whether 
the P2Y11 receptor would show the same preference or whether the stereoselective 
discrimination would be different between the two receptors. The 1321N1 cells stably 
expressing the P2Y11GFP receptor were used for testing the potency of several ATP 
diastereoisomers in inducing intracellular calcium rise. Pα borano (ATP-α-B) or sulfur (ATP-
α-S) substituted ATP analogues were selected as chiral probes to investigate the 
stereoselectivity of the P2Y11 receptor. 
Aim 3: Furthermore, to gain insight into the structural determinants of the activity of 
adenine nucleotides at the receptor, mutational analysis based on a molecular model of the 
P2Y11 receptor was initiated. Amino acid residues putatively involved in the binding of 
ligands at the P2Y11 receptor were selectively mutated and then the activity of agonists at 
these receptor mutants was determined. Structural differences between the P2Y1 and P2Y11 
receptors were kept in consideration while designing the mutations, since these differences 
will be essential for further studies focusing on the development of P2Y11 receptor selective 
drugs. In addition, some receptor mutants were also tested for stereoselective activation by 
ATP-α-S diastereoisomers.  
Aim 4: Moreover, the emerging fact that GPCRs can form homo- or hetero-oligomers has 
provided a new view on receptor organization and signaling in recent times. GPCR 
oligomerization was shown to have functional consequences. Among others these 
consequences can affect the agonist-induced internalization and ligand selectivity of GPCRs 
(Hansen and Sheikh, 2004). Both P2Y1 and P2Y11 receptors are co-expressed by several 
tissues, but it has not been studied so far whether a crosstalk or functional interaction is 
present between these receptors. Additionally, there are indications that such an interaction 
might exist, because the pharmacology of the endogenously expressed receptors not always 
resembles the profile found at the heterologously expressed receptors. Thereby, we were 
interested to know if the P2Y1 and P2Y11 receptors interact to form a hetero-oligomer. 
Moreover, with our experimental approach we wanted to test the hypothesis that the 
discrepancy between the behavior of endogenous and heterologously expressed receptors is 
due to the formation of this hetero-oligomer. Specifically, we focused on the physical 
association of the receptors in cells and the functional outcome of this interaction.  
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The experiments of the project were carried out in the following order: 
1. Functional expression of the P2Y11 receptor in 1321N1 cells as a GFP fusion protein. 
2. Investigation of the stereoselective preference of agonists at the P2Y11 receptor by 
measuring intracellular calcium concentration using fura-2 in stably transfected 
1321N1 cells. ATP-α-B and ATP-α-S derivatives were used as chiral probes. 
3. Mutational analysis of amino acid residues putatively involved in ligand recognition at 
the P2Y11 receptor. Receptor mutants were tested for loss or gain of function using 
intracellular calcium measurements. 
4. To study the probable organization of the P2Y1 and P2Y11 receptor in hetero-
oligomers by biochemical means and investigate functional consequences of the 
interaction in inducing receptor endocytosis and in alteration of ligand selectivities. 
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2 MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Cell lines 
Human Embryonic Kidney cells (HEK293, epithelial), Human astrocytoma cells (1321N1, 
glioma) 
2.1.2 Bacterial strains 
 Strain Genotype Reference 
XL1-Blue 
supE44, hsdR17, recA1, endA1, 
gyrA46, thi, relA1, lac, [F’ 
proAB, lacIq, Z∆M15, 
Tn10(tetr)] 
Sambrook et al., 
1989 
Bacteria: E coli 
DH5αF´ 
F´/endA1, hsdR17 (rk-mk+), 
glnV44, thi-1, recA1, gyrA 
(Nalr), relA1, ∆(laclZYA-
argF)U169, deoR, 
(φ80dlac∆(lacZ)M15) 
Woodcock et.al., 
1989 
2.1.3 Plasmid vectors 
Name Size(Kb) Antibiotic 
resistance Manufacturer 
pcDNA3.1 (+) 5.5 ampicillin/ 
neomycin Invitrogen, Karlsruhe, Germany 
pcDNA3.1/Myc-His 
(A) 5.5 
ampicillin/ 
neomycin Invitrogen, Karlsruhe, Germany 
pCMV-HA 3.8 ampicillin Clontech, Heidelberg, Germany 
pEGFP-N1 4.7 kanamycin/ 
neomycin “ 
pEYFP-N1 4.7 kanamycin/ 
neomycin “ 
pGEX 4.9 ampicillin GEHealthcare, München, Germany 
pmCerulean-C1 4.7 kanamycin/ 
neomycin 
David W. Piston, VUMC, 
Nashville, USA 
pVL1392 9.6 ampicillin BD Biosciences, Heidelberg, Germany 
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2.1.4 Enzymes 
 
2.1.5 Kits 
 
Enzymes and buffer Manufacturer 
Shrimp Alkaline Phosphatase Boehringer, Mannheim, Germany 
T4 DNA Ligase Invitrogen 
T4 DNA Polymerase “ 
BamHI MBI Fermentas, St. Leon-Roth, Germany 
BglII “ 
EcoRI “ 
EcoRV “ 
HindIII “ 
NotI “ 
SmaI “ 
XhoI “ 
O+ buffer “ 
Y/Tango+ (10X) buffer “ 
dNTP mix “ 
ApaI New England Biolabs, Beverly, MA, USA 
BlpI “ 
BspEI “ 
NEBuffer 1-4 “ 
Type of kit Usage Manufacturer 
cAMP EIA kit determination of cellular cAMP 
content 
assay designs, Ann Arbor, 
Michigan, USA 
BigDye Terminator Cycle 
Sequencing 
Ready Reaction kit  
DNA sequencing Applied Biosystems, Warrington, UK 
iScript cDNA synthesis kit Making of cDNA for Real-Time PCR BioRAD, München, Germany 
iQ SYBr Green supermix Real-Time PCR “ 
AccuPrime PCR (proof reading polymerase) Invitrogen, Karlsruhe, Germany 
HiSpeed Plasmid Midi kit Plasmid isolation Qiagen, Hilden, Germany 
MinElute Gel extraction kit Purification of DNA from Agarose-Gel 
“ 
QIAquick PCR purification kit Purification of PCR products “ 
Taq Master Mix kit  PCR with Taq DNA polymerase “ 
Omniscript Reverse 
Transcription kit Making of cDNA 
“ 
RNase-Free DNase Set Removal of genomic DNA during RNA isolation 
“ 
RNeasy Mini kit  Isolation of RNA “ 
Supersignal West Pico kit Detection of western blot Pierce, Rockford, IL, USA 
QuikChange Site-directed 
Mutagenesis kit 
Generation of point-mutations in 
plasmid vectors Stratagene, LaJolla,CA,USA 
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2.1.6 Laboratory instruments 
 
Instrument Manufacturer 
ABI PRISMTM 310 Genetic Analyzer Applied Biosystems Division, Foster City, CA, USA 
Mighty Small II (for western blotting electrophoresis) Amersham Pharmacia Biotech Buckinghamshire, UK 
Sonoplus sonicator Bandelin electronic, Berlin, Germany 
Avanti 30 centrifuge Beckman Coulter, Krefeld, Germany 
T3 Thermocycler Biometra, Göttingen, Germany 
Electrophoresis power supply Bio-Rad Laboratories, München, Germany 
Gel electrophoresis system “ 
Semi-dry Transfer Cell “ 
GS-800 Calibrated Densitometer “ 
iCycler (Real-Time PCR) “ 
LSM510 laser scanning confocal microscope Axiovert 
135 fluorescence microscope  
Carl Zeiss, Jena, Germany 
Axiovert 135 fluorescence microscope (calcium 
imaging) 
“ 
CTI Controller 3700 digital (CO2 controller confocal 
microscope) 
“ 
temp control-37-2 digital (temperature controller 
confocal microscope) 
“ 
Sorvall RC-5B Refrigerated Superspeed Centrifuge Dupont Instruments, Hamburg, Germany 
Thermomixer comfort Eppendorf, Wesseling-Berzdorf, Germany 
Biofuge A, 13 R, 3.2 RS (centrifuge) Heraeus, Hamburg, Germany 
HB2448 LaminAir (clean bench) “ 
Function line incubator (5% CO2) “ 
Rotina 35 R centrifuge Hettich Zentrifugen, Leipzig, Germany 
Magnet plate IBA, Göttingen, Germany 
Discovery 90 Ultracentrifuge Kendro, Langenselbold, Germany 
pH Meter (pH763) Knick, Berlin, Germany 
Vacuum oven Memmert, Schwabach, Germany 
Microplate reader Molecular Devices 
Innova 4230 Refrigerated incubator shaker New Brunswick Scientific, Nürtingen, Germany 
UV/visible Spectrophotometer Pharmacia Biotech 
Gel-blotting-papers Schleicher & Schuell, Dassel, Germany 
Protran BA83 Cellulosenitrat (E) (0.2 µm) “ 
Liquid blocker, Super Pap pen Sigma, Deisenhofen, Germany 
Eagle Eye Still video system Stratagene, Heidelberg, Germany 
Polychrom II monochromator TILL Photonics, Gräfelfing, Germany 
CCD camera IMAGO type VGA “ 
TILLvision version 4.0 “ 
Nuaire CO2-Water-Jacketed Incubator (10% CO2) Zapf Instruments, Sarstedt, Germany 
Ismatec Reglo pump Windaus Labortechnik, Magdeburg, Germany 
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2.1.7 Chemicals and reagents 
Chemicals Manufacturer 
2-MeS-ATP-α-S Bilha Fischer, Bar-Ilan University, Ramat-Gan, Israel 
2-neopentenyl-thio-ATP Bilha Fischer, Bar-Ilan University, Ramat-Gan, Israel 
Ampicillin Biochrom, Berlin, Germany 
ATP-α-B, 2-Cl-ATP-α-B, 2-MeS-ATP-α-B Bilha Fischer, Bar-Ilan University, Ramat-Gan, Israel 
Bacto Agar BD Bioscience (Clontech), Heidelberg, Germany 
Bacto Tryptone BD Bioscience (Clontech), Heidelberg, Germany 
Bacto Yeast extract BD Bioscience (Clontech), Heidelberg, Germany 
Bio-Rad protein assay dye reagent concentrate Bio-Rad Laboratories, München, Germany 
CaCl2 + EDTA Roth, Karlsruhe, Germany 
Complete Protease Inhibitor Cocktail Roche Diagnostic, Mannheim, Germany 
Deoxycholic acid SERVA, Heidelberg, Germany 
Dimethyl sulfoxide (DMSO) SIGMA, Deisenhofen, Germany 
DMEM + HAM’S F12 (1:1) Biochrom, Berlin, Germany 
DOTAP transfection reagent Roche Diagnostic, Mannheim, Germany 
Dulbecco’s Modified Eagle’s Medium (DMEM) Biochrom, Berlin, Germany 
Fetal calf serum (FCS) Biochrom, Berlin, Germany 
FuGENETM 6 transfection reagent Roche Diagnostic, Mannheim, Germany 
Fura-2AM Molecular Probes Invitrogen, Karlsruhe, Germany 
G418 Sulphate Calbiochem, La Jolla, CA, USA 
Glücksklee, non-fat dry milk Nestle, Germany 
Glucose*H2O + Glycine + Glycerol Roth, Karlsruhe, Germany 
Glutathione Sepharose 4 Fast Flow GE Healthcare, München, Germany 
HBSS (w/o Ca2+ and Mg2+) Biochrom, Berlin, Germany 
HEPES Roth, Karlsruhe, Germany 
Igepal CA630 SIGMA, Deisenhofen, Germany 
ImmersolTM 518N (Immersion oil for microscopy) Carl Zeiss, Oberkochen, Germany 
Kanamycin sulphate Biochrom, Berlin, Germany 
KCl Roth, Karlsruhe, Germany 
KH2PO4 Merck, Darmstadt, Germany 
MATra solution IBA, Göttingen, Germany 
MgCl2 Roth, Karlsruhe, Germany 
MgSO4 Roth, Karlsruhe, Germany 
MRS2179 SIGMA, Deisenhofen, Germany 
Na2HPO4*2H2O Roth, Karlsruhe, Germany 
NaCl Roth, Karlsruhe, Germany 
NaHCO3 Roth, Karlsruhe, Germany 
NF157 M.U. Kassack, Universität Bonn, Germany 
Penicillin and Streptomycin Biochrom, Berlin, Germany 
PFA Fluka Chemika, Sigma, Germany 
Pluronic acid Molecular Probes Invitrogen, Karlsruhe, Germany 
Poly-L-Lysine SIGMA, Deisenhofen, Germany 
Ponceau S solution (0.2% in acetic acid) Boehringer, Mannheim, Germany 
Protein A/G Plus Agarose Santa Cruz, Heidelberg, Germany 
Purine-/ pyrimidine nucleotides and derivatives SIGMA, Deisenhofen, Germany 
Rp/Sp-ATP-α-S Biolog, Bremen, Germany 
Saccharose + SDS Roth, Karlsruhe, Germany 
TEMED SIGMA, Deisenhofen, Germany 
Template Suppression Reagent (TSR) Applied Biosystems Division, Foster City, CA, USA 
Triton-X-100 SERVA, Heidelberg, Germany 
Trypanblue Biochrom, Berlin, Germany 
Trypsin/EDTA Biochrom, Berlin, Germany 
Tween 20 SIGMA, Deisenhofen, Germany 
β-mercaptoethanol SIGMA, Deisenhofen, Germany 
RNAse Roth, Karlsruhe, Germany 
Materials and Methods 
 24
2.1.8 Antibodies 
2.1.9 Molecular mass markers 
2.1.9.1 Nucleic acid standard marker 
GeneRuler 100bp DNA Ladder (1 kb)   MBI Fermentas, St. Leon-Rot, Germany 
GeneRuler DNA Ladder Mix (10 kb)    “ - “ 
2.1.9.2 Protein standard marker 
Precision Plus (All Blue) (250-10 kDa)  Bio-Rad, München, Germany 
2.1.10 Buffers and solvents 
2.1.10.1 Cell culture media and solutions 
• HEK-293 cells - DMEM/HAM’S F12 (1:1) with 2 mM Glutamine, 10% FCS,        
100 U/ml Penicillin, 100 µg/ml Streptomycin  
• 1321N1 cells – DMEM with 2 mM Glutamine, 5% FCS, 100 U/ml Penicillin,         
100 µg/ml Streptomycin 
•
 HBSS (Hanks’ balanced salt solution) without Ca2+ and Mg2+ 
• PBS 
• Trypsin/EDTA 
• G418 Sulphate- stock solution: 500 mg/ml, working concentration: 500 µg/ml 
• Poly-L-Lysine:  0.1 mg/ml H2O 
 
 
 
 
 
Antibody Manufacturer 
rabbit polyclonal anti-hP2Y1 Alomone labs, Jerusalem, Israel 
rabbit polyclonal anti-hP2Y11 “ 
mouse monoclonal IgG against HA-tag Cell Signalling, Danvers, MA, USA 
peroxidase-conjugated anti-mouse and anti-rabbit IgG  Dianova, Hamburg, Germany 
mouse monoclonal antibody anti-Myc Invitrogen, Karlsruhe, Germany 
rabbit polyclonal anti-GFP “ 
Alexa555 anti-mouse IgG and Alexa488 anti-rabbit IgG  Molecular Probes, Invitrogen, Karlsruhe, Germany 
rabbit polyclonal anti-GST Santa Cruz, Heidelberg, Germany 
rabbit polyclonal anti-myc Sigma, Deisenhofen, Germany 
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2.1.10.2 Microbial Media and solutions 
• Luria bertini (LB)- 1 lt  
 
Bacto-tryptone  10 g  
Bacto yeast extract  5 g 
NaCl    10 g 
pH 7.0 
bacto agar (for plates) 15 g 
Ampicillin   100 µg/ml (final conc.) 
Kanamycin   50 µg/ml   (final conc.) 
 
• SOC – 250 ml 
 
Bacto tryptone 5 g 
Yeast extract  1.25 g 
NaCl   0.15 g 
KCl   0.125 g 
1M Glucose  5 ml    (final 20 mM) 
1M MgCl2  2.5 ml (final 10 mM) 
1M MgSO4  2.5 ml (final 10 mM) 
 
• TSB buffer-150 ml 
 
2x LB-media  75 ml  1x LB (final conc.) 
DMSO  7.5 ml  5% (final conc.) 
1 M MgCl2  1.5 ml  10 mM (final conc.) 
1 M MgSO4  1.5 ml  10 mM (final conc.) 
PEG 4000  15 g  10% (final conc.) 
Sterile filtered with 0.2 µm Filter 
 
• 2x LB-100 ml 
bacto tryptone  2 g 
Yeast extract  1 g 
NaCl   2 g 
pH    7.0-7.4 
 
• Mini-Prep Solutions 
Solution I  50 mM Glucose 
   25 mM Tris/HCl (pH 8.0) 
   10 mM EDTA (pH 8.0) 
   100 µg/ml RNAse 
Solution II  0,2 N NaOH 
   1% SDS 
Solution III  3 M Potassiumacetat 
   11,5 % Acetic acid 
TER   10 mM Tris/HCL (pH 8.0) 
   1 mM EDTA 
   200 µg/ml RNAse 
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• 5xKCM buffer: 0.5 M KCl 
0.15 M CaCl2 
0.25 M MgCl2 
2.1.10.3 Molecular Biology: buffers and solutions 
1x PBS:   137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2HPO4,  
1.4 mM KH2PO4, pH 7.4 
 
1x NaHBS:   145 mM NaCl, 5,4 mM KCl, 1mM MgCl2, 1.8 mM CaCl2 
    
25 mM Glucose, 20 mM HEPES, pH 7.4 
 
1x TAE:   40 mM Tris, 5 mM NaOAc, 1 mM EDTA, pH 7.4 
 
1x TE:    10 mM Tris/HCl, pH 7.4, 1 mM EDTA, pH 8.0 
 
Ethidium bromide solution:  10 mg/ml 
 
4% PFA solution:  4% PFA (Paraformaldehyde), 120 mM sodium phosphate,  
pH 7.4, 4% Saccharose  
 
FSBB:    Blocking and Wash buffer (immunostaining)-12 ml 
FCS     2 ml 
10% Triton-X100   0.365 ml 
240 mM Na3PO4   1 ml 
4 M NaCL    1.35 ml 
H2O     ad 12 ml 
 
High Salt buffer:  500 mM NaCl, 20 mM Na2HPO4 
 
Low Salt buffer:  150 mM NaCl, 10 mM Na2HPO4 
 
RIPA-buffer:    50 mM Tris (pH 7.4), 1% Igepal CA630,  
0.25% Na-deoxycholate, 150 mM NaCl, 1 mM EDTA,  
1 mM NaF, one tablet Complete Protease Inhibitor Cocktail 
per 50 ml 
 
Hypotonic buffer pH 8.1: 5 mM Tris/HCl (pH 8.1), 50 µM CaCl2, 3 mM MgCl2, 
0.1% Igepal CA630, 2 mM DTT, one tablet Complete Protease 
Inhibitor Cocktail per 50ml 
 
60% Acrylamid/Bis:   Acrylamid    58.4 g/100ml 
N,N‘-Methylen-bisacrylamid  1.6 g/100ml 
 
Resolving buffer:  750 mM Tris/HCl, pH 8.8 (SDS-PAGE-Laemmli) 
 
Stacking buffer:  250 mM Tris/HCl, pH 6.8 (SDS-PAGE-Laemmli) 
 
SDS solution:   10% (w/v) SDS in H2O 
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PER solution:   10% (w/v) Ammoniumperoxodisulfat in H2O 
 
4x Laemmli Sample buffer: 500 mM Tris/HCl, pH 6.8, 8% SDS, 40% Glycerol,  
0.005% Bromophenolblue 
 
1x Running buffer:  25 mM Tris, 192 mM Glycin, 0.1% SDS, pH 8.5 
(SDS-PAGE-Laemmli) 
 
1x Transfer buffer:  25 mM Tris, 192 mM Glycine, 20% (v/v) Methanol  
(for Laemmli gels with NC membrane) 
 
Membrane Stripping buffer: 62.5 mM Tris, pH 6.8, 100 mM β-Mercaptoethanol, 2% SDS 
2.1.11 Oligonucleotides 
All oligonucleotides were from Operon/ Qiagen, except the RT-PCR and sequencing primers 
(MWG), DECERFRETRV (Invitrogen) and GST cloning primers (MWG). 
2.1.11.1 RT-PCR primer 
Primer Accession-Nr. Sequence Tm (°C) PCR product 
hGAPDH5 5’-TCC AAA ATC AAG TGG GGC GAT GCT-3’ 
hGAPGH3 NM_002046 5’-ACC ACC TGG TGC TCA GTG TAG CCC-3’ 60 600 bp 
hsP2X4Fw 5’-GCC TTC CTG TTC GAG TAC GAC-3’ 
hsP2X4Rev NM_002560 5’-CGC ACC TGC CTG TTG AGA CTC-3’ 55 420 bp 
hsP2X7Fw 5’-GTC ACT CGG ATC CAG AGC ATG-3’ 
hsP2X7Rev NM_002562 5’-TTG TTC TTG ATG AGC ACA GTG-3’ 55 532 bp 
hsP2Y1Fn 5’-TCT TCC ACA TGA AGC CC-3’ 
hsP2Y1Rn NM_002563 5’-AGA GGA GAG TTG TCC AGA-3’ 55 531 bp 
hsP2Y2Fn 5’-CTT CAA CGA GGA CTT CAA GT-3’ 
hsP2Y2Rn NM_002564 5’-CAC GTA ACA GAC AAG GAT GA-3’ 55 579 bp 
hsP2Y6Fn 5’-CGC TGA ACA TCT GTG TCA TT-3’ 
hsP2Y6Rn NM_176797 5’-ATA GCA GAC AGT GCG GTT AC-3’ 55 409 bp 
NHSP2Y11Fw 5’-CGA GGT GCC AAG TCC TGC CCT-3’ 
NHSP2Y11Rv NM_002566 5’-CGC CGA GCA TCC ACG TTG AGC-3’ 60 809 bp 
hsPAR2-sense 5’-GCCATCCTGCTAGCAGCCTCTC-3’ 
hsPAR2-antisense U61373 5’-GATGACAGAGAGGAGGTCAGCC-3’ 60 341 bp 
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2.1.11.2 Cloning primers 
Primer Accession-
Nr. 
Sequence Tm 
(°C) 
Usage 
DECERATGFW 5’-TC CCG CTG GAT CCA CCG GTC GCC ACC ATG GTG–3’ 
DECERATGRV 5’-CTT GAG CGC GGC CGC TGA GTC CTT ACT TGT AC–3’ 
Subcloning 
of Cerulean 
from 
pmCer-C1 
in pP2Y1N1 
DECERFRETRV 
- 
5’-ACC GTC GAC TGC AGG ATC CGA AGC TTG 
AGC–3’ 
58 
Construction 
of a FRET 
positive 
control 
THGSTFW 5’-GAT CTG ATA TCA TGT CCC CTA TAC TAG–3’ 
THGSTRV 
- 
5’-GAA GAT CTT CAA TCC GAT TTT GGA GGA 
TGG TCG CC–3’ 
60 
Cloning of 
GST from 
pGEX 
vector 
DEHSP2Y1ATGFW 5’-GATC GAA TTC ATG ACC GAG GTG CTG TGG CCG–3’ 
DEHSP2Y1SMAIRV 
NM_002563 5’-CAG AAT GGA GAT ACA AGC CTG GGC CCG 
GGG TGA C-3’ 
58 
Cloning of 
the hP2Y1 
receptor 
2.1.11.3 Mutagenesis primer 
Primer Sequence Usage 
DEP2Y1K280A-Fw 5’-CCT TTC CAT GTG ATG GCC ACG ATG AAC TTG AGG-3’ 
DEP2Y1K280A-Rv 5’-CCT CAA GTT CAT CGT GGC CAT CAC ATG GAA AGG-3’ 
Mutagenesis-PCR: 
P2Y1-R K280A 
mutant 
DEP2Y11F109IUP 5´-CTG GAG CGC TTC CTC ATC ACC TGC AAC CTG CTG-3´ 
DEP2Y11F109ILOW 5´-CAG CAG GTT GCA GGT GAT GAG GAA GCG CTC CAG-3´ 
Mutagenesis-PCR: 
P2Y11-R F109I 
mutant 
DEP2Y11E186AUP 5´-AGC GTG GCC AGG CCC GCG GCC TGC ATC AAG TGT-3´ 
DEP2Y11E186ALOW 5´-ACA CTT GAT GCA GGC CGC GGG CCT GGC CAC GCT-3´ 
Mutagenesis-PCR: 
P2Y11-R E186A 
mutant 
DEP2Y11R106AUP 5’-GCG TGC CGC CTG GAG GCC TTC CTC TTC ACC TGC–3’ 
DEP2Y11R106ALOW 5’-GCA GGT GAA GAG GAA GGC CTC CAG GCG GCA CGC–3’ 
Mutagenesis-PCR: 
P2Y11-R R106A 
mutant 
DEP2Y11Y261AUP 5’-CTC TAC GCC AGC TCC GCG GTG CCC TAC CAC ATC–3’ 
DEP2Y11Y261ALOW 5’-GAT GTG GTA GGG CAC CGC GGA GCT GGC GTA GAG–3’ 
Mutagenesis-PCR: 
P2Y11-R Y261A 
mutant 
DEP2Y11R268AUP 5´-CCC TAC CAC ATC ATG GCG GTG CTC AAC GTG GAT-3´ 
DEP2Y11R268ALOW 5´-ATC CAC GTT GAG CAC CGC CAT GAT GTG GTA GGG-3´ 
Mutagenesis-PCR: 
P2Y11-R R268A 
mutant 
DEP2Y11R268QUP 5´-CCC TAC CAC ATC ATG CAG GTG CTC AAC GTG GAT-3´ 
DEP2Y11R268QLOW 5´-ATC CAC GTT GAG CAC CTG CAT GAT GTG GTA GGG-3´ 
Mutagenesis-PCR: 
P2Y11-R R268Q 
mutant 
DEP2Y11R307AUP 5’-GGC TAC CAG GTG ATG GCG GGC CTC ATG CCC CTG–3’ 
DEP2Y11R307ALOW 5’-CAG GGG CAT GAG GCC CGC CAT CAC CTG GTA GCC–3’ 
Mutagenesis-PCR: 
P2Y11-R R307A 
mutant 
DEP2Y11A313NUP 5’-GGC CTC ATG CCC CTG AAC TTC TGT GTC CAC CCT–3’ 
DEP2Y11A313NLOW 5’-AGG GTG GAC ACA GAA GTT CAG GGG CAT GAG GCC–3’ 
Mutagenesis-PCR: 
P2Y11-R A313N 
mutant 
DECitrinemutaFW 5’-TTC GGC TAC GGC CTG ATG TGC TTC GCC CGC TAC-3’ 
DECitrinemutaRV 5’-GTA GCG GGC GAA GCA CAT CAG GCC GTA GCC GAA-3’ 
Mutagenesis-PCR: 
mutate YFP to 
Citrine (YFP-
Q69M mutant) 
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2.1.11.4 Sequencing primers 
Primer Sequence Usage 
DEpeGFPN1-fw 5’-GAT CCA CCG GTC GCC ACC ATG G-3’ 
DEpeGFPN1-rv 5’-CCT CTA CAA ATG TGG TAT GGC-3’ 
Sequencing of 
fluorescent tags in N1 
Clontech vectors 
T7 fw 5’-TAA TAC GAC TCA CTA TAG GGA-3’ sequencing of vectors 
with T7 promotor 
BGH rv 5’-TAG AAG GCA CAG TCG AGG-3’ 
sequencing of vectors 
with BGH 
polyadenylation site 
THHSP2Y1FW1 5’-AGG TTC ATC TTT CAT GTG AAC-3’ 
THHSP2Y1FW3 5’-TAC CTG GTA ATC ATT GTA CTG-3’ 
THHSP2Y1RV2 5’-CAG TTT ACA CAT GGC ATC CCC-3’ 
THHSP2Y1RV4 5’-CCT CAG AGG AGA GTT GTC CAG-3’ 
Sequencing of the 
hP2Y1 receptor 
THP2Y11FW1 5’-ACC TGC ATC AGC CTC AAC CGC-3’ 
THP2Y11FW2 5’-TGG CCC TCT ACG CCA GCT CCT A-3’ 
THP2Y11FW3 5’-TGT GTC CAC CCT CTA CTC TAC A-3’ 
THP2Y11RV1 5’-AGC GGT TGA GGC TGA TGC AGG T-3’ 
THP2Y11RV2 5’-TAG GAG CTG GCG TAG AGG GCC A-3’ 
THP2Y11RV3 5’-TGT AGA GTA GAG GGT GGA CAC A-3’ 
Sequencing of the 
hP2Y11 receptor 
 
2.1.11.5 siRNA 
DEP2RY1_1 siRNA   sense r(CUC UCC UCU GAG GAG AAA A)dTdT 
control (non-silencing) siRNA sense r(UUC UCC GAA CGU GUC ACG U)dTdT 
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2.2 Methods 
2.2.1 Methods in molecular biology 
2.2.1.1 Isolation of nucleic acids 
2.2.1.1.1 RNA isolation from animal cells 
Total RNA was isolated from cultured cells (wild type and transfected) using the RNeasy 
Mini kit (Qiagen, Hilden). The medium was aspirated from the culture dish (5 cm) and cells 
were lysed with 350 µl Buffer RLT. Cells were homogenized completely by pipetting with 1 
ml tip, and to this homogenized suspension 700 µl of 70% ethanol was added and mixed well 
by pipetting. The sample (700 µl) was applied to a RNeasy mini spin column sitting in a 2-ml 
collection tube, and centrifuged for 1 min at 10,000 rpm. For washing, 350 µl Buffer RW1 
was pipetted onto the RNeasy column, and centrifuged for 1 min at 10,000 rpm to wash the 
silica-gel-membrane. Now on-column DNase digestion was performed to remove genomic 
DNA using the RNase-Free DNase kit (Qiagen, Hilden). Therefore, 10 µl of DNase I stock 
solution (2.73 Kunitz units/ µ l) mixed in 70 µl Buffer RDD (DNase I incubation mix) was 
added directly onto the spin-column membrane and incubated at room temperature for 15 
min. For a second washing step 350 µl Buffer RW1 was pipetted into the spin column and 
centrifuged for 1 min at 10,000 rpm. The RNeasy column was transferred into a new 2-ml 
collection tube. Buffer RPE (500 µl) was pipetted onto the RNeasy column, and centrifuged 
for 1 min at 10,000 rpm. This step was repeated but this time the column was centrifuged for 
2 min at maximum speed to dry the RNeasy membrane. The RNeasy column was transferred 
into a new 1.5-ml collection tube, and 30 µl RNase-free water was pipetted onto the RNeasy 
membrane. Incubated at room temperature for 10 min and then centrifuged for 2 min at 
12,000 rpm to elute. Stored at –80°C. 
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2.2.1.1.2 Plasmid DNA isolation from bacteria (Mini-Preparation, Mini-Prep) 
Single colonies were picked from agar plates and grown overnight in 5 ml of selective LB 
medium (LB-Medium with 100 µg ampicillin or 50 ng kanamycin/ ml). About one third of 
the bacteria culture (1.5 ml) was transferred into a suitable reaction tube and centrifuged for 
30 s at maximum speed. The supernatant was discarded and the pellet was resuspended in 100 
µl of solution I. Solution II (200 µl) was added to the bacteria suspension and mixed carefully 
by inverting the tube 5-6 times. After 5 min incubation at room temperature, 150 µl of 
Solution III was added and again mixed carefully. The tubes were placed on ice for 15 min to 
allow quantitative precipitation of bacterial proteins. The precipitate was removed by 
centrifugation for 15 min at maximum speed and the supernatant was transferred to a new 
reaction tube without taking along any precipitate. Then 300 µl of isopropanol was added and 
the mixture incubated for 5 min at room temperature to precipitate plasmid DNA. After 
centrifugation for 10 min at maximum speed the supernatant was discarded and the pellet 
washed with 250 µl of 70% Ethanol. The tubes were again centrifuged at maximum speed for 
10 min, the ethanol containing supernatant discarded and the pellets dried at 37°C for 30 min. 
After all remaining ethanol had evaporated, the pellets were dissolved in 50 µl TER buffer 
and the DNA-solution incubated at 37°C for 1 h to destroy contaminating RNA. At this step 
the mini-preps were analyzed with the appropriate restriction enzymes to check for successful 
plasmid isolation and positive clones after cloning. For this, 2-5 µl of the DNA-solution was 
analyzed in a single or double digestion (section 2.2.1.2.2). 
Positive clones were once more precipitated with 50 µl 4M NH4OAc, plus 300 µ l 
absolute ethanol. The mixture was centrifuged for 10 min at maximum speed and the 
supernatant discarded. The pellet was washed with 70% Ethanol and again centrifuged. After 
the pellet was fully dried it was resuspended in 30 µl H2O or 10 mM Tris/HCl (pH 8.0) 
depending on the further usage (H2O: Sequencing with ABI PRISMTM 310 Genetic Analyzer; 
Tris/HCl: Sequencing at Seqlab GmbH, Göttingen, Germany). 
2.2.1.1.3 Plasmid DNA isolation from bacteria (Midi-preparation) 
Plasmid DNA from transformed bacteria was harvested using the HiSpeed Plasmid Midi Kit 
(Qiagen, Hilden). 50 ml of overnight grown transformed bacteria culture was centrifuged for 
15 min at 5000 rpm to recover cell pellet. Bacterial pellet was resuspended in 6 ml of Buffer 
P1 containing RNase A. Buffer P2 (6 ml) was added, mixed gently, and incubated at room 
temperature for 5 min.  
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Then 4 ml of chilled Buffer P3 was added, mixed immediately but gently and the lysate 
was poured into the barrel of the QIAfilter Midi Cartridge. Incubated at room temperature for 
10 min to allow precipitation of protein and genomic DNA at the top of the solution. In the 
mean time Buffer QBT (4 ml) was applied to equilibrate a Qiagen-tip 500 and the column was 
allowed to empty by gravity flow. Then the cap from the QIAfilter outlet nozzle was removed 
and the plunger gently inserted into the cartridge. The cell lysate was filtered into an already 
equilibrated Qiagen-tip. The cleared lysate was allowed to enter the resin by gravity flow. The 
Qiagen-tip was washed with 2 x 10 ml Buffer QC. After washing the cartridge was placed in a 
fresh falcon tube and plasmid DNA was eluted with 5 ml of Buffer QF. DNA was precipitated 
with 3.5 ml of isopropanol (room temperature) and transferred onto a QIAprecipitator. The 
filter was washed with 2 ml 70% Ethanol and dried by pressing air through it using a 20 ml 
syringe. The DNA was eluted with 500 µl - 1 ml of Buffer TE. Stored at -20°C. 
2.2.1.1.4 Isolation of DNA fragments from agarose gel 
To isolate DNA fragments (PCR or cDNA-insert in plasmid) from agarose gel, the MinElute 
Gel Extraction kit (Qiagen) was used. The area containing the DNA fragment was cut from 
the gel. Care was taken to minimize the surrounding agarose excised with the fragment. For 
1% agarose gel maximum 400 mg of gel slices was used per 1.5 ml tube. The gel slice was 
weighed and 3 volumes of Buffer QG to 1 volume of gel (100 mg ~ 100 µl) was added. The 
gel slices were incubated in buffer at 50°C for minimum 10 min at 500 rpm (Eppendorf 
Thermomixer). The tubes were additionally mixed every 3 min. After the gel slice appeared to 
be dissolved 1 volume of isopropanol was added and mixed carefully.  
To bind DNA the sample was applied to a QIAquick column and centrifuged for 1 min at 
13.000 rpm. The flow-through was discarded and 500 µl of Solubilization buffer (QG) was 
added to the cartridge and centrifuged again. Discarded the flow-through. Wash buffer PE 
(750 µl) was added (containing ethanol) to the cartridge and incubated for 5 min at room 
temperature. Then centrifuged for 1 min at 13,000 rpm. Discarded the flow-through. 
Centrifuged again to remove residual wash buffer. The cartridge was placed into a fresh 1.5 
ml recovery tube and 15 µl of Buffer EB was added directly to the center of the silica-gel-
membrane. After an incubation of 10 min at room temperature the cartridge was centrifuged 
for 1 min at 13,000 rpm. Discarded the cartridge and stored the DNA at -20°C. 
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2.2.1.1.5 Cleaning of DNA fragment 
DNA fragments after PCR amplification and restriction digestion were cleaned using the 
QIAquick PCR purification kit (Qiagen). Five volumes of buffer PB (Binding Solution) was 
added to 1 volume of amplification reaction. The sample mix was applied to the cartridge 
placed in a 2.0 ml wash tube and centrifuged for 1 min at 13.000 rpm. Discarded the flow-
through. Wash Buffer PE (700 µl, containing ethanol) was added to the cartridge and 
centrifuged for 1 min at 13.000 rpm. Discarded the flow-through and centrifuged again to 
remove the residual wash buffer. The cartridge was placed into a new 1.5 ml receiver tube and 
30 µl of Buffer EB was added directly onto the center of the cartridge. After incubation for 10 
min at room temperature the cartridge was centrifuged for 1 min at 13.000 rpm. Discarded the 
cartridge and stored the cleaned DNA at -20°C. 
2.2.1.1.6 Precipitation of Sequencing PCR DNA 
Sequencing PCR product was precipitated with sodium acetate and 100% ethanol. Briefly, to 
80 µl H2O added 10 µl of 3 M sodium acetate. To this 20 µl of sequencing PCR reaction 
mixture was added and mixed thoroughly. Then added 250 µl of chilled 100% ethanol and 
incubated on ice for 5 min. Centrifuged for 15 min at 14,000 rpm. Supernatant discarded and 
pellet resuspended in 300 µl of 70% ethanol. Centrifuged again for 15 min at 14,000 rpm. 
Discarded the supernatant carefully and allowed the pellet to air-dry or at 37°C. DNA sample 
prepared for Sequencer (ABI PRISMTM 310 Genetic Analyzer). DNA pellet was then 
resuspended in 25 µl of Template Suppression Reagent (TSR) buffer (ABI PRISM, Applied 
Biosystems Division, Foster City, CA, USA). Vortexed and centrifuged briefly. Sample 
denatured for 2 min at 95°C and then kept on ice for 2 min. Reaction mixture then transferred 
to the small 0.5 ml sequencing tube (without lid) and capped with rubber stopper suitable for 
the capillary in the sequencing machine. 
2.2.1.1.7 Quantification of Nucleic acids  
Quantity of Isolated DNA and RNA was measured by the UV absorption ratio 260 nm /280 
nm using an Ultrospec 2000 UV/visible spectrophotometer (Pharmacia Biotech, Freiburg, 
Germany). A 1:10 dilution of sample was prepared and measured in a quartz cuvette (5.00 
mm thickness). Measurement at 260 nm gave the absorption of nucleic acid, at 280 nm the 
protein absorption and 320 nm gave the salt present in the sample. The sample concentration 
was obtained in µg/ ml. A factor of 2 was used to calculate the actual concentration of the 
nucleic acid present in sample in µg/ ml. Absorption ratio of 260 nm/ 280 nm gave the quality 
of the nucleic acid ( ratio > 1.7 considered okay). Quality of the nucleic acid was checked on 
a 1% agarose/TAE gel pre-stained with ethidium bromide (10 mg/ml). 
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2.2.1.2 Molecular cloning techniques 
2.2.1.2.1 Generation of DNA insert by PCR 
To clone a particular DNA fragment into plasmid vector for generating a recombinant 
plasmid, PCR was done to amplify the full coding sequence interest from the gene. Cloning 
primers were designed from the sequences available in the Genbank. 30-33 bp long primers 
were designed flanking the 5’ and 3’ region of interest. Care was taken to have similar 
annealing temperature for the primer pair. Suitable restriction enzyme sites were included in 
the primer based on the multiple cloning site (MCS) of the plasmid vector into which the 
fragment was to be cloned. DNA fragment to be cloned was checked for the presence of 
sequence matching the restriction site. Primers were designed in a way to ensure that the right 
amino acid codon frame remained intact in the recombinant plasmid. For cloning the full 
cDNA, stop codon was mutated in the 3’ primer when cloned into a vector with a 3’ detection 
tag. 
The cloning PCR was done using the AccuPrime kit (Invitrogen). The following reaction 
setup was used: 
  cDNA or recombinant plasmid 1-2 µl (~ 200 ng) 
  10 x AccuPrime reaction mix 1 x 
  sense primer    20 pmol 
  antisense primer   20 pmol 
  Pfx DNA Polymerase   1 µl 
  H2O     variable 
         50 µl 
 
The PCR reaction was done using the following programme (for Pfx DNA polymerase): 
Lid temperature:  110°C  
Preheating:   On 
Initial denaturation 95°C   2 min 
Denaturation   94°C   30 sec  35 cycles from this step 
Annealing   variable  30 sec 
Extension   68°C   1 min per kb 
Final extension  68°C   10 min 
pause    4°C 
The total amount of PCR product was loaded on an agarose gel and the fragment with the 
correct size was cut from the gel and purified using the MinElute Gel extraction kit (Qiagen, 
chapter 2.2.1.1.4). Then the cleaned fragment was digested with the appropriate restriction 
enzymes, again purified (QIAquick PCR purification, Qiagen) to remove the digestion buffer 
and finally quantified to calculate the volume needed to set the ligation reaction. 
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2.2.1.2.2 Hydrolysis of DNA with restriction endonucleases 
Restriction digestion of DNA was done with restriction enzyme and its appropriate 10x 
reaction buffer. Recombinant plasmids were cut either with one or two enzymes 
simultaneously. In general, for single digestion appropriate reaction buffer (10x) was used at a 
final concentration of 1x, while for double digestion Y+/Tango buffer (10x) used at a final 
concentration of 2x (see scheme below). 
    Single digestion        Double digestion 
DNA    1-2 µg     2-3 µg 
Enzyme 1 (10 u/µl)  2 µl      2 µl 
Enzyme 2 (10 u/µl)    -      2 µl 
Buffer (10x)   1x      2x 
H2O    variable     variable 
20 µl      30 µl 
Incubation time    1-2 h at 37°C 
For double digestion with SmaI, samples were first digested with smaI at 30°C. After heat 
inactivation of the enzyme the second restriction endonuclease was added plus additional 10x 
buffer and samples were incubated at 37°C. Double digestion with ApaI and BspEI was done 
in separation due to incompatibility of 10x buffers and incubation temperature. Samples were 
first treated with ApaI in NEBuffer 4 plus 1% BSA at 25°C. Then the enzyme was heat 
inactivated and the linearized DNA precipitated with 3 M NaOAc, plus absolute ethanol. The 
pelleted DNA was then resuspended in H2O and digested with BspEI in NEBuffer 3 at 37°C. 
Single digestion with BamHI was always done in 2x Y+/Tango buffer. 
2.2.1.2.3 Formation of blunt ends by fill-in of 5’ overhang  
For subcloning of DNA fragments from one plasmid vector into another, it was sometimes 
necessary to fill-in 5’ overhangs after digestion with a sticky end producing restriction 
enzyme, when the target vector had only a suitable blunt end restriction site. After digestion 
and heat inactivation of the restriction enzyme (sticky ends) 1 µl of each, dNTP mix and T4 
DNA Polymerase were directly added to the digestion mixture and incubated for 20 min at 
25°C. Then the polymerase was heat inactivated and the DNA digested with a second enzyme 
or purified by agarose gel extraction. 
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2.2.1.2.4 Dephosphorylation of digested plasmid  
The restriction enzyme treated plasmid was dephosphorylated with Shrimp Alkaline 
Phosphatase (Boehringer) to remove the phosphate groups from the linear plasmid and avoid 
self-ligation during the ligation process. 
Restriction digested DNA    1-2 µg 
Shrimp Alkaline Phosphatase (1 U/µl)  2 µl  
Dephosphorylation buffer (10x)  3x  
H2O       variable 
   30 µl 
Incubated for 1 h at 37°C followed by 10 min at 65°C for denaturing the enzyme. After 
phosphatase reaction, plasmid vector was purified again to remove the dephosphorylation 
reaction buffer. 
2.2.1.2.5 Ligation of plasmid and DNA insert 
To generate recombinant plasmid, restriction digested plasmid (dephosphorylated, when 5’ 
and 3’ end were similarly cut) was ligated with the DNA insert having the appropriate 
restriction sites at their 5’ and 3’ end using the T4 DNA Ligase (Invitrogen). 
Plasmid vector   15 fmol 
DNA insert   45 fmol 
T4 DNA Ligase (1 u/µl)  2 µl 
5x Ligase buffer   4 µl (1x)  
H2O     variable  
   20 µl  
Ligation was done in T3 Thermocycler (Biometra) at 16°C for 18 h. The ligation mixture was 
then used to transform bacteria to generate recombinant plasmid. 
2.2.1.3 Gel electrophoresis 
2.2.1.3.1 Agarose gel electrophoresis of DNA 
To check the quality of DNA (PCR product, recombinant plasmid DNA, restriction analysis) 
a 1.5% agarose (SIGMA) gel in 1x TAE buffer was made. The gel was pre-stained with 
ethidium bromide (10 mg/ml). DNA samples were prepared in 6x loading buffer (containing 
bromophenol blue dye, MBI Fermentas). Gel was run in 1x TAE for around 30 min at 80 V. 
Depending on the fragment size either GeneRuler 100bp DNA Ladder (1 kb) or GeneRuler 
DNA Ladder Mix (10 kb) was used as standard marker. DNA bands were visualized under 
UV-Transilluminator in an Eagle Eye II video system (Stratagene, Heidelberg, Germany). 
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2.2.1.4 Polymerase Chain Reaction (PCR) 
To check for the expression of genes of interest on RNA level in cell lines used in this study, 
PCR was applied. For non-quantitative analysis of RNA-expression in cells, isolated RNA 
was reverse transcribed using the Omniscript kit and PCR was performed with the Taq Master 
Mix kit (Qiagen). In case of quantitative analysis of RNA-expression in relation to a reference 
gene, Real-time PCR was carried out. Here, cDNA was generated using the iScript kit and the 
Sybr Green kit used to perform PCR (Bio-Rad). 
2.2.1.4.1 Non-quantitative RT-PCR 
To reverse transcribe (RT) the isolated total RNA from cells, 1 µg of total RNA was used to 
make cDNA in a 0.5 µl tube with Omniscript Reverse Transcription kit. RT reaction was set 
as follows: 
RNA       1 µg 
RT Buffer (10x)     2 µl 
dNTP mix (5 mM each)    2 µl 
Oligo-dT primer (0.5 µg/µl)    2 µl 
Omniscript Reverse Transcriptase (4 U/µl)  1 µl 
H2O      variable 
  20 µl 
RT was done in T3 Thermocycler (Biometra). The reaction was incubated for 1 h at 37°C, 
followed by 5 min at 95°C and then rapidly cooled to 4°C. cDNA was stored at -20°C. 
PCR was done with the cDNA generated from the RT step using the Taq Master Mix kit. 
The reaction mixture was pipetted as follows: 
cDNA      1 µl 
Taq Master Mix     25 µl 
5‘ primer (10 pmol/µl)    2 µl 
3‘ primer (10 pmol/µl)    2 µl 
H2O       variable 
  50 µl 
The following programme was applied to do the PCR reaction (for Taq polymerase): 
Lid temperature: 110°C  
Preheating:  On 
Initial denaturation:  98°C   2 min 
Denaturation    94°C   1 min (35 cycles from here) 
Annealing   variable  90 sec 
Extension    72°C   2 min 
Final extension   72°C   10 min 
pause     4°C 
8 µl of the amplification was used for agarose gel electrophoresis to check for the presence of 
the desired gene product. 
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2.2.1.4.2 Real-time PCR 
For analysis of the relative expression of genes of interest in various cell lines (wild type or 
transfected) the Real-time PCR approach was chosen. Total isolated RNA (1 µg) from cells 
was reverse transcribed using the iScript kit. The reaction setup is shown below: 
   RNA      1 µg 
   iScript mix (5x)    1x 
   Reverse Transcriptase   1 µl 
   RNase free H2O    variable 
           20 µl 
The reaction mix was put in the T3 Thermocycler and kept for 5 min at 25°C, then heated to 
42°C for 30 min, followed by a 5 min incubation at 85°C and finally cooled to 4°C. Generated 
cDNA was stored at –20°C. 
PCR was done in 25 µl reaction volume with the generated cDNA (described above) 
applying the following reaction setup: 
   SYBR Green supermix   12.5 µl 
   primer mix     2 µl 
   cDNA      1 µl 
   H2O      9.5 µl 
Samples were put in the iCycler (Bio-Rad) and a gradient programme was run: 
Initial denaturation:  95°C   4 min 30 sec 
Denaturation    94°C   30 sec  
40 cycles Annealing   Gradient  90 sec 
Extension    72°C   1 min 
       95°C  1 min 
       56°C  1 min 
The specificity of amplification was proved by melting curve analysis and agarose gel 
electrophoresis. Relative expression was calculated, using the number of cycles, determined 
from a preset threshold value, referred to the GAPDH cycles. 
2.2.1.4.3 Mutagenesis-PCR 
For site-directed mutagenesis the QuikChange kit (Stratagene) was used to make point 
mutations. Plasmid DNA (100 ng) was used as template. Primer containing the mutated codon 
were designed so that 15 bp were flanking the codon both up- and downstream and the primer 
pairs being complementary to opposite strands of the vector. After annealing of the 
mutagenesis oligonucleotides to the template they were extended by Pfu Turbo DNA 
Polymerase (high fidelity) to generate a mutated plasmid containing staggered nicks. After 
digestion of the parental plasmid DNA by DpnI restriction endonuclease, half of the reaction 
setup was transformed into bacteria. Isolated plasmid DNA (Mini-Prep) was then checked for 
incorporation of the mutation by sequencing. 
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The reaction setup was done following the scheme below: 
   10x Reaction buffer    1x 
   Plasmid DNA     100 ng 
   primer Fw     12.5 pmol 
   primer Rv     12.5 pmol 
   dNTP mix     1 µl 
   H2O      variable 
           50 µl 
   + 1 µl PfU Turbo DNA Polymerase 
Samples were put in the T3 Thermocycler (Biometra) and a specific programme applied: 
Initial denaturation:  98°C   30 sec 
Denaturation    95°C   30 sec 
15 cycles Annealing   55°C   1 min 
Extension    68°C   12 min 
pause     4°C 
Directly after programme was finished, 1 µl of DpnI was added and samples incubated at 
37°C for 1 h. Transformation of the products was done using the KCM method. 
2.2.1.4.4 Sequencing-PCR 
For sequencing reaction, 150-300 ng of recombinant plasmid DNA was used with 2 µl primer 
(10 pmol/µl) and 4 µl Big dye reagent (contained DNA polymerase, fluorescent dye-labeled 
dNTPs, buffer) (Applied Biosystems), diluted with H2O to a final volume of 20 µl. The PCR 
conditions were:  
Initial Denaturation   98°C   2 min 
Denaturation    96°C   30 sec 
25 cycles Annealing    55°C   30 sec 
Extension    60°C   4 min  
+ 25 sec increment/cycle  
pause     4°C  
After PCR, DNA was precipitated and prepared for capillary electrophoresis and analysis 
in the ABI PRISMTM 310 Genetic Analyzer (Applied Biosystems). 
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2.2.1.5 Transformation of bacteria 
2.2.1.5.1 Making of competent cells 
A single colony of XL1-Blue or DH5αF E.coli strain was allowed to grow overnight in 5 ml 
LB media (without antibiotic) at 37°C, shaking at 250 rpm. Then 1 ml of overnight bacterial 
culture was transferred to 150 ml of fresh LB media and allowed to grow till an OD600 of 0.6. 
The cell suspension was then centrifuged for 10 min at 5000 rpm at room temperature. The 
supernatant was discarded and the pellet resuspended in 15 ml (1/10 volume) of TSB buffer. 
After a 10 min incubation of the suspension on ice it was aliquoted to 500 µl each in 
Eppendorf safelock tubes. Tubes were frozen in liquid nitrogen and stored at -80°C. 
2.2.1.5.2 KCM Transformation method 
To transform KCM competent cells using plasmid DNA, 20 µl of KCM buffer was added to 
either 20 µl of ligation mix or 10-20 ng of super-coiled plasmid DNA and diluted with H2O to 
100 µl. Mixed nicely and left on ice. In the mean time the KCM competent cells were put on 
ice for thawing. The transformation reaction was mixed properly with 100 µl of competent 
cells and incubated on ice for 10 min (re-trafo) or 50 min (ligation). Afterwards the mix was 
incubated for 10 min at room temperature (very important). Then 1 ml of SOC media was 
added and incubated for 1 h at 37°C with shaking at 300 rpm. Thereafter, the complete 
transformation mixture was pelleted for transformation of ligation reaction and plated on LB-
agar containing suitable antibiotic. The plates were incubated up-side down at 37°C overnight 
to allow for growth of transformants. For retrafo and subsequent plasmid Midi preparation, 50 
ml of LB media + antibiotic was inoculated with the transformation mixture. 
2.2.2 Methods in Cell Biology 
2.2.2.1 Cell culture 
The medium used for culturing of cells was sterile and ready-to-use (Biochrom). Thawing of 
cells (HEK293, 1321N1): frozen cells were rapidly thawed in 37°C water bath and the cryo-
preserved cell suspension + 9 ml of complete cell culture medium were centrifuged at 200 g 
for 3 min at room temperature. The cell pellet was resuspended in complete medium and 
seeded on a tissue culture dish (10 cm) (Nunc, Denmark). HEK293 (Human embryonic 
kidney, epithelial) cells were cultured in DMEM (Dulbecco minimum essential medium) / 
HAM’S F12 (1:1) with 2 mM Glutamine, 10% FCS (fetal calf serum), 100 U/ml Penicillin 
and 100 µg/ml Streptomycin (Biochrom) in a Function line incubator (Heraeus) with 
humidified atmosphere of 95% air, 5% CO2 at 37°C.  
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1321N1 astrocytoma cells were cultured in DMEM containing 3.7 g/L NaHCO3, 4.5 g/L 
D-glucose, 1.028 g/L N-Acetyl L-alanyl-L-glutamine and 5% FCS, 100 U/ml Penicillin, 100 
µg/ml Streptomycin in a Nuaire incubator (Zapf Instruments) with humidified atmosphere of 
90% air, 10% CO2 at 37°C. Culture medium was changed every 2-3 days.  
For cell passage, HEK293 cells were detached from the culture dish with Trypsin/EDTA 
(Biochrom) for 5 min at room temperature after aspirating the medium. For 1321N1 cells, the 
cells were first washed twice with HBSS or PBS and then incubated in the cell incubator with 
Trypsin/EDTA 1 ml per 10 cm dish for 1 min at 37°C. Cells were centrifuged at 200 g for 3 
min, resuspended in medium and seeded 1:20 in fresh complete medium. 
2.2.2.2 Freezing of cells 
Cells were frozen in DMSO for long storage. Briefly, cells grown in 10 cm culture dish were 
frozen in 3 cryo tubes (Nunc). To each cryo tube 100 µl DMSO (sterile) was added. Already 
detached, centrifuged and resuspended cells (900 µl) were added and fastly mixed with 
DMSO in the cryo tube and immediately stored at -20°C for 24 h. Then shifted to -80°C and 
soon after to liquid nitrogen for long storage. 
2.2.2.3 Transfection of cells 
2.2.2.3.1 DOTAP Lipofection 
HEK293 cells were stably transfected with the P2Y1GFPN1 or P2Y11GFPN1 constructs using 
the Liposomal transfection reagent DOTAP (Roche Diagnostic). Plasmid DNA was isolated 
using the HiSpeed Midi kit (Qiagen) to obtain DNA of best quality. Cells were grown 50-70% 
confluent for 2-3 days. The transfection mix was prepared using 5 µg of plasmid DNA made 
to 50 µl with 20 mM HEPES in a siliconized reaction tube. In another tube, 30 µl DOTAP 
was mixed with 70 µl of 20 mM HEPES. After a 5 min incubation both solutions were mixed 
nicely and incubated for 30 min at room temperature. Meanwhile, the medium of the cells 
was aspirated and replaced by serum- and antibiotic-free medium. After 30 min, the 
transfection mixture was given drop wise onto the cells. Cells were incubated in the 
transfection media for 8 h and then replaced by full medium containing serum (FCS) and 
antibiotics. 24-48 h after transfection cells were visualized under the fluorescent microscope 
to check for expression of fusion protein containing the GFP tag (green fluorescent protein). 
For stable transfection G418 Sulphate antibiotic (kanamycin and neomycin derivative) was 
added after 48 h at a rate of 500 µg/ml (stock: 500 mg/ml). 
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2.2.2.3.2 Fugene 6 Lipofection 
1321N1 astrocytoma cells were transfected with various plasmids using the Fugene 6 
transfection reagent. This is a multi-component lipid-based reagent that complexes with DNA 
and enables high transfection efficiency. Cells were seeded at a density of 100.000 cells/ 35 
mm
2
 a day prior to transfection. Before preparation of the transfection mix, the normal growth 
medium of the cells was replaced by serum- and antibiotic free medium. The Fugene 6 
reagent (3µl) was added to serum-free medium to make a volume of 100 µl in a siliconized 
reaction tube. To this mixture 2 µg of plasmid DNA was added (Fugene 6 : DNA ratio = 3:2), 
mixed properly and incubated for 30 min at room temperature. The complex mixture was then 
added drop wise to the cells and they were incubated for 8 h in the transfection medium. Then 
transfected cells were changed to normal growth medium. After 24-48 h cells were checked 
for positive transfection or further used for experiments. For stable transfection G418 
Sulphate antibiotic (kanamycin and neomycin derivative) was added after 24-48 h at a rate of 
500 µg/ml (stock: 500 mg/ml). 
2.2.2.3.3 Magnet assisted transfection 
For transient expression of proteins in HEK293 cells and siRNA transfection for gene 
silencing the Magnet assisted transfection (MATra) method was applied. Cells were prepared 
as described above (2.2.2.3.1). 5 µg of plasmid DNA (for double transfection: 2.5 µg of each 
plasmid) or 20µl of a 100 µM siRNA stock solution was diluted with 400 µl of serum-free 
medium. Then 6.6 µl of magneto beads suspension (MATra A solution) was added and mixed 
carefully by pipetting and gently tapping the siliconized reaction tube. The mixture was 
incubated for 20 min at room temperature and then applied to the cell culture dish. Culture 
dishes were put on a magnet plate (placed in the incubator) and incubated for 15 min at 37°C. 
Then transfection medium was replaced by full growth medium and cells put back in the 
incubator. Experiments were done 48 h post-transfection. 
2.2.2.3.4 Selection of stably transfected cell clones 
Stably transfected cell clones were separated from non-transfected, G418 resistant cell clones 
by flow cytometry. Cells transfected with fusion proteins containing a GFP tag were sorted 
with a FACS diva cells sorter (Becton Dickinson, equipped with a 488 nm laser) 3-4 days 
post-transfection. Positive clones were collected and depending on the number of cells seeded 
in an appropriate dish. Quality of the clones was checked with a fluorescent microscope and 
after two passages, part of the cells were frozen for long-time storage in liquid nitrogen. 
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2.2.3 Methods in Protein chemistry 
2.2.3.1 Whole Cell lysate 
To make whole cell lysate, 80% confluent cells (6 cm dish) were washed 2x with ice-cold 
PBS and lysed in 0.5 ml of RIPA buffer during a 10 min incubation on ice. Cell debris was 
collected in 1.5 ml tubes using a cell scraper. The cell lysate was gently mixed on a rotator for 
15 min at 4°C. The lysate was then sonicated on ice in an Ultrasonificator for 3 x 10 sec (40% 
power). Afterwards centrifuged at 14,000 x g for 15 min at 4°C. The supernatant was 
transferred into a fresh tube and pellet discarded. Protein concentration was determined by 
Bradford method using 1% bovine serum albumin as standard. Lysate stored at -20°C. 
2.2.3.2 Subfractionation of cells (cell membrane preparation) 
Confluent cells (10 cm dish) were washed twice with 3 ml ice-cold PBS and incubated in 1 ml 
of hypotonic buffer pH 8.1 for 10 min on ice. Then cells were scraped from the dish and the 
lysate sonicated for 5 x 1 sec (40% power). Thereafter, the lysate was centrifuged at 1000 x g 
for 5 min in a 4°C cold centrifuge. Supernatant was saved and the pellet, containing nuclei 
and mitochondria, discarded. The collected supernatant was centrifuged again at 50,000 x g 
for 30 min at 4°C. The resulting supernatant contained the cytosolic fraction and the pellet 
plasma membrane, endoplasmic reticulum and microsomes. The cytosolic fraction was 
transferred to a fresh tube and the pellet resuspended in 250 µl of hypotonic buffer. Fractions 
were subjected to protein estimation and stored at –20°C. 
2.2.3.3 Co-Pulldown 
Lysates (containing GST fusion proteins) were diluted with RIPA-buffer to a final protein 
concentration of 500 µg/ml in a predefined end volume (500-800 µl). Then 20 µl of a pre-
equilibrated GSH-bead suspension (50%) (Glutathion Sepharose) was added and incubated 
overnight on a rocker (15 rpm) at 4°C. Next day, the beads were washed 2x with RIPA-buffer 
after centrifugation for 5 min at 500 rpm in a pre-cooled centrifuge. After a further washing 
step beads were centrifuged at 13.000 rpm for 5 min to destroy bead structure and allow for 
total removal of the supernatant. Then 15 µl of 2x Laemmli sample buffer was added to 
denature adherent proteins and prepare for loading on a SDS-PAGE. 
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2.2.3.4 Co-Immunoprecipitation 
Lysates (containing myc fusion proteins) were diluted with RIPA-buffer to a final protein 
concentration of 250 µg/ml in a predefined end volume (500-800 µl). Then 1.5 µg of anti-myc 
antibody (mouse monoclonal, Invitrogen) was added and incubated with the lysate overnight 
on a rocker (15 rpm) at 4°C. Next morning, 20µl of Protein A/G Plus Agarose suspension was 
added and lysates were again incubated for at least 2 hours at 4°C. Thereafter, the beads were 
washed 2x with RIPA-buffer after centrifugation for 5 min at 2000 rpm in a pre-cooled 
centrifuge. After a further washing step beads were centrifuged at 13.000 rpm for 5 min to 
destroy bead structure and allow for total removal of the supernatant. Then 15 µl of 2x 
Laemmli sample buffer was added to denature adherent proteins and prepare for loading on a 
SDS-PAGE 
2.2.3.5 SDS PAGE (Laemmli) Gel preparation  
(for 2 gels with 1 mm thickness and 8 cm width) 
Components 10% Resolving gel  
(ml)  
4% Stacking gel 
(ml) 
60% acrylamide/Bis 2.0 0.335 
Resolving gel buffer 6.0 - 
Stacking gel buffer - 2.5 
H2O 3.8 2.065 
10% SDS solution 0.12 0.05 
1x PER solution 0.06 0.04 
TEMED  0.024 0.01 
Bromophenol blue - 0.002 
2.2.3.6 SDS-PAGE and immunoblotting 
Defined amounts of cell lysates were precipitated (directly loaded on the gel, if protein 
concentration sufficient) using Methanol/Aceton 1:1 in 4-fold excess and then denatured in 1x 
Laemmli sample buffer. For immunoprecipitation or co-pulldown, beads were washed and 
denatured in 2x sample buffer. Protein samples were denatured without boiling but incubation 
at 4°C overnight or 15 min at room temperature in sample buffer. The gel-electrophoretic 
resolution of the proteins was done in a Vertical-Minigel apparatus (Bio-Rad) using 10% 
SDS-PAGE. Proteins were transferred to nitrocellulose membrane (Protran BA79, 0.2 µm) 
using a semi-dry transfer system (Bio-Rad) at constant voltage (10 V) and 200 mA current for 
60 min. Successful transfer was checked, visualizing the protein bands on the membrane by 
0.2% Ponceau S staining.  
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The membrane was blocked in 5% non-fat dry milk (made in PBS-Tween, 0.1%) 
overnight at 4°C. Depending on the antibody used for specific detection of protein bands, 
membrane was incubated at room temperature for 1 h or at 4°C overnight. Then the 
membrane was washed three times with PBS-Tween 0.1% and incubated with secondary 
antibody (peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG; Dianova) for 1 h at room 
temperature. The membrane was again washed as described before and then incubated with 
ECL reagent (Supersignal West Pico kit, Pierce). Chemiluminescence signals were detected 
on chemiluminescence film (Hyperfilm ECL, GEHealthcare) after developing. 
2.2.3.7 Stripping of membrane for reprobing 
To reprobe the membrane with a second primary antibody this procedure was followed: ECL 
reagent was washed out by washing for around half an hour in PBS-Tween (0.1%). Then the 
membrane was incubated in stripping buffer for 30 min at 55°C. Afterwards, the membrane 
was first washed extensively in H2O and then in PBS-Tween to remove β-mercaptoethanol. 
The blocking procedure was repeated and then the membrane was reprobed with another 
primary antibody as described above. 
2.2.3.8 Immunocytochemistry 
Cells (wild-type or transfected) cultured on 22 mm coverglasses or in glass bottom dishes 
(MatTek, Ashland MA, USA) were fixed in 4% paraformaldehyde for 20 min at room 
temperature, then washed and stored in 120 mM Sodiumphosphate solution. Fixed cells were 
blocked and permeabilised in FSBB buffer for 20 min. Then incubated in mouse monoclonal 
anti-myc 0.8 µg/µl (Invitrogen) overnight at 4°C. The cells were washed 3x 10 min in High 
salt buffer. Then secondary antibodies were applied (Alexa IgG Goat-anti-mouse A555-1:200; 
Molecular Probes) for 2 h at room temperature. The washing step was repeated 1x in High 
salt buffer and further washing was done 1x with 120 mM Sodiumphosphate solution and 3x 
with 5 mM Sodiumphosphate solution. Cells were mounted in Vectashield mounting media 
(Axxora, Grünberg, Germany) and visualized with a LSM510 Confocal laser scanning 
microscope (Carl Zeiss).  
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2.2.3.9 cAMP-EIA 
HEK293 cells stably expressing the P2Y11GFP receptor were seeded in a 6-well plate at a 
density of 100.000 cells/ well and grown for 2 days till 80% confluency. Prior to stimulation 
the medium was aspirated and replaced by NaHBS buffer containing 0.5 M IBMX (isobutyl-
methyl-xanthine). Cells were incubated in this buffer for 30 min at 37°C either with or 
without P2Y receptor antagonists. Then cells were stimulated with various agonists for 10 
min. After stimulation, the buffer was aspirated and cells were lysed with 0.1 M HCL. Cells 
were scraped from the dish and collected in a 1.5 ml safelock reaction tube. A 100 µl aliquot 
was kept for later protein estimation. The rest of the tube was centrifuged at 1000 x g for 10 
min and supernatant transferred into a fresh tube.  
Determination of intracellular cAMP was done using the Direct cAMP EIA kit (assay 
designs). The appropriate amount of EIA strips coated with goat anti-rabbit IgG was placed in 
a suitable rack. In all wells 50 µl of neutralizing reagent was pipetted. Then 100 µl standards 
or samples were pipetted in the appropriate wells (for determination of nonspecific binding 
(NSB) and maximal binding, 100 µl of 0.1 M HCL was pipetted in the appr. wells). To that 
came 50 µl of alkaline phosphatase solution conjugated with cAMP as tracer plus 50 µl of a 
rabbit polyclonal antibody directed against cAMP (except NSB wells). After an incubation of 
2 h with shaking at 500 rpm the plate was washed 3x with wash buffer. Then 200 µl of p-
nitrophenyl phosphate as enzyme substrate was added and incubated in the dark for 1 h. At 
the end 50 µl stop solution (Na3PO4) was added and the optical density was read at 405 nm 
with correction at 595 nm. The cAMP concentration (pmol/ml) was calculated by 
interpolating the percentage of bound tracer for each sample on the simultaneously 
determined standard curve. The resulting values were normalized to the protein concentration 
of each sample, so that results were expressed as pmol cAMP/ mg protein. At last, results for 
all stimulated samples were normalized to unstimulated control, expressed as n-fold 
stimulation. 
2.2.4 [Ca2+]i measurements 
The cells were plated on coverslips (diameter = 22 mm), and single cell measurement was 
done after 3 days, when the cells were 30-50% confluent. The changes of free intracellular 
Ca2+ concentration ([Ca2+]i) were measured, as described before (Ubl et al., 1998).  
Materials and Methods 
 47
Briefly, cells were preincubated with 2 µM fura-2AM at 37°C for 30 min in NaHBS (for 
1321N1 cells 0.02% Pluronic acid was added for better solubility of fura-2AM) and then 
stimulated under continuous superfusion of pre-warmed NaHBS at 370C with different 
concentrations of various agonists. Fluorescence intensity was recorded alternatively at 340 
and 380 nm excitation and 520 nm emission. Changes were monitored in single cells bathed 
in a perfusion chamber which was placed on the microscope stage of a fluorescence imaging 
system from TILL Photonics with a X40/ 1.30 oil immersion objective and a flow rate of 1 
ml/min (Vöhringer et al., 2000).  
Calcium data were analyzed with the Excel program applying basal deduction to the 
calcium traces and calculating the peak height (Rmax) for each cell. Concentration-response 
data obtained with average values from 40 to 70 single cells were further analyzed to derive 
EC50 values (half-maximal response) using the SigmaPlot program (Jandel). Calculation of 
the EC50 values and curve fitting was performed using the following equation with a standard 
slope: ( )xEC
RR
Ry
−+
−
+=
50log
minmax
min
101
. If the free curve fit extended beyond the experimental data 
the maximal response (Rmax) was adjusted to the experimentally obtained plateau value for the 
other experiments. 
2.2.5 Confocal imaging 
All images were taken on a Zeiss inverted LSM 510 META laser scanning confocal 
microscope. 
2.2.5.1 Immunocytochemistry 
1321N1 cells transiently co-transfected with P2Y11GFP and P2Y1mycHis and stained with 
anti-myc antibody and Alexa Fluor 555 IgG Goat-anti-mouse as secondary antibody were 
visualized using a Plan-Apochromat x63 objective. The GFP-tag was excited with a 488-nm 
argon/krypton laser and fluorescence detected using a 505-530 nm band pass filter. The Alexa 
Fluor 555 was detected using a 543-nm helium/neon laser for excitation and a 560-nm long-
pass filter. Ten sections 0.5 µm apart along the Z-axis were taken from the bottom to the top 
of each cell. Images were processed using the Zeiss confocal microscopy software (LSM 
Image examiner). Sections were projected onto XZ- and YZ-plane images using the Ortho 
option of the software.  
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2.2.5.2 Agonist-induced internalization 
HEK293 cells stably expressing the P2Y11GFP receptor were seeded on coverslips (30 mm 
diameter) precoated with 0.01% PLL and grown for 3 days till 40-50% confluency. Cells 
were then placed in a POC-chamber (PeCon GmbH, Erbach, Germany) and incubated on 
stage in a chamber of 5% CO2 at 37°C in complete culture medium. Images were taken using 
a Plan-Apochromat x63 objective, a 488-nm argon/krypton laser and a 505 nm long pass 
filter. Thirteen to fifteen sections 1 µm apart were taken serially every ten minutes from the 
bottom to the top of each cell after stimulation. Cells were stimulated with various agonists 
and live-imaging was done for 90 minutes. 
2.2.5.3 Analysis of fluorescence intensities 
Fluorescence intensities of confocal images were analyzed using the Zeiss LSM 510meta 
software histo macro. Region of interests (ellipse 30-39 µm2) were set in the cytosol of single 
cells and the average fluorescence intensity in the ROI determined over time (0 min, 10 min, 
30 min, 60 min). The intensity values for 10-60 min were normalized to the starting value at 0 
min which was set to be 1. 
2.2.6 Flow cytometry 
The expression levels of wild type and mutant receptors in 1321N1 cells were analyzed by 
flow cytometry using a FACS LSR (BD Biosciences, Heidelberg). Cells were grown in 5 cm 
culture dishes (Nunc, Wiesbaden) to 80 % confluency, harvested and resuspended in culture 
medium. The expression levels of 10.000 cells were analyzed by determining the intensity of 
the GFP fluorescence per cell using the Flow Jo software. 
2.2.7 Data analysis 
Statistical analysis of the data was done using Graph pad prism. First data were checked for 
Gaussian distribution. In the case of Gaussian distributed data, further analysis was done 
using the one-way ANOVA test and the Tukey test as a post test. For non-Gaussian 
distributed data the Kruskal-Wallis test was applied using the Dunns test as a post test. 
Significant difference appeared at a P value < 0.05. 
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3 RESULTS 
3.1 Diastereoselectivity of the P2Y11 receptor: Pα substituted ATP 
analogues 
3.1.1 Heterologous expression of the P2Y11GFP receptor in 1321N1 cells 
To express the P2Y11 receptor as a GFP construct in 1321N1 astrocytoma cells, the DNA 
sequence of the receptor was cloned between the EcoRI and BamHI restriction sites of the 
eGFPN1 expression vector. The DNA of the human P2Y11 receptor (GenBankTM/EBI 
accession number AF030335) was kindly provided by Dr. Communi. The P2Y11GFP receptor 
construct was used to transfect 1321N1 astrocytoma cells. The 1321N1 astrocytoma cell line 
lacks endogenously expressed P2Y receptors (Lazarowski et al., 1995; Gendron et al., 2003), 
which was also confirmed by us for the currently used cell batch. By RT-PCR the mRNA 
expression level of P2X and P2Y receptors in the cells was investigated. We detected signals 
for the P2Y6, P2Y11, P2X4 and P2X7 receptor mRNA (Fig. 6A). However, wild type cells as 
well as mock-transfected 1321N1 cells did not display any significant Ca2+ responses when 
challenged with 100 µM UDP or ATP. The wild type cells responded only sporadically (5 out 
of 53 cells) to 100 µM ADP (Fig. 6B). This confirmed the lack of functionally expressed P2 
receptors in the 1321N1 cell batch used in this study. 
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Figure 6:  Non-functional expression of P2X and P2Y receptors in wild type 1321N1 cells 
[A] Agarose gel resolved RT-PCR products generated from cDNA of 1321N1 wild type cells. Signals were 
detected for the P2Y6 (409 bp), P2Y11 (809 bp), P2X4 (420 bp), P2X7 (532 bp) receptors and GAPDH (600 
bp). [B] Calcium traces of wild type 1321N1 cells stimulated with 100 µM ADP (black bar). Displayed are 
5 out of 53 cells that significantly responded with an increase in intracellular calcium, detected with fura-2 
calcium indicator. 
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The well characterized batch of 1321N1 cells was then transfected with the GFP-tagged 
human P2Y11 receptor. The protein expression was verified by western blot analysis of 
cytosol and membrane fractions from stably transfected cells (Fig. 7). To demonstrate 
functional expression of the P2Y11-GFP receptor in stably transfected cells, various agonists 
were tested for their ability to induce an intracellular [Ca2+]i increase. The cells were 
monitored for the change in fluorescence intensity of the calcium indicator fura-2 after agonist 
stimulation, as described in the methods section. The obtained EC50 values ± s.e.m (n = 3-4, 
as indicated) for ATPγS, BzATP, ATP and 2-MeS-ATP were 1.3±0.3 µM (4), 1.5±0.3 µM 
(3), 3.0±0.87 µM (4) and 13.8±5.58 µM (3), respectively. The order of potency was found to 
be ATPγS = BzATP > ATP > 2-MeS-ATP, which is similar to previously reported findings 
(Communi et al., 1999).  
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Figure 7:  Western blot detection of the P2Y11GFP receptor in stably transfected 1321N1 cells 
Cell lysates of wild type and transfected cells were subfractionated and resolved on SDS-PAGE. After 
immunoblotting, protein expression was checked using an anti-GFP antibody (dilution 1:1000), as 
described in the methods section. The blot displays the cytosol fractions (1, 3 and 5) as well as the 
membrane fractions (2, 4 and 6) of differently transfected 1321N1 cells. (1) Cytosolic and (2) membrane 
fraction of untransfected 1321N1 cells. (3) Cytosolic and (4) membrane fraction of mock-transfected 
1321N1 cells (eGFP ~27 kD). (5) Cytosolic and (6) membrane fraction of P2Y11GFP (~ 69 kD) transfected 
1321N1 cells. 
3.1.2 Calcium measurements with pairs of different ATP diastereoisomers 
3.1.2.1 Adenosine-5’-O-(α-boranotriphosphate) diastereoisomers 
To characterize the diastereoselectivity of the stably expressed P2Y11 receptor in 1321N1 
cells, several borano-modified diastereoisomers of ATP were tested by analyzing the calcium 
responses (described in methods section). These ATP analogues had been chosen, as they 
exhibited a stereoselective activation of the P2Y1 receptor (Nahum et al., 2002).  
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The diastereoisomers show substitution of one of the non-bridging oxygen atoms of Pα by 
borane. Thereby, a new chiral centre in the ATP molecule is introduced. The absolute 
configuration around the Pα was assigned to the resulting diastereoisomers, and the Rp 
configuration was attributed to the (A) isomers and the Sp configuration to the (B) isomers of 
the borano-modified analogues (Major et al., 2004).  
All the different ATP-α-B diastereoisomeric pairs (ATP-α-B (A/B), 2-MeS-ATP-α-B 
(A/B), 2-Cl-ATP-α-B (A/B)) displayed the same stereoselective preference in activating the 
P2Y11 receptor. The concentration response curves obtained for the different ATP-α-B 
derivatives and the parent compounds are displayed in Fig. 8, A-C. The corresponding (A) 
and (B) isomers of the ATP-α-B derivatives exhibited a clear difference in potency for 
elevation of intracellular calcium. All (B) isomers were found to be more potent than the (A) 
isomers, ranging from 3- to 10-fold, as seen by the EC50 values in Table 3 (page 56).  
The (B) isomer of ATP-α-B (EC50 = 340±53.0 nM) displayed a 7-fold higher potency 
than ATP (EC50 = 2.83±0.82 µM) and its corresponding (A) isomer (EC50 = 2.38±0.56 µM) 
was equipotent with ATP (Fig. 8A). The tendency that the (B) isomers are preferred by the 
P2Y11 receptor was the same for all the other ATP-α-B derivatives tested. The (B) isomer of 
2-MeS-ATP-α-B was the most potent ligand of all compounds tested in this study with an 
EC50 value of 260±33.0 nM. The corresponding (A) isomer (EC50 = 1.35±0.52 µM) was 5-
fold less potent, but displayed a much higher potency than 2-MeS-ATP (EC50 = 13.8±5.58 
µM). The difference in potency was one order of magnitude (Fig. 8B). 
The 2-Cl-substitution had a negative influence on the potency of ATP-α-B at the P2Y11 
receptor. The (A) isomer of 2-Cl-ATP-α-B (EC50 = 4.19±3.41 µM) displayed the lowest 
potency of all the diastereoisomers used in this study. Only the (B) isomer (EC50 = 467±246 
nM) showed a potency that was comparable to that of the other α-borano (B) isomers. The 
parent compound 2-Cl-ATP, where the phosphate moiety was left unchanged, was too weak 
an agonist at the P2Y11 receptor to determine a complete concentration response curve using 
single cell calcium measurements. At a concentration of 100 µM only 60% of the maximal 
ATP response were obtained. Therefore, in Fig. 8C the concentration-effect curve of ATP is 
displayed for comparison as well as the incomplete curve for 2-Cl-ATP (EC50 > 30 µM). 
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Figure 8: Concentration-response curves for ATP-α-B analogues and parent compounds at the 
P2Y11 receptor 
1321N1 cells stably expressing the P2Y11 receptor GFP fusion protein, preincubated with 2 µM fura-2-AM, 
were stimulated with varying concentrations of agonists and the change in fluorescence (∆F340nm/F380nm) was 
detected. Data represent the mean values and standard error from 40 to 70 single cells and were obtained in 
at least three separate experiments. [A]: Curves for 2-unsubstituted ATP-α-B diastereoisomers. [B]: Data 
obtained with the 2-MeS-ATP-α-B isomers. The maxima of the curve for the (A) isomer and the parent 
compound have been fixed as described in methods. [C]: Curves for 2-Cl-ATP-α-B diastereoisomers. The 
ATP curve is shown for comparison as well as the incomplete curve for 2-Cl-ATP. The maxima of the 
curve for both isomers have been fixed as described in methods. 
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The action of the ATP-α-B diastereoisomers at the P2Y11 receptor presented here stands in 
contrast to the diastereoselectivity at the P2Y1 receptor, as seen previously by us. At the P2Y1 
receptor the (A) isomers were more potent than the (B) isomers in inducing a calcium 
response (Nahum et al., 2002) or in causing receptor endocytosis (Tulapurkar et al., 2004). 
For comparison, the EC50 values for the ATP-α-B derivatives at the P2Y1 receptor are also 
included in Table 3. However, it should be noted that in that study the P2Y1 receptor was 
heterologously expressed in HEK293 cells. For a better and more valid comparison, the action 
of 2-Cl-ATP-α-B isomers at the P2Y1-GFP receptor protein stably expressed in 1321N1 cells 
was additionally investigated (Fig. 9). It was not possible to carry out a complete investigation 
of the potencies of all ligands used in this study, as the amount of compounds was not 
sufficient. The stereoselectivity of the 2-Cl-ATP-α-B diastereoisomers at the P2Y1 receptor 
was conserved, whether the receptor was expressed in 1321N1 cells or in HEK293 cells. 
Thus, the diastereoselectivity is independent of the receptor expression system used. The (A) 
isomer displayed a higher potency (EC50 = 20±5.0 nM, n=3) than the (B) isomer (EC50 = 
649±51.7 nM, n=3). Moreover, the difference in potency of the (A) isomer at the P2Y1 
receptor compared to the potency at the P2Y11 receptor is striking.  
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Figure 9: Concentration-response curves for 2-Cl-ATP-α-B analogues at the P2Y1 receptor 
Concentration-response curves obtained with 1321N1 cells stably expressing the P2Y1 receptor GFP fusion 
protein for 2-Cl-ATP-α-B isomers in inducing intracellular [Ca2+]i rise. The maximum of the curve for the 
(B) isomer has been fixed as described in methods. Cells preincubated with 2 µM fura-2-AM were 
stimulated with varying concentrations of agonist and the change in fluorescence (∆F340nm/F380nm) was 
detected. Data represent the mean values and standard error from 40 to 70 single cells and were obtained in 
at least three separate experiments.  
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3.1.3 Adenosine-5’-O-(α-thiotriphosphate) diastereoisomers 
The action of adenosine 5’-O-(1-thiotriphosphate) derivatives (ATP-α-S) at the P2Y11 
receptor was also investigated. The diastereoisomers show substitution of one of the non-
bridging oxygen atoms of Pα by sulphur. Again, a new chiral centre in the ATP molecule is 
introduced. The absolute configuration around the Pα was assigned to the resulting 
diastereoisomers, and the Sp configuration was attributed to the (A) isomers and the Rp 
configuration to the (B) isomers of the thio-modified analogues. The difference in assignment 
for the borane-/sulphur modified isomers is due to the group priorities around Pα, which are 
opposite for the ATP-α-B and ATP-α-S derivatives. Sulphur is of higher priority in the 
chemical nomenclature compared to oxygen, and borane is of lower priority than oxygen. 
The concentration-response curves for each ATP-α-S diastereoisomeric pair are presented 
in Fig. 10, in comparison to the respective parent compound, which has an unchanged 
phosphate moiety. The two different pairs (ATP-α-S (A/B) and 2-MeS-ATP-α-S (A/B)) 
displayed the same diastereoselective activity at the P2Y11 receptor as the ATP-α-B 
derivatives. The (B) isomers were found to be more potent than the (A) isomers, as shown by 
the summary of the resulting EC50 values in Table 3 (page 56). However, the difference 
between these diastereoisomers was not as pronounced as with the α-borano substituted ATP 
analogues. 
The (B) isomer of ATP-α-S (EC50 = 270±64.0 nM) was found to be the most potent of the 
α-sulfur substituted compounds tested, whereas the corresponding (A) isomer with an EC50 
value of 1.71±0.55 µM displayed a 6-fold lower potency (Fig. 10A). However, both 
substances had a higher potency at the P2Y11 receptor than ATP itself. The (B) isomer of 2-
MeS-ATP-α-S (EC50 = 640±128 nM) showed only a 4-fold increase in potency, compared to 
its corresponding (A) isomer (EC50 = 2.64±1.10 µM) but was found to be 20-fold more potent 
than the parent compound, 2-MeS-ATP (EC50 = 13.8±5.58 µM) (Fig. 10B). Nevertheless, the 
maxima of the concentration effect curves for both isomers were considerably lower than the 
other agonist-evoked maxima, which makes a definite comparison of the EC50 values rather 
difficult. 
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Figure 10: Concentration-response curves for ATP-α-S analogues and parent compounds at the 
P2Y11 receptor 
1321N1 cells stably expressing the P2Y11 receptor GFP fusion protein, preincubated with 2 µM fura-2, were 
stimulated with varying concentrations of agonists and the change in fluorescence (∆F340nm/F380nm) was 
detected. Data represent the mean values and standard error from 40 to 70 single cells and were obtained in 
at least three separate experiments. [A]: Curves for 2-unsubstituted ATP-α-S diastereoisomers. The 
maximum of the curve for the (A) isomer has been fixed as described in methods. [B]: Curves for 2-MeS-
ATP-α-S diastereoisomers. The maximum of the 2-MeS-ATP curve has been fixed as described in 
methods. 
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Importantly, the stereoselective activity at the P2Y11 receptor is again in contrast to the 
activity of the α-thio-modified compounds at the P2Y1 receptor. The P2Y1 receptor was found 
to prefer the (A) over the (B) isomers of these substances (Major et al., 2004). The EC50 
values for the ATP-α-S derivatives at the P2Y1 receptor are also included in Table 3. Again, 
in that study the P2Y1 receptor was stably expressed in HEK293 cells. Therefore, we also 
investigated the action of ATP-α-S diastereoisomers at the P2Y1GFP receptor stably 
expressed in 1321N1 cells. Like for the 2-Cl-ATP-α-B isomers, we obtained similar results 
with 1321N1 cells as with HEK293 cells concerning the stereoselective preference. The (A) 
isomer (EC50 = 21.9±10.1 nM, n=6) of ATP-α-S was more potent than the (B) isomer (EC50 = 
108±14.7 nM, n=5). 
Table 3: Potencies of ATP-α-B analogues and ATP-α-S analogues, respectively, and the parent 
compounds at P2Y11 and P2Y1 receptor for [Ca2+]i rise. Data are expressed as EC50 values ± s.e.m. (µM). 
They represent the mean and standard error and were obtained from at least three separate experiments (n = 
3-6, as indicated) with 40 to 70 single cells per concentration of agonist investigated. *For the GFP-tagged 
P2Y1 receptor data are from previous analysis (see reference (Nahum et al., 2002; Major et al., 2004)), 
where the receptor was analyzed similarly stably expressed in HEK293 cells. 
 Nucleotide Isomer Absolute 
configuration Receptor 
   P2Y11 * P2Y1 
 
  
Potency  
(EC50 value; µM) 
ATP   2.83±0.82  (4) 0.20±0.04     (4) 
2-MeS-ATP   13.8±5.58  (3) 0.001±0.001 (3) 
2-Cl-ATP   >30 µM  n.d. 
Pα-borano analogues 
A Rp 2.38±0.56  (6) 0.12±0.02     (3) ATP-α-B 
B Sp 0.34±0.05  (6) 1.20±0.18     (3) 
A Rp 1.35±0.52  (3) 0.002±0.001 (3) 2-MeS-ATP-α-B 
B Sp 0.26±0.03  (4) 0.06±0.01     (3) 
A Rp 4.19±3.41  (3) 0.004±0.002 (3) 
2-Cl-ATP-α-B 
B Sp 0.47±0.25  (3) 0.04±0.01     (3) 
Pα-thio analogues 
A Sp 1.71±0.55  (4) 0.009±0.002 (3) ATP-α-S 
B Rp 0.27±0.06  (5) 0.07±0.02     (3) 
A Sp 2.64±1.10  (6) 0.001±0.001 (3) 2-MeS-ATP-α-S 
B Rp 0.64±0.12  (5) 0.02±0.005   (3) 
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3.2 Ligand recognition at the P2Y11 receptor 
3.2.1 Selection of residues putatively involved in ligand recognition 
The residues considered to be involved in ligand recognition at the P2Y11 receptor were 
selected using the data obtained by molecular modelling. The P2Y11 receptor model was 
constructed in collaboration with Prof. B. Fischer from the Department of Chemistry, Gonda-
Goldschmied Medical Research Center, Bar-Ilan University in Ramat-Gan, Israel. Bovine 
rhodopsin and the previously generated P2Y1-R:ATP complex model (Major and Fischer, 
2004) were both used as templates. The P2Y11 receptor model displays a binding pocket with 
specific residues interacting with the docked ATP molecule (Fig. 11). Most of these residues 
(Arg106, Phe109, Arg268, Arg307) were selected for mutational analysis. Moreover, Ala313 
of the P2Y11 receptor was also selected as all other P2Y receptors have an asparagine at the 
corresponding position (7.45) (Fig. 4A). This alanine residue might be responsible for the low 
potency of 2-alkylthio-ATP derivatives at the P2Y11 receptor. The Ala313 is located near to a 
hydrophobic pocket of the nucleotide binding pocket and could interfere with the coordination 
of 2-alkylthio substituents at the ATP molecule into this pocket. 
 
Figure 11: Docked ATP and interacting residues in a molecular model of the P2Y11 receptor 
The ATP molecule is surrounded by interacting residues that are involved in shaping the binding pocket of 
the P2Y11 receptor. Distances (Å) between interacting atoms (heavy atoms: N, P, O) are indicated. 
In addition, other residues selected for a site-directed mutagenesis approach were 
identified by sequence comparison of the P2Y1 and P2Y11 receptors. A tyrosine residue 
(Tyr261) in the TM6 of the P2Y11 receptor was chosen because the corresponding tyrosine in 
the P2Y1 receptor (6.48) was found to be a molecular switch for receptor activation (Costanzi 
et al., 2004). Glu186 (EL2) was mutated, as it was considered to take part in determining the 
diastereoselectivity of the P2Y11 receptor. 
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3.2.2 Introduction of point mutations into the P2Y11 receptor DNA sequence 
Site-directed-mutagenesis was performed by PCR using specifically designed primers (listed 
in materials). Mutations were introduced at the preselected positions in the P2Y11 receptor 
sequence which was present in the eGFPN1 vector.  
GCCAGCAATGGCCTGGCCCTGTACCGCTTCAGCATCCGGAAGCAGCGCCCATGGCACCCC
121 ---------+---------+---------+---------+---------+---------+ 180
GCCGTGGTCTTCTCTGTCCAGCTGGCAGTCAGCGACCTGCTCTGCGCTCTGACGCTGCCC
181 ---------+---------+---------+---------+---------+---------+ 240
CCGCTGGCCGCCTACCTCTATCCCCCCAAGCACTGGCGCTATGGGGAGGCCGCGTGCCGC
241 ---------+---------+---------+---------+---------+---------+ 300
R106A - - - - -GCC
F109I - - - - - - - - - ATC
CTGGAGCGCTTCCTCTTCACCTGCAACCTGCTGGGCAGCGTCATCTTCATCACCTGCATC
301 ---------+---------+---------+---------+---------+---------+ 360
AGCCTCAACCGCTACCTGGGCATCGTGCACCCCTTCTTCGCCCGAAGCCACCTGCGACCC
361 ---------+---------+---------+---------+---------+---------+ 420
AAGCACGCCTGGGCCGTGAGCGCTGCCGGCTGGGTCCTGGCCGCCCTGCTGGCCATGCCC
421 ---------+---------+---------+---------+---------+---------+ 480
ACACTCAGCTTCTCCCACCTGAAGAGGCCGCAGCAGGGGGCGGGCAACTGCAGCGTGGCC
481 ---------+---------+---------+---------+---------+---------+ 540
E186A - - - - -GCG
AGGCCCGAGGCCTGCATCAAGTGTCTGGGGACAGCAGACCACGGGCTGGCGGCCTACAGA
541 ---------+---------+---------+---------+---------+---------+ 600
GCGTATAGCCTGGTGCTGGCGGGGTTGGGCTGCGGCCTGCCGCTGCTGCTCACGCTGGCA
601 ---------+---------+---------+---------+---------+---------+ 660 
GCCTACGGCGCCCTCGGGCGGGCCGTGCTACGCAGCCCAGGCATGACTGTGGCCGAGAAG
661 ---------+---------+---------+---------+---------+---------+ 720
Y261A - - - - - - - - - - - - - - - - - - - - - - - - - - - GCG
CTGCGTGTGGCAGCGTTGGTGGCCAGTGGTGTGGCCCTCTACGCCAGCTCCTATGTGCCC
721 ---------+---------+---------+---------+---------+---------+ 780
R268A - - - - - - - -GCG
R268Q - - - - - - - -CAG
TACCACATCATGCGGGTGCTCAACGTGGATGCTCGGCGGCGCTGGAGCACCCGCTGCCCG
781 ---------+---------+---------+---------+---------+---------+ 840
AGCTTTGCAGACATAGCCCAGGCCACAGCAGCCCTGGAGCTGGGGCCCTACGTGGGCTAC
841 ---------+---------+---------+---------+---------+---------+ 900
R307A - - - - - - GCG
A313N - - - - - - - - - - - - - - - AAC
CAGGTGATGCGGGGCCTCATGCCCCTGGCCTTCTGTGTCCACCCTCTACTCTACATGGCC
901 ---------+---------+---------+---------+---------+---------+ 960 
 
Figure 12:  Introduction of mutations into the DNA-Sequence of the P2Y11 receptor 
Partial DNA sequence (single strand) of the P2Y11 receptor (GenBank accession number: AF030335; cds 
121-960). Selected positions (codons) for a mutational analysis are shown in blue. The change of amino 
acids upon site-directed mutation is indicated on the left side and the introduced codon is displayed in 
orange. The restriction sites of ApaI (red) and BspEI (green) are also highlighted. 
The preselected residues were: Arg106 (3.29), Phe109 (3.32), Glu186 (EL2), Tyr261 
(6.48), Arg268 (6.55), Arg307 (7.39) and Ala313 (7.45). Most of these residues were mutated 
to alanine, except Phe109 and Ala313 (Fig. 12). The phenylalanine Phe109 was mutated to 
isoleucine to retain the hydrophobic and spatial properties at this position, and to only delete 
the aromatic nature. Ala313 was mutated to asparagine as this was the conserved residue at 
the corresponding position (7.45) in all other P2Y receptors. For the arginine at position 6.55 
(Arg268) an additional conservative mutation to glutamine was generated.  
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The DNA constructs of the mutated clones were digested with ApaI and BspEI restriction 
enzymes and ligated into the mother vector to avoid unwanted mutations in the vector 
sequence. For subcloning of the Arg307 and Ala313 mutants, plasmids were cut with EcoRI 
and BamHI restriction endonucleases as the point mutations were located downstream of the 
BspEI restriction site. 
3.2.3 Expression of P2Y11 receptor mutants in 1321N1 cells 
1321N1 cells were used to stably express the mutant receptors as GFP fusion proteins. The 
expression level was analyzed by flow cytometry detecting the GFP fluorescence intensity per 
cell. While three of the mutant receptors (Phe109Ile, Arg268Gln, Ala313Asn) displayed 
fluorescence intensities comparable to that of the wild type receptor, two receptor mutants 
(Glu186Ala, Arg268Ala) showed a higher expression level and three other mutants 
(Arg106Ala, Tyr261Ala, Arg307Ala) had around 80% expression level as compared to the 
wild type receptor (Table 4, next page).  
The subcellular localization of the mutant receptors was also determined by taking 
confocal images from the stably transfected cells. The localization of the mutant P2Y11 
receptors was found to be comparable to that of the wild type receptor for the Glu186Ala, 
Arg268Ala, Arg268Gln, Ala313Asn mutants. Although the Phe109Ile mutant receptor was 
only partially located at the plasma membrane, it still exhibited a significant potency for ATP 
(section 3.2.4.1). Therefore, the potency of ATP found at the Phe109Ile mutant as well as the 
potency at the mutants with a similar subcellular localization (Arg106Ala, Tyr261Ala, 
Arg307Ala) likely reflects the intrinsic activity of these constructs. 
3.2.4 Pharmacological characterisation of the P2Y11 receptor mutants 
The functional activity of the mutant receptors was determined by monitoring in stably 
transfected cells the intracellular [Ca2+]i rise induced after agonist stimulation employing the 
calcium indicator fura-2 (described in methods section).  
3.2.4.1 Potency of ATP and ATPγS 
To functionally characterize the mutant receptors, we investigated the potency of ATP as the 
natural agonist and ATPγS as one of the most potent agonists at the P2Y11 receptor. The 
concentration response curves obtained for ATPγS and ATP with the different P2Y11 receptor 
mutants are displayed in Figs. 13 and 14, respectively. The EC50 values resulting from these 
curves are summarized in Table 4.  
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A strong influence on the potency of ATP was found after mutation of three cationic 
residues to alanine located in TM3, 6 and 7. The two arginine residues at positions 3.29 and 
7.39 were found to be most critical for P2Y11 receptor activation. After mutation to alanine, 
the ability of ATP to trigger a calcium signal at these receptors was almost abolished. Only at 
concentrations ≥10 mM an increase in calcium levels could be observed (Table 4). Mutation 
of the cationic residue in TM6 (Arg268) did not lead to a complete loss of receptor activation 
as for the other two arginines but resulted in a drastically decreased potency of ATP at the 
mutant receptor (Table 4, Fig. 14). The change in potency was about three orders of 
magnitude as compared to the wild type P2Y11 receptor. Interestingly, when this arginine was 
substituted by glutamine, the potency of ATP at this receptor could be partially rescued. 
ATPγS, as one of the most potent P2Y11 receptor agonists, did also show a clear decrease in 
potency at both Arg268 mutant receptors but this decrease was far less pronounced than that 
for ATP (compare Figs. 13 and 14).  
Table 4: Functional characteristics of mutant P2Y11GFP receptors: intracellular calcium rise induced by 
receptor stimulation. Receptor expression levels in 1321N1 cells were analyzed by flow cytometry 
detecting the GFP fluorescence intensity. Data represent mean EC50 values (µM) ± s.e.m. and (n) numbers 
obtained from concentration response curves of 1321N1 cells stably expressing the wild type or mutated 
receptor. a ATP induced no significant increase in intracellular calcium up to concentrations of 10 mM.    
n.d. = not determined. 
EC50 values (µM) 
construct residue 
ATP ATPγS 
Receptor expression 
level (%) 
wt   2.37±0.88  (4) 1.04±0.38    (4)            100 
Arg106Ala 3.29 a n.d.    76.05±4.70     (4) 
Phe109Ile 3.32  10.7±2.29  (5) n.d.      102 ±13        (7) 
Glu186Ala EL2  32.8±21.1  (5) 4.92±1.07    (4)       111±10        (9) 
Tyr261Ala 6.48 a n.d.    77.35±3.91     (4) 
Arg268Ala 6.55 1806±354   (3)  247±178     (8)       143±23        (3) 
Arg268Gln 6.55   102±20     (5) 10.3±2.59    (3)    95.59±8.07     (7) 
Arg307Ala 7.39 a n.d.    87.53±5.94     (4) 
Ala313Asn 7.45  4.52±0.99  (7) n.d.    97.63±11.98   (4) 
 
Another residue in TM6 (Tyr261) also seems to be critical for normal receptor function. 
After mutation of Tyr261 (6.48) to alanine, ATP was not able to elicit a response at this 
receptor at concentrations up to ≥10 mM. Therefore, this tyrosine seems to play an important 
role in P2Y11 receptor activation. It can be assumed that Tyr261 is solely involved in receptor 
activation, since it was not found to be directly interacting with the docked ATP in the P2Y11-
R model. 
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Figure 13: Concentration-response curves for ATPγS at the wild type and mutant P2Y11GFP 
receptor stably expressed in 1321N1 cells 
Cells preincubated with 2 µM fura-2-AM were stimulated with varying concentrations of ATPγS and the 
change in fluorescence (∆F340nm/F380nm) was detected. Data represent the mean values and standard error 
from 40 to 70 single cells. Results were obtained in at least three separate experiments. The maxima of the 
curves were fixed to the plateau value of the ATPγS curve at the wild type receptor. 
The nucleotide binding pocket of P2Y receptors has been shown to consist not only of 
residues located in the transmembrane domains of the receptors but also of residues from the 
extracellular loop 2 (EL2). For this reason we selected a glutamate residue in the EL2 of the 
P2Y11 receptor putatively involved in ligand recognition. Mutation of Glu186 to alanine 
resulted in a decreased potency of ATP at the receptor. The shift was more than one order of 
magnitude (Table 4, Fig. 14). However, for the more potent P2Y11 receptor agonist ATPγS the 
shift in potency was only 5-fold, compared to the wild type receptor (Fig. 13). This suggests 
that Glu186 interacts with phosphates Pα,β of the triphosphate moiety. 
The potency of ATP at two (Phe109, Ala313) out of all the other mutant receptors was 
only slightly affected. The aromatic amino acid in TM3 (Phe109) that was indicated from the 
P2Y11-R model (Fig. 11) to possibly interact with the adenine moiety via π-stacking 
interaction seems to be not very critical for receptor activation. The EC50 value of ATP was 
increased only by a factor of 4 after mutation of phenylalanine to isoleucine (Table 4, Fig. 
14). The mutation of Phe109 to isoleucine at the P2Y11 receptor did probably not much 
disturb the recognition of ATP, since isoleucine is also a bulky, hydrophobic amino acid and 
therefore the loss in potency was not dramatic.  
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The alanine residue at position 7.45 (Ala313) is a unique feature of the P2Y11 receptor, as 
all other P2Y receptors have an asparagine amino acid at this position (Fig. 4A, page 13). At 
the Ala313Asn mutant receptor, recognition of ATP was not much influenced. ATP was only 
2-fold less potent as compared to the wild type receptor (Table 4, Fig. 14). 
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Figure 14: Concentration-response curves for ATP at the wild type and mutant P2Y11GFP receptor 
stably expressed in 1321N1 cells 
Cells preincubated with 2 µM fura-2-AM were stimulated with varying concentrations of ATP and the 
change in fluorescence (∆F340nm/F380nm) was detected. Data represent the mean values and standard error 
from 40 to 70 single cells. Results were obtained in at least three separate experiments. The maxima of the 
curves were fixed to the plateau value of the ATP curve at the wild type receptor. 
3.2.4.2 Diastereoselectivity of the P2Y11 receptor mutants 
To decipher the molecular basis of the diastereoselectivity of the P2Y11 receptor (as described 
in section 3.1), two mutant receptors were selected to test if the preference of the ATP-α-S 
(B) isomer is lost after mutation of the selected residues. The glutamate residue (Glu186) in 
the EL2 of the receptor was considered to be a putative candidate to take part in the 
determination of the P2Y11 receptor’s diastereoselectivity. The corresponding residue in the 
P2Y1 receptor (Asp204) was found to coordinate a Mg2+ ion in the vicinity of the phosphate 
binding pocket which in turn is responsible for the diastereoselective discrimination at the 
P2Y1 receptor (Major et al., 2004). In addition, the arginine (Arg268) at position 6.55 in the 
P2Y11 receptor was also selected as it was facing the glutamate residue (Glu186) in the P2Y11 
receptor model. Therefore, both residues could be involved in the preferential interaction with 
one of the Pα conformations, as they are on opposite sites of the phosphate chain from the 
ATP docked in the model. 
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Table 5: Intracellular calcium rise induced by stimulation of mutant P2Y11GFP receptors with ATP-α-S 
isomers. Data represent mean EC50 values (µM) ± s.e.m. obtained from concentration response curves of 
1321N1 cells stably expressing the wild type or mutated receptor in (n) numbers of experiments. 
EC50 values of ATP-α-S (µM) construct (A) isomer (B) isomer 
wt 1.71±0.55 (4) 0.27±0.06 (5) 
Glu186Ala 10.2±4.52 (6) 0.85±0.26 (7) 
Arg268Ala 30.8±16.3 (5) 26.4±16.0 (4) 
Arg268Gln 3.28±1.04 (4) 2.69±0.79 (4) 
Glu186Ala, Arg268Gln 19.8±3.27 (4) 13.7±2.00 (5) 
 
The Glu186Ala P2Y11 mutant receptor did not show a loss in preference of the ATP-α-S 
(B) isomer. On the contrary, the difference in potency between the (A) and (B) isomer was 
even increased as compared to the difference at the wild type receptor (Table 5, Fig. 15A). 
Interestingly, the EC50 value of the (B) isomer at the Glu186Ala mutant receptor (EC50 = 
854±260 nM) was decreased only 3-fold, as compared to the wild type receptor (EC50 = 
270±64.0 nM). However, the shift in potency for the (A) isomer was more pronounced. At the 
Glu186Ala receptor mutant the EC50 value for the ATP-α-S (A) isomer was 10.2±4.52 µM 
compared to 1.71±0.55 µM at the wild type receptor. This suggests that the recognition of the 
(B) isomer of ATP-α-S is not much disturbed after substitution of the glutamate in EL2 by 
alanine, whereas the (A) isomer is recognized to a lesser extent.  
After mutation of Arg268 (6.55) to alanine or glutamine a loss of preference for the ATP-
α-S (B) isomer was observed (Table 5, Fig. 15B). For the Arg268Ala P2Y11 receptor mutant 
the decrease in potency for the (B) isomer (EC50 = 26.4±16.0 µM) was about two orders of 
magnitude, whereas the shift in potency for the (A) isomer (EC50 = 30.8±16.3 µM) was only 
20-fold as compared to the wild type receptor. Taken together, at the Arg268Ala receptor 
mutant both isomers were found to be equipotent.  
The shift in potency for the ATP-α-S (A) isomer at the Arg268Ala mutant receptor is 
least pronounced in comparison with all other agonists tested. Thus, the recognition of the (A) 
isomer is less disturbed by mutation of this important cationic residue, and the binding mode 
is apparently different from that for the other agonists. Furthermore, at the Arg268Gln P2Y11 
receptor mutant, the activity of the ATP-α-S (A) isomer (EC50 = 3.28±1.04 µM) was nearly 
rescued. The change in potency compared to the wild type receptor (EC50 = 1.71±0.55 µM) 
was only 2-fold. The (B) isomer (EC50 = 2.69±0.79 µM) was 10-fold less potent at the 
Arg268Gln receptor mutant than at the unmutated P2Y11 receptor. Thus, the activity of both 
isomers was affected to the same degree after substitution of the arginine by glutamine and 
again both isomers appeared to be equipotent at this receptor mutant. 
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Figure 15: Concentration-response curves for ATP-α-S (A) and (B) isomers at the wild type and 
mutant P2Y11GFP receptors stably expressed in 1321N1 cells 
Cells preincubated with 2 µM fura-2-AM were stimulated with varying concentrations of ATP-α-S (A) and 
(B) isomers and the change in fluorescence (∆F340nm/F380nm) was detected. Data represent the mean values 
and standard error from 40 to 70 single cells. Results were obtained in at least three separate experiments 
[A] Curves obtained at the E186A receptor mutant. The maxima of the curves for the (B) isomer at the 
E186A mutant and the (A) isomer at the wild type receptor were fixed to the plateau value of the ATP curve 
at the wild type receptor. [B] Curves obtained at the R268A and R268Q receptor mutants. The maxima of 
the curves for the isomers at the R268 mutants and the (A) isomer at the wild type receptor were fixed to the 
plateau value of the ATP curve at the wild type receptor. [C] Curves obtained at the E186A, R268Q double 
mutant receptor. The maxima of the curves for the isomers at the double mutant and the (A) isomer at the 
wild type receptor were fixed to the plateau value of the ATP curve at the wild type receptor. 
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A double mutant was constructed, to test whether a further change in the 
diastereoselectivity of the P2Y11 receptor can be seen after simultaneous mutation of the 
glutamine in EL2 and the arginine in TM6. The mutant receptor contained the Glu186Ala and 
Arg268Gln mutations. In addition to the potency of the ATP-α-S diastereoisomers, the 
activity of ATP was also tested at this mutant receptor. The loss in potency for ATP at the 
double mutant receptor (EC50 = 886±231 µM, n = 4) was more than two orders of magnitude 
as compared to the wild type receptor (EC50 = 2.37±0.88). Therefore, the right shift of the 
concentration response curve was additive for the double mutant in comparison to the two 
corresponding single point mutants (Table 4). The diastereoselectivity of the Glu186Ala, 
Arg268Gln mutant receptor showed characteristics similar to the ones found for                   
the single Arg268Gln and single Arg268Ala mutant. Both ATP-α-S isomers (A and B) were 
found to be equipotent at the double mutant receptor. The change in potency for the (A) 
isomer (EC50 = 19.8±3.27 µM) was about one order of magnitude and for the (B) isomer 
(EC50 = 13.7±2.0 µM) the change was 50-fold as compared to the unmutated P2Y11 receptor 
(Table 5, Fig. 15C). After mutating two positions in the P2Y11 receptor, the additive effect 
concerning the loss in potency for the (B) isomer was very clear, whereas the additive 
decrease in potency for the (A) isomer was only 2-fold when compared to the Glu186Ala 
single mutant receptor. 
3.2.4.3 Recognition of 2-alkylthio substituted ATP derivatives 
At the entrance to a hydrophobic pocket which is located in the vicinity of the ATP C2 
position in the P2Y11-R model (Fig. 16) an alanine residue (Ala313) is situated. This Ala313 
is a unique feature of the P2Y11 receptor, as all other P2Y receptors have an asparagine amino 
acid at this position (Fig. 4A). It was expected, that this Ala313 might be involved in the 
reduction in potency for C2-substituted ATP derivatives at the P2Y11 receptor. Therefore, we 
investigated the potency of 2-MeS-ATP at the Ala313Asn receptor mutant and compared it to 
the potency at the wild type receptor.  
As already described in section 3.2.4.1, ATP was found to be 2-fold less potent at the 
Ala313Asn receptor mutant as compared to the unmutated receptor. Interestingly, 2-MeS-
ATP (EC50 = 8.37±2.05 µM, n=8) displayed a slight gain in potency as compared to the wild 
type receptor (EC50 = 11.1±6.30 µM, n=3). This gain in potency is not statistically significant, 
but obvious, when we consider the slightly reduced potency of ATP itself.  
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Figure 16: Section of the molecular model of the P2Y11 receptor displaying a hydrophobic pocket 
Nucleotide binding pocket of the P2Y11 receptor with docked 2-MeS-ATP. The entrance to the hydrophobic 
pocket is highlighted in pink. The A313 residue is positioned directly at the entrance to the hydrophobic 
pocket. Other important residues for ligand recognition at the receptor are also indicated. 
Unexpectedly, 2-neopentylS-ATP, did not have any activity at the Ala313Asn mutated 
receptor. The 2-neopentylS substituent did not fit into the hydrophobic pocket of the P2Y11-R 
model, consistent with the inactivity of the analogue at the wild type receptor. The mutation 
of Ala313 to asparagine was suggested to improve the fit of 2-neopentylS-ATP into the 
binding pocket. However, a clear influence on the recognition of the 2-alkylthio-ATP 
derivatives at the P2Y11 receptor could not be verified for the unique alanine residue in TM7. 
3.3 Hetero-oligomerization of the P2Y1 and the P2Y11 receptor 
3.3.1 Agonist-induced internalization of the P2Y11GFP receptor in HEK293 cells 
In order to decipher the characteristics of the P2Y11 receptor endocytosis, we fused a GFP tag 
to the C-Terminus of the receptor and stably expressed the receptor in HEK293 cells. The 
expression of the receptor was visualized by confocal microscopy and it was found to localize 
clearly to the plasma membrane (Fig. 17). For detection of endocytosis of the P2Y11GFP 
receptor, live cell imaging was done on a Zeiss inverted LSM 510 META laser scanning 
confocal microscope before and during agonist stimulation, as described in the methods 
section. 
The HEK293 cell line used was found to express endogenously several P2Y receptor 
mRNA transcripts (P2Y1, P2Y2, P2Y4) (Schafer et al., 2003). Therefore, the P2Y11GFP 
receptor internalization was induced by the most potent and relatively specific receptor 
agonist BzATP to avoid stimulation of the endogenous P2Y receptors.  
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After continuous stimulation with 100 µM BzATP for 60 min no endocytosis of the 
P2Y11GFP receptor was observed (Fig. 17, A3). However, a clear response in intracellular 
calcium rise and cAMP accumulation was found upon stimulation of the cells with 100 µM 
BzATP, suggesting the expression of a fully functional P2Y11GFP receptor. The calcium 
response is given in Fig. 18 in comparison to the response of mock transfected cells (dotted 
line). The cAMP response is displayed in Fig. 33.  
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Figure 17: Live imaging of agonist-induced internalization of the P2Y11GFP receptor stably 
expressed in HEK293 cells 
HEKP2Y11GFP cells were visualized with a LSM510meta confocal microscope and stimulated with various 
agonists for up to 60 min at 37°C (5% CO2) as described in methods. Pictures show unstimulated (US) cells 
and cells after 30 and 60 min of agonist stimulation, as indicated. (A1-3) Stimulation with 100 µM BzATP 
(n=3). (B1-3) Stimulation with 100 µM ATP (n=5). (C1-3) Cells preincubated for 30 min with 10 µM 
NF157 and stimulated with 100 µM ATP (n=3). Scale bars indicate 50 µm in the overall picture and 5 µm 
in the zoomed picture. The arrow points to cells selected for the inserted zoomed picture. 
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To test if the lack of internalization was an agonist-specific feature, cells were stimulated 
with the natural agonist of the P2Y11 receptor, namely ATP. A slight endocytosis of the 
receptor was seen after 30 min of continuous stimulation with 100 µM ATP (Fig. 17, B2). 
Further stimulation until 60 min increased the amount of endocytosed receptor, but the 
internalization remained incomplete, as part of the receptor was still visible at the plasma 
membrane (Fig. 17, B3). Preincubation of the cells with the specific P2Y11 receptor antagonist 
NF157 (10 µM) was done 30 min before the ATP-induced internalization to prove that 
endocytosis of the P2Y11GFP receptor was a result of its direct stimulation. However, as 
shown in Fig. 17, C2-3, preincubation with NF157 did not inhibit the internalization of the 
receptor induced by stimulation with 100 µM ATP for 30 or 60 min. In addition, the calcium 
response to ATP also remained unaffected by NF157 pretreatment (Fig. 18). Thus, the results 
of these endocytosis experiments did not mirror the pharmacology known for the P2Y11 
receptor. Therefore, the involvement of a crosstalk between the P2Y receptors was 
hypothesized. 
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Figure 18: Intracellular calcium rise in stably transfected HEK293 cells  
Peak values of [Ca2+]i rise of mock-transfected (blank bars) and HEKP2Y11GFP transfected (black bars) 
cells stimulated with 100 µM agonist (BzATP, ATP) +/- preincubation with 100 µM MRS2179 or 10 µM 
NF157. Data represent the mean values ±s.e.m from 30-100 cells obtained in at least three separate 
experiments. The dotted and dashed line in the graph indicate the response upon expression and stimulation 
of the P2Y11GFP receptor compared to mock transfected HEK293 cells. 
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3.3.2 Co-Internalization of the P2Y1 and P2Y11GFP receptor in HEK293 cells 
First the quantitative expression of mRNA transcripts of P2Y receptors responsive to 
ATP was analyzed by real time PCR to test our hypothesis of a receptor crosstalk. As 
expected, the HEKP2Y11GFP cells were found to express the P2Y1 and P2Y2 receptor (Fig. 
19) but the latter was only weakly expressed. Therefore, further experiments concentrated on 
the P2Y1 receptor as a putative crosstalk partner in the P2Y11GFP receptor endocytosis.  
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Figure 19: Expression levels of mRNA of different GPCRs in HEK293 cells 
Real time PCR was done using cDNA generated from total RNA of HEKP2Y11GFP, HEKA268P2Y11GFP or 
mock-transfected cells, as described in the material and methods section. The expression of several GPCRs 
was normalized to GAPDH. Bar graphs show relative expression (%) in relation to the expression of the 
P2Y1 receptor in each of the differently transfected cells. n.d. = not determined 
The possible involvement of the P2Y1 receptor in contributing to the P2Y11 receptor 
internalization was investigated using the specific P2Y1 receptor antagonist MRS2179. 
Preincubation of HEKP2Y11GFP cells with 100 µM MRS2179 for 30 min followed by 
subsequent stimulation with 100 µM ATP completely abolished the receptor endocytosis (Fig. 
21, A1-3). In addition, stimulation of the cells with the natural P2Y1 receptor agonist ADP 
(100 µM) resulted in complete internalization of the P2Y11 receptor (Fig. 21, B2-3). As ADP 
at this concentration is also able to stimulate the P2Y11 receptor, the effect of a more selective 
P2Y1 receptor agonist was also tested. 2-MeS-ADP was found to be inactive at the P2Y11 
receptor at concentrations up to 100 µM (Communi et al., 1997), whereas it is highly potent at 
the P2Y1 receptor (Palmer et al., 1998).  
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Stimulation of HEKP2Y11GFP cells with 10 µM 2-MeS-ADP resulted in complete 
internalization of the P2Y11 receptor (Fig. 21, C2-3), comparable to the pattern observed after 
ADP stimulation. Thus, the agonist profile found strongly supports the hypothesis of a 
crosstalk between the P2Y1 and P2Y11 receptor.  
The specificity of the functional interaction between the P2Y11GFP receptor and the 
endogenous P2Y1 receptor in HEK293 cells was tested next. HEKP2Y11GFP cells were found 
to express the P2Y2 receptor and the protease-activated-receptor 2 (PAR2) receptor, as 
analyzed by real time PCR. Treatment of the cells with 100 µM UTP acting on the 
endogenous P2Y2 receptor and simultaneous imaging of P2Y11 receptor trafficking showed no 
movement of the P2Y11GFP receptor even after 60 min of stimulation (Fig. 21, D3). Also, 
stimulation of the PAR2 receptor did not result in endocytosis of the P2Y11GFP receptor 
when the PAR2 receptor was activated with the protease trypsin (50 nM) in serum-free 
medium (Fig. 21, E3). Moreover, stimulation with the PAR2-activating peptide (PAR2-AP, 
100 µM) which activates the PAR2 receptor without cleavage (Luo et al., 2005), did also not 
result in P2Y11GFP endocytosis (Fig. 21, F3). However, a clear increase in intracellular 
calcium was observed after stimulation of the cells with 100 µM UTP, 50 nM trypsin and 100 
µM PAR2-AP (Fig. 20). The latter confirms the functional expression of the endogenous 
P2Y2 and PAR2 receptors in HEK293 cells. 
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Figure 20:  Intracellular calcium rise in HEKP2Y11GFP cells 
Peak values of [Ca2+]i increase in HEKP2Y11GFP cells stimulated with 100 µM ADP, 10 µM 2-MeSADP, 
100 µM UTP, 50 nM Trypsin and 100 µM PAR2-AP. Data represent the mean values ±s.e.m from 30-90 
cells obtained in at least three separate experiments. 
Therefore, the specific interaction of the P2Y11 receptor with the P2Y1 receptor underlies the 
receptor crosstalk-induced endocytosis of the P2Y11GFP receptor in HEK293 cells. 
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Figure 21: GPCR crosstalk in agonist-induced P2Y11GFP receptor endocytosis 
HEKP2Y11GFP cells were visualized with a LSM510meta confocal microscope and stimulated with various 
agonists for up to 60 min at 37°C (5% CO2) as described in methods. Pictures show unstimulated (US) cells 
and cells after 30 and 60 min of agonist stimulation. (A1-3) Cells preincubated with 100 µM MRS2179 and 
stimulated with 100 µM ATP (n=3). (B1-3) Stimulation with 100 µM ADP (n=5). (C1-3) Stimulation with 
10 µM 2-MeS-ADP (n=3). (D1-3) Stimulation with 100 µM UTP (n=4). (E1-3) Stimulation with 50 nM 
trypsin (n=3). (F1-3) Stimulation with 100 µM PAR2-AP (n=3). Scale bar represents 5 µm. n = number of 
experiments. 
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3.3.3 Co-internalization of the P2Y1 and P2Y11 receptor in 1321N1 cells 
Next, we aimed at testing whether the co-internalization of the P2Y1 and P2Y11 receptor was a 
general property or a cell type-specific phenomenon of the receptor crosstalk. For this 
purpose, the P2Y1 receptor bearing a mycHis tag and the P2Y11GFP receptor were 
coexpressed in 1321N1 cells. This cell line lacks endogenous functional P2Y receptors, as 
described in section 3.1.1 and elsewhere (Lazarowski et al., 1995). Thus, stimulation of the 
cells with nucleotides is affecting only the heterologously expressed P2Y receptors. 
Preliminary experiments were made to test the functionality of the endocytosis machinery 
in the 1321N1 cells. This was addressed by using 1321N1 cells stably expressing the 
P2Y1GFP receptor (mentioned in section 3.1). For detection of endocytosis of the GFP tagged 
receptor, living cells were imaged on a Zeiss inverted LSM 510 META laser scanning 
confocal microscope before and during agonist stimulation, as described in the methods 
section. 1321N1-P2Y1GFP cells were stimulated with 10 µM 2-MeS-ADP and the receptor 
trafficking was observed for 60 min. After 30 min of stimulation, a clear beginning of 
receptor endocytosis was detected (data not shown) that was almost complete at the end of 60 
min (Fig. 22, A2). This supports a normal functioning of the GPCR internalization cascade in 
the 1321N1 cells that resembled previous findings on the endocytosis of the P2Y1GFP 
receptor in HEK293 cells (Tulapurkar et al., 2006).  
In contrast, 1321N1-P2Y11GFP cells did not show any sign of receptor endocytosis even 
after 60 min of stimulation with 100 µM ATP (Fig. 22, B2). This substantiates the conclusion 
of a lack in agonist-induced receptor internalization of the P2Y11 receptor.  
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Figure 22: Agonist-induced internalization of the P2Y1GFP and P2Y11GFP receptor in 1321N1 cells 
1321N1 cells were visualized with a LSM510meta confocal microscope and stimulated with various 
agonists for up to 60 min at 37°C (5% CO2) as described in methods. Pictures show unstimulated (US) cells 
and cells after 60 min of agonist stimulation. (A1-2) 1321N1P2Y1GFP cells stimulated with 10 µM 2-MeS-
ADP. (B1-2) 1321N1P2Y11GFP cells stimulated with 100 µM ATP. 
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The next set of experiments was done to analyze whether the P2Y11 receptor 
internalization could be induced by co-expression of the P2Y1 receptor. 1321N1 cells were 
transiently co-transfected with the P2Y1mycHis and P2Y11GFP receptor. Cells were 
stimulated with either 100 µM ATP or 10 µM 2-MeS-ADP at 48 h post-transfection and fixed 
after 60 min of stimulation. Fixed cells were stained with anti-myc antibody and visualized on 
a Zeiss inverted LSM 510 META laser scanning confocal microscope, as described in the 
methods section.  
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Figure 23: Co-internalization of the P2Y1mycHis and P2Y11GFP receptor in 1321N1 cells 
Transiently co-transfected 1321N1 cells were stimulated with nucleotides for 60 min, fixed with 4% PFA 
and stained with anti-myc antibody, as described in methods. Images taken on a Zeiss inverted LSM 510 
META confocal microscope display the GFP fluorescence (1) and myc-staining (2) separately, as well as a 
merged picture (3). (A1-3) Unstimulated cells. (B1-3) Stimulation with 100 µM ATP. (C1-3) Stimulation 
with 10 µM 2-MeS-ADP. Scale bar indicates 10 µm. White lines in the merged picture illustrate the x-z or 
y-z section-plane displayed in the enlarged view on top and besides the image. 
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The green fluorescence of the P2Y11GFP receptor (Fig. 23, A1) and the red fluorescence of 
the Alexa555 dye visualizing the myc-staining (Fig. 23 A2) co-localized nicely as shown in the 
merged image (Fig. 23, A3). Both receptors showed a normal distribution at the plasma 
membrane. Upon addition of 100 µM ATP for 60 min, endocytosis of the P2Y1mycHis 
receptor (Fig. 23, B2) and the P2Y11GFP receptor (Fig. 23, B1) was observed. The receptors 
co-internalized to intracellular compartments (Fig. 23, B3). The enlarged view in Fig. 23, B3 
emphasizes the co-localization of the P2Y1mycHis and P2Y11GFP receptor in the same 
intracellular structures. Similar observations were made after stimulation of the co-transfected 
cells with 10 µM 2-MeS-ADP (Fig. 23, C1-C3). Again the myc-staining of the P2Y1mycHis 
receptor and the green fluorescence of the P2Y11GFP receptor co-localized in the same 
intracellular compartments (Fig. 23, C3). Thus, the results clearly show that the endocytosis-
reluctance of the P2Y11 receptor can be overcome upon co-expression and stimulation of the 
P2Y1 receptor. 
3.3.3.1 Endocytosis-Reluctance of the A268P2Y11 receptor mutant stably expressed in 
HEK293 cells 
As 2-MeS-ADP was able to induce the endocytosis of the P2Y11GFP receptor in HEK293 
cells (Fig. 21C) and the P2Y11 receptor ligand BzATP was ineffective (Fig. 17A), we 
examined whether an unresponsive P2Y11 receptor was able to be co-internalized by P2Y1 
receptor activation. The R268A-P2Y11 receptor mutant (A268P2Y11) shows a 1000-fold 
reduced potency for ATP, as we reported recently (Zylberg et al., 2007) and described in 
section 3.2.4.1. Therefore, we stably expressed the A268P2Y11 receptor in HEK293 cells. For 
detection of receptor endocytosis, the HEKA268P2Y11GFP cells were stimulated on stage with 
an ATP concentration (100 µM) that was not able to activate the mutant receptor and cells 
were imaged by confocal microscopy. Live imaging was done for up to 60 min and during the 
total time period of imaging the GFP tagged A268P2Y11 receptor did not show any sign of 
internalization. The receptor remained at the plasma membrane (Fig. 24). The same was true 
when cells were stimulated with 2-MeS-ADP (data not shown). A difference in the expression 
level of the P2Y1 receptor in HEKA268P2Y11GFP cells, compared to HEKP2Y11GFP cells, was 
not found in this experiment. The mRNA expression level of the P2Y receptors were 
comparable in both cell clones (Fig. 19). Therefore, we conclude that a functionally inactive 
mutant P2Y11 receptor was not able to interact with the P2Y1 receptor in agonist-induced co-
internalization. 
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Figure 24: Live-imaging of the A268P2Y11GFP receptor in HEK293 cells 
HEKA268P2Y11GFP cells were visualized with a LSM510 meta confocal microscope and stimulated with 
100 µM ATP for up to 60 min at 37°C (5% CO2) as described in methods. Pictures show unstimulated (US) 
cells and cells after 30 and 60 min of agonist stimulation. Scale bar represents 5 µm. 
3.3.3.2 Knock-down of the endogenous P2Y1 receptor in HEK293 cells with small 
interfering RNA (siRNA) 
The concept that a cross-talk between the P2Y1 and P2Y11 receptor is necessary for sufficient 
endocytosis of the latter receptor was tested by decreasing the expression of the endogenous 
P2Y1 receptor in HEK293 cells. For this purpose knock-down of the P2Y1 receptor expression 
was done using siRNA. Oligonucleotides selected against a specific region in the coding 
sequence of the receptor (section 2.1.11.5 in materials) were applied to HEKP2Y11GFP cells 
using magnet-assisted transfection (MATra) reagent. This transfection method was already 
known from our previous experience to achieve nearly quantitative transfection rates. Cells 
were harvested at 48 h after siRNA transfection. Real-time PCR as well as western blot 
analysis was done to check for knock-down of the P2Y1 receptor expression, as described in 
the methods section. Cells treated with the P2Y1-R siRNA showed approximately 50% 
knock-down in the mRNA level of the P2Y1 receptor (Fig. 25). The P2Y1 receptor expression 
remained nearly unaffected when cells were treated with MATra reagent only or with control 
siRNA (Fig. 25). The decrease in P2Y1 receptor expression after treatment with P2Y1-R 
siRNA was also confirmed on the protein level (Fig. 25, inset). 
Then HEKP2Y11GFP cells were imaged 48 h post-transfection with siRNA on a LSM510 
meta confocal microscope to detect P2Y11 receptor internalization after agonist stimulation as 
described before. Cells not treated with siRNA behaved normally (Fig. 26, A1-3), as they 
displayed significant internalization of the GFP-tagged P2Y11 receptor after 60 min of ATP 
stimulation (Fig. 26, A3), similar to the already described characteristics in section 3.3.1. The 
same was true for cells treated only with the transfection reagent (Fig. 26, B2-3) as well as for 
cells treated with control siRNA (Fig. 26, C2-3). In contrast, treatment with the specific P2Y1 
receptor siRNA diminished the agonist-induced endocytosis of the P2Y11GFP receptor (Fig. 
26, D2-3). 
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Figure 25:  Expression level of P2Y1 receptor mRNA in HEKP2Y11GFP cells after siRNA treatment 
Real time PCR was done using cDNA generated from total RNA of HEKP2Y11GFP cells and specific 
primers as described in the material and methods section. The expression of the endogenous P2Y1 receptor 
was normalized to GAPDH. Bar graphs show expression (%) of the P2Y1 receptor in cells treated for 48 h 
with the transfection reagent (MATra) only or siRNA in relation to the P2Y1 receptor expression in 
untreated cells. The decrease in protein expression was determined by western blot analysis using a P2Y1 
receptor antibody as shown in the inset. 
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Figure 26: Treatment with P2Y1-R siRNA reduces internalization of the P2Y11GFP receptor in 
HEK293 cells 
HEKP2Y11GFP cells were monitored on a Zeiss LSM510 meta confocal microscope 48 hours after 
transfection with siRNA and stimulated with 100 µM ATP for up to 60 min at 37°C (5% CO2) as described 
in methods. Images show unstimulated cells (US), cells after 30 min and 60 min of stimulation. (A1-3) 
Cells not treated with siRNA or transfection reagent. (B1-3) Cells treated with MATra reagent only. (C1-3) 
Cells treated with control siRNA. (D1-3) Cells treated with P2Y1 siRNA. Scale bar represents 5 µm. 
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A quantitative analysis of the fluorescence intensities in the cytosol over time is shown in Fig. 
27. The increase in fluorescent P2Y11GFP receptor transported to the cytosol was delayed for 
at least 10 min and then significantly smaller in cells transfected with P2Y1-R siRNA. The 
inhibition of the P2Y11 receptor endocytosis amounted to 30 %.  
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Figure 27:  Fluorescence intensities of the P2Y11GFP receptor in cytosol of siRNA transfected 
HEK293 cells upon agonist stimulation 
Images of HEKP2Y11GFP cells transfected with siRNA and stimulated with 100 µM ATP for up to 60 min 
were taken on a Zeiss LSM510 meta confocal microscope 48 h after transfection and fluorescence 
intensities analyzed using the Zeiss software. Regions of interests were set in the cytosol of n single cells in 
at least three independent experiments and the average fluorescence intensity determined. Fluorescence 
intensity values for 10-60 min were normalized to the starting value at 0 min (F0) which was set to be 1, as 
described in methods. Curves show the increase in fluorescence intensity in the cytosol of untreated (n=16), 
MATra treated (n=19), control siRNA treated (n=18) and P2Y1-R siRNA (n=21) treated cells over time. 
Asterisks indicate significant difference (* p<0.05) compared to untreated cells, analyzed using one way 
ANOVA and the Tukey’s test. 
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3.3.4 Co-Pulldown Experiments 
3.3.4.1 Interaction of the heterologously expressed P2Y1mycHis and P2Y11GST 
receptors in HEK293 cells 
As a next step, we attempted to analyze whether the functional interaction of the P2Y1 and 
P2Y11 receptor in internalization was a result of their ability to associate physically. Protein-
protein interaction was studied using a co-pulldown approach. The P2Y11 receptor GST 
fusion-protein and the P2Y1 receptor bearing a mycHis tag were transiently co-expressed in 
HEK293 cells. Cells were harvested 48 h post-transfection and total cell lysates were 
incubated with GSH beads overnight. Samples were resolved by SDS-PAGE and transferred 
to nitrocellulose membrane, as described in the methods section. Western blot was done using 
a myc-antibody to check for co-pulldown of the P2Y1mycHis receptor with the P2Y11GST 
receptor trapped on the GSH beads. 
Western blot analysis of lysates from co-transfected cells revealed smearlike anti-myc 
reactive bands around 37 kDa and between 75 to 100 kDa (Fig. 28A, lane 1). The molecular 
mass predicted from amino acid sequence for the P2Y1 receptor is 42 kDa. The smearlike 
staining at around 37 kDa probably represents several glycosylated forms of the receptor as 
reported previously (Yoshioka et al., 2001). The higher molecular mass bands may 
correspond to oligomerized receptor, as reported before for the A1-P2Y1 receptor hetero-
oligomer (Yoshioka et al., 2002). Western blot analysis applying a GST-antibody resulted in 
anti-GST reactive bands of the predicted molecular mass (~65 kDa) for the P2Y11GST 
receptor (Fig. 28B, lane 1).  
Pulldown experiments with lysates of co-expressing cells showed that the P2Y1mycHis 
receptor was attached together with the P2Y11GST receptor at the GSH beads (Fig. 28A, lane 
5). The interaction of the P2Y1 and P2Y11 receptor was strong as the myc-staining in the co-
pulldown sample was much more intense than in the 10% input (Fig. 28A, compare lanes 5 
and 1, respectively). To test for the specificity of the co-pulldown experiment, several control 
conditions were investigated. The GST pulldown experiment with single transfected HEK293 
cells, expressing either the P2Y1mycHis or the P2Y11GST receptor showed no myc-
immunoreaction in the Western blot analysis (data not shown).  
Results 
 79
The P2Y1mycHis receptor did not interact with the GST tag as examined using GST 
preloaded GSH beads and lysate of single P2Y1 receptor transfected HEK293 cells in a 
pulldown test. The myc-blot showed no immunoreaction proving that the P2Y1 receptor could 
not interact with the GST tag (Fig. 28A, lane 6). This was further confirmed by removing the 
P2Y11 receptor from the GST fusion protein at the Factor Xa (FXa) cleavage site using this 
protease. The FXa treatment led to the disappearance of the myc-immunoreaction in the 
pulldown sample (Fig. 28A, lane 7). The GST-immunoreaction appeared at 27 kDa 
corresponding to GST only after FXa cleavage (data not shown).When we used mixed lysates 
from single transfected HEK293 cells (HEKP2Y1mycHis or HEKP2Y11GST), the pulldown 
fraction did not show any myc-immunoreaction (Fig. 28A, lane 4). This excludes the 
formation of aggregates during the pulldown procedure as a possible cause of the positive co-
pulldown result. 
The specificity of the P2Y1 and P2Y11 receptor interaction was examined in further 
experiments. For this, the P2Y11GST receptor was co-transfected with a non-related GPCR, 
the PAR2 receptor (bearing a HA tag). The PAR2-HA protein showed a smear band (~37-70 
kDa) (Fig. 28C, lane 2) which is consistent with our previous results (Luo et al., 2006). The 
co-pulldown experiment revealed no HA-immunoreactivity, thereby excluding a physical 
interaction of both receptors (Fig. 28C, lane 8). However, co-transfection of the P2Y11GST 
receptor with the P2Y4-HA receptor resulted in a physical interaction of both receptors (Fig. 
28C, lane 9), indicating a possible P2Y receptor pooling in HEK293 cells. 
Furthermore, we analyzed the probability that the transiently overexpressed receptors 
were present in small membrane patches of HEK293 cells without direct physical interaction. 
Therefore, the total lysate of P2Y1mycHis and P2Y11GST co-transfected cells were extracted 
for 2 h at 4°C in RIPA buffer and then centrifuged at 50.000 x g for 30 min to remove 
undissolved membrane patches. These extracts were then used to perform a co-pulldown 
experiment. After that procedure, the P2Y1mycHis receptor could still be found together with 
the P2Y11GST receptor at the GSH beads when we performed a pulldown experiment with 
these extracts (Fig. 29A, lane 4). These data again support the direct physical interaction of 
the receptors. 
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Figure 28:  Co-pulldown of the P2Y1mycHis and P2Y11GST receptor from HEK 293 cells 
For pulldown (PD) experiments, total lysates of transfected HEK293 cells expressing the indicated 
receptors were incubated overnight with GSH beads at 4°C, as described in methods. Samples were 
resolved by SDS-PAGE and transferred to nitrocellulose. Western blot (WB) analysis was performed using 
anti-myc (A), anti-GST (B) or anti-HA (C) antibodies. Lane 1-3: Input signals from total lysates (10% of 
PD samples) of P2Y1mycHis/P2Y11GST (lane 1), PAR2HA/P2Y11GST (lane 2) and P2Y4HA/P2Y11GST 
(lane 3) co-expressing HEK293 cells. Lane 4: Mixture of lysates from P2Y1mycHis and P2Y11GST single 
transfected cells and subsequent incubation with GSH beads. Lane 5: Co-pulldown of the P2Y1mycHis and 
P2Y11GST receptor from lysates of co-transfected cells. Lane 6: Lysate of P2Y1mycHis single transfected 
cells incubated with GST preloaded GSH beads. Lane 7: P2Y1mycHis/P2Y11GST receptor co-pulldown 
beads after incubation with FXa. Lane 8: Lysates of PAR2-HA/P2Y11GST co-transfected cells incubated 
with GSH beads. Lane 9: Co-pulldown of the P2Y4-HA and P2Y11GST receptor from lysates of co-
transfected cells. The molecular mass markers are shown in kDa (approximate molecular mass: smearlike 
staining around 37 and 75 kDa; P2Y11GST ~ 65 kDa; PAR2-HA ~ smearlike bands from 37-70 kDa; P2Y4-
HA ~ 40 kDa). Western blots shown are representative for at least two independent experiments. * indicates 
positive pulldown signal. 
3.3.4.2 Physical interaction of the A268P2Y11 receptor mutant with the P2Y1 receptor 
in HEK293 cells 
The endocytosis-resistant A268P2Y11 receptor mutant (section 3.3.3.1) was tested for physical 
interaction with the P2Y1 receptor to check if the resistance to internalize was a result of loss 
in protein-protein interaction. For this, the A268P2Y11 receptor was transiently expressed as a 
GST fusion protein together with the P2Y1mycHis receptor in HEK293 cells and co-pulldown 
experiments were done as described above.  
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Western blot analysis showed that the P2Y11 receptor mutant was still able to physically 
interact with the P2Y1 receptor (Fig. 29A, lane 3) similar to the unmutated receptor (Fig. 29A, 
lane 4). The interaction was still detectable after extracting the receptors from cell membranes 
(centrifugation at 50.000 x g, 30 min, section 3.3.4.1). Thus, the endocytosis-reluctance of the 
A268P2Y11 receptor mutant in HEK293 cells is not due its inability to physically interact with 
the P2Y1 receptor. 
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Figure 29: Co-Pulldown of the P2Y1mycHis and A268P2Y11 receptor from HEK 293 cells 
Cell extracts of differently transfected HEK293 cells were obtained by centrifugation at 50.000 x g for 30 
min. For pulldown (PD), extracts were incubated overnight with GSH beads at 4°C, as described in 
methods. Samples were resolved by SDS-PAGE and transferred to nitrocellulose. Western blot (WB) 
analysis was performed using anti-myc (A) or anti-GST (B) antibodies. Lane 1-2: Input signals from 
extracts (10% of PD samples) of P2Y1mycHis/A268P2Y11GST (lane 1) and P2Y1mycHis/P2Y11GST (lane 2) 
co-expressing cells. Lane 3-4: Co-pulldown of the P2Y1mycHis receptor with the A268P2Y11GST receptor 
(lane 3) or the wild type P2Y11GST receptor (lane 4) from lysates of co-transfected cells. The molecular 
mass markers are shown in kDa. Approximate molecular mass: P2Y1mycHis ~ smearlike staining around 
37 and 75 kDa; P2Y11GST ~ 65 kDa. Western blots shown are representative of at least two independent 
experiments. 
3.3.5 Co-immunoprecipitation of P2Y1mycHis and P2Y11GST receptors 
Co-immunoprecipitation of the P2Y11GST receptor by an anti-myc antibody from 
P2Y1mycHis receptor co-transfected cells, further proved the stability of the interaction 
between both receptors. The P2Y1mycHis receptor was immunoprecipitated from total lysates 
of HEK293 cells transiently (48 h) expressing both receptors using a myc-antibody. Samples 
were resolved by SDS-PAGE and transferred to nitrocellulose membrane, as described in the 
methods section. 
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The P2Y11GST receptor clearly co-immunoprecipitated together with the myc-tagged 
P2Y1 receptor, as detected by Western blot analysis using a GST-antibody (Fig. 30A, lane 3). 
The signal was specific as lysates precipitated with an unspecific IgG showed no anti-GST 
reactive bands (Fig. 30A, lane 4). Moreover, when lysates of HEK293 cells single transfected 
with either the P2Y1mycHis or P2Y11GST receptor were mixed, immunoprecipitation of the 
P2Y1mycHis receptor did not result in co-precipitation of the P2Y11GST receptor (Fig. 30A, 
lane 2). Thus, the protein-protein interaction of the P2Y1 and P2Y11 receptor could also be 
confirmed using an immunoprecipitation approach. 
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Figure 30: Co-Immunoprecipitation (IP) of the P2Y1mycHis and P2Y11GST receptors from HEK293 
cells 
Total lysates of differently transfected HEK293 cells were incubated first overnight with anti-myc antibody 
and then with Agarose Plus A/G beads at 4°C as described in methods. Samples were resolved by SDS-
PAGE and transferred to nitrocellulose. Western blot (WB) analysis was performed using anti-GST (A) or 
anti-myc (B) antibodies. Lane 1: Input signal from total lysate (10% of IP samples) of P2Y1mycHis 
/P2Y11GST co-expressing cells. Lane 2: Mixture of lysates from P2Y1mycHis and P2Y11GST single 
transfected cells immunoprecipitated with anti-myc antibody. Lane 3: Co-IP of P2Y1mycHis and 
P2Y11GST receptor from lysates of co-transfected cells using anti-myc antibody (arrow points to P2Y11GST 
protein). Lane 4: Precipitation of lysates from P2Y1mycHis/P2Y11GST cells using unspecific mouse IgG 
(negative control). The molecular mass markers are shown in kDa. Approximate molecular mass: 
P2Y1mycHis ~ smearlike staining around 37 and 75 kDa; P2Y11GST ~ 65 kDa. Here and in Fig. 3, Western 
blots shown are representative of at least two independent experiments testing the various conditions. The 
arrowhead indicates a signal corresponding to Protein A. * the indicated band represents non-reduced IgG 
due to unboiled samples. 
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3.3.6 Pharmacological characteristics of the receptor hetero-oligomer 
3.3.6.1 Intracellular calcium rise 
The hetero-oligomerization of the P2Y11GFP receptor with the endogenous P2Y1 receptor 
seems to modify the activity of known agonists and antagonists at the P2Y11 receptor, as 
observed in the endocytosis experiments (section 3.3.1 and 3.3.2). BzATP was ineffective in 
inducing receptor-endocytosis and NF157 could not inhibit ATP-induced internalization of 
the P2Y11GFP receptor. Therefore, we also investigated the pharmacology of intracellular 
calcium rise induced by P2Y11GFP receptor activation in HEK293 cells. As described in 
methods, cells were subjected to single-cell calcium measurement applying the calcium 
indicator fura-2. Results are summarized in Fig. 31 and 32. 
P2Y11GFP receptor-expressing HEK293 cells responded to the potent P2Y11 receptor 
agonist BzATP, but the recently developed P2Y11 receptor antagonist NF157 was not able to 
inhibit this response (Fig. 31A). However, when HEKP2Y11GFP cells were preincubated with 
the specific P2Y1 receptor antagonist MRS2179 (100 µM) no response to BzATP (100 µM) 
could be detected (Fig. 31A).  
This antagonist sensitivity was different at the single P2Y11GFP receptor expressed in 
1321N1 cells, where MRS2179 showed no effect on the activity of BzATP, but preincubation 
with NF157 totally abolished the activity of BzATP at the P2Y11 receptor (Fig. 31A). Thus, 
the interaction of the P2Y11GFP receptor with the endogenous P2Y1 receptor in HEK293 cells 
seems to influence the pharmacology of the receptor. 
As the A268P2Y11GFP receptor did not functionally interact with the endogenous P2Y1 
receptor in HEK293 cells with regard to internalization, we examined the influence of this 
mutant P2Y11 receptor on the pharmacological interaction with the P2Y1 receptor. Therefore, 
the intracellular calcium rise in HEKA268P2Y11GFP cells was measured. The cells responded 
to 100 µM ATP (Fig. 31B) in the same way as mock-transfected cells confirming the inability 
of 100 µM ATP to stimulate the P2Y11 receptor mutant. However, the more potent P2Y11 
receptor agonist BzATP elicited a significant response at a concentration of 100 µM at the 
R268A mutant (Fig. 31A) which was not seen in the mock-transfected cells (Fig. 31A). 
Nevertheless, the amplitude of the response to 100 µM BzATP of the HEKA268P2Y11GFP 
cells was clearly smaller (25%) than the [Ca2+]i increase in HEKP2Y11GFP cells (Fig. 31A).  
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Pretreatment of the HEKA268P2Y11GFP cells with MRS2179 did not affect the action of 
BzATP at the P2Y11 receptor (Fig. 31A) in contrast to the observations made at the unmutated 
receptor (Fig. 31A). Thus, the R268A mutation of the P2Y11 receptor seems to disrupt the 
interaction with the P2Y1 receptor concerning the P2Y1 receptor mediated internalization of 
the P2Y11 receptor (section 3.3.3.1) and the ligand selectivities in inducing [Ca2+]i rise. 
Moreover, real-time PCR showed that the differently transfected HEK293 cells display a 
comparable expression profile of P2Y receptor mRNAs, as depicted in the above figure at 
page 70 (Fig. 19). HEKA268P2Y11GFP, mock-transfected, as well as HEKP2Y11GFP cells all 
showed similar levels of P2Y1 receptor mRNA. The P2Y11 receptor expression was 
significantly increased in the accordingly transfected HEK293 cells compared to mock-
transfected cells. The P2Y2 receptor expression was very weak and only clearly detectable in 
HEKP2Y11GFP cells. The P2Y6 receptor was not expressed in any of these cell clones. Thus, 
different P2Y receptor expression profiles apparently are not the reason for the diversity in the 
ligand selectivities at the unmutated and R268A mutated P2Y11 receptor in HEK293 cells. 
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Figure 31:  Peak values of intracellular calcium rise induced by P2Y receptor stimulation 
(A) Bar graphs display the [Ca2+]i rise in HEK293 cells transfected with GFP only (mock) (blank bar), 
P2Y11GFP (black bars), A268P2Y11GFP (striped bars) and the calcium rise in 1321N1P2Y11GFP cells (green 
bars). Cells were stimulated with BzATP at the indicated concentrations (µM). Preincubation with 100 µM 
MRS2179 or 1 µM NF157 is also indicated. [Ca2+]i rise was detected using fura-2 as described in methods. 
(B) Bar graphs display the [Ca2+]i rise in response to 100 µM ATP of HEK293 cells transfected with GFP 
only (blank bar), P2Y11GFP (black bar), A268P2Y11GFP (striped bar). Data represent the mean±s.e.m 
obtained in at least three independent experiments analyzing 20-100 cells. The dashed lines in (A) and (B) 
give the comparison of the responses to that of mock transfected HEK293 cells.  
 
Results 
 85
Furthermore, a significant increase in intracellular calcium upon stimulation of the cells 
with 100 µM UDP was observed (Fig. 32). UDP is known to activate the P2Y6 receptor 
(Nicholas et al., 1996) but this receptor was not expressed in our HEK293 cells. Interestingly, 
only the green fluorescent, i.e. positively P2Y11GFP transfected, cells responded. After 
preincubation with MRS2179, the response was dramatically reduced (Fig. 32). The P2Y11 
receptor antagonist NF157 was able to inhibit 46 % of the calcium response to 100 µM UDP. 
When HEKA268P2Y11GFP cells were challenged with UDP, the intracellular calcium 
concentration was only slightly increased (Fig. 32), which was comparable to the value in 
HEKP2Y11GFP cells after incubation with MRS2179. Mock-transfected HEK293 cells (Fig. 
32) and 1321N1P2Y11GFP cells (data not shown) showed no significant calcium response to 
UDP. 
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Figure 32:  Peak values of intracellular calcium rise induced by UDP in HEK293 cells 
Bar graphs display the [Ca2+]i rise in HEK293 cells transfected with GFP only (blank bars), P2Y11GFP 
(black bars), A268P2Y11GFP (striped bars). Cells were stimulated with 100 µM UDP. Preincubation with 100 
µM MRS2179 or 10 µM NF157 is indicated. [Ca2+]i rise was detected using fura-2 as described in methods. 
Data represent the mean±s.e.m obtained in at least three independent experiments analyzing 40-100 cells. 
3.3.6.2 Determination of cAMP accumulation 
The P2Y11 receptor not only couples to the Gq protein, but also to the Gs protein, thereby 
inducing the activation of adenylyl cyclase and subsequent cAMP production in the cells. 
Therefore, it was interesting to know whether the interaction of the P2Y11 receptor with the 
P2Y1 receptor also influences the receptor pharmacology with respect to cAMP accumulation. 
HEKP2Y11GFP cells were stimulated with various agonists and/or antagonists, the reaction 
was stopped by addition of 0.1 M HCl and the cAMP content was measured after cell lysis, as 
explained in the methods section. 
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Stimulation of the cells with 100 µM BzATP led to a substantial increase in the cAMP 
concentration that was about 17-fold as compared to that of unstimulated cells (Fig. 33). 
Preincubation with 100 µM MRS2179 did not affect the response to BzATP. In contrast, cells 
preincubated with 10 µM NF157 showed a significantly reduced (by 40 %) response to 
BzATP. No cAMP accumulation was induced when cells were treated with 100 µM UDP or 
10 µM 2-MeSADP. Thus, the pharmacology of adenylyl cyclase activation found in 
HEKP2Y11GFP cells represents the profile known for the P2Y11 receptor ligands. 
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Figure 33:  Stimulation of cAMP accumulation in HEKP2Y11GFP cells 
Cells preincubated with IBMX (500 µM) and antagonists (as indicated) were stimulated with various 
nucleotides. The cAMP content was measured using an Enzyme-Linked-Immunoassay (EIA) as described 
in methods. Bar graphs represent the average stimulation (normalized to unstimulated cells) and s.e.m from 
at least three independent experiments. Asterisks indicate significance (* p<0.05) and ‘ns’ indicates non 
significant differences analyzed using one-side ANOVA and the Tukey’s test. 
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4 DISCUSSION 
The purinergic P2Y receptors are a family of GPCRs that respond to a variety of nucleotides. 
Thereby body tissues can react to extracellular nucleotides. Among the P2Y receptors, the 
P2Y1 and P2Y11 receptor are closely related (Costanzi et al., 2004). Agonists acting at the 
P2Y11 receptor are also capable of activating the P2Y1 receptor. Therefore, mechanisms are 
required to regulate activation of one or the other receptor in tissues or cells where both are 
expressed. One mechanism can be the desensitization of the receptor responses. Interestingly, 
the P2Y1 receptor can be rapidly desensitized (Bourdon et al., 2006), whereas the P2Y11 
receptor can not (Communi et al., 1999). A regulated activation of the P2Y1 or the P2Y11 
receptor can also be realized by appropriate pharmacological tools. The design and synthesis 
of these pharmacological tools relies on sufficient experimental evaluation of the agonist and 
antagonist selectivities of the receptors.  
The present study focussed on the detailed characterization of the less studied P2Y11 
receptor in terms of pharmacology, ligand recognition, desensitization and P2Y receptor 
crosstalk. The results are discussed in the same order. 
4.1 Diastereoselective activation is opposite for the P2Y1 receptor and the 
P2Y11 receptor  
The potency of different novel diastereomeric analogues of ATP at the P2Y11 receptor was 
investigated. Through substitution of one of the non-bridging oxygen atoms of Pα by borane 
or sulfur a new chiral centre in the ATP molecule was introduced. The resulting 
diastereoisomers were separated and the absolute configuration around the Pα was assigned 
(Major et al., 2004). The Rp configuration was attributed to the (A) isomers of the borano-
modified and the (B) isomers of the thio-substituted analogues. This difference in assignment 
is due to the group priorities around Pα, which are opposite for the borane derivatives (ATP-
α-B) and sulfur derivatives (ATP-α-S). Sulfur is of higher priority in the chemical 
nomenclature compared to oxygen, and borane is of lower priority than oxygen. The increase 
in intracellular [Ca2+]i in 1321N1 astrocytoma cells stably expressing a P2Y11 receptor GFP 
fusion protein was determined upon stimulation with these analogues. The successful 
expression of the P2Y11GFP receptor in 1321N1 cells was confirmed by western blot analysis. 
Moreover, the 1321N1-P2Y11GFP cells showed the typical pharmacology profile of agonists 
that had already been described for this receptor. The novel diastereoisomeric compounds 
tested, activated the P2Y11 receptor with EC50 values in the low micromolar range. 
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 Introduction of a borane or sulfur group at Pα of ATP results in potent P2Y11 
receptor agonists 
The diastereoisomers showed striking differences in the potencies at the P2Y11 receptor as 
compared to their parent compounds ATP, 2-MeS-ATP, and 2-Cl-ATP. Specifically, the 
introduction of a borane/sulfur group resulted in more potent ligands at the P2Y11 receptor. 
The effect of the borane substitution on the potency of the ATP derivatives for the P2Y11 
receptor is in contrast to the findings at the P2Y1 receptor. At the P2Y1 receptor the 
introduction of borane into ATP or 2-MeS-ATP did not create more potent ligands (Nahum et 
al., 2002), while the introduction of sulfur at Pα of ATP led to an increase in potency at the 
P2Y1 receptor (Major et al., 2004). However, the 2-MeS-ATP-α-S analogues were as potent 
as 2-MeS-ATP itself. This demonstrates that the introduction of sulfur at Pα leads to an 
increased potency of ATP at the P2Y1 receptor but is not able to further increase the potency 
of 2-methylthioether derivatives, which are already very potent agonists at this receptor. This 
underlines that the 2-methylthio substitution plays a pivotal role in the potency of the ATP 
derivatives at the P2Y1 receptor (Schachter et al., 1996; Palmer et al., 1998).  
In contrast, at the P2Y11 receptor both sulfur- and borano-substitution increased the 
potency of ATP as well as 2-MeS-ATP and 2-Cl-ATP. Moreover, the shift in potency was 
more distinct for the (B) isomers of 2-MeS-ATP-α-B/S derivatives, compared to the parent 
compound than for the (B) isomers of the 2-unsubstituted ATP-α-B/S analogues compared to 
ATP. This shows that the introduction of a borane/sulfur group at Pα determines the potency 
of the derivative at the P2Y11 receptor, overriding the negative influence of a substituent at 
position 2 of the ATP molecule. 
 The P2Y1 and P2Y11 receptors prefer different diastereoisomers 
Interestingly, at the P2Y11 receptor, for all Pα substituted derivatives the corresponding 
(B) diastereoisomers were found to be more potent than the (A) isomers. This stereoselective 
action of the ligands is opposite at the P2Y1 receptor. The latter prefers the (A) isomers 
(Nahum et al., 2002; Major et al., 2004). In contrast, the P2Y2 and P2Y4 receptor display the 
same stereoselectivity as P2Y11 receptor regarding the activity of α-thio diastereoisomers. At 
both P2Y2 and P2Y4 receptors the Rp-UTP-α-S isomer was more potent than the Sp isomer 
but their potency was weak compared to that of UTP (Jacobson et al., 2006). All the receptors 
mentioned above belong to one phylogenetic subgroup (Costanzi et al., 2004).  
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Surprisingly, the amino acid sequence of the P2Y11 receptor protein is more closely 
related to the P2Y1 receptor, although besides the P2Y2 receptor the human P2Y11 receptor is 
an “ATP-receptor”. Still, the pharmacological profiles of both ATP-preferring receptors differ 
much more than the profiles of the P2Y11 and P2Y1 receptor (Burnstock and Knight, 2004). 
Both receptors are activated by adenine nucleotides exclusively and are blocked by Reactive 
Blue, whereas the P2Y2 receptor can also be activated by uridine nucleotides and shows an 
affinity for PPADS which is not shared by the P2Y1 and P2Y11 receptors (Burnstock and 
Knight, 2004).  
Another P2Y receptor at which the action of α-thio diastereoisomers had been 
investigated is the P2Y12 receptor. The ATP-α-S isomers were found to be antagonists at the 
P2Y12 receptor with only a slightly higher affinity for the (A) isomer (Cusack and Hourani, 
1982). Since the determination of the antagonistic action of the ATP-α-S isomers at the P2Y12 
receptor was done by measurement of adenylyl cyclase activity in platelets it is rather difficult 
to compare these results with our investigations (Cusack and Hourani, 1982). 
Furthermore, the P2Y11 receptor displays the same diastereoselectivity for borano-
/thiophosphate nucleotide analogues like the catalytic site of ecto-nucleotidase NTPDase 1 
(CD39, EC 3.6.1.5) (Cusack et al., 1983; Nahum et al., 2002). The ATP-α-B (B) isomers 
were found to be about ten times less stable in an assay to test the enzymatic stability 
regarding NTPDase 1 than the corresponding (A) isomers, but they showed a hydrolysis rate 
that was still two times slower than that of ATP itself. The 1321N1 cells possess an ecto-
nucleotidase activity characteristic for NTPDase 1, with a high micromolar range Km value of 
66 µM ± 13 for ATP hydrolysis (Lazarowski et al., 1997). If this is taken into consideration, 
the potencies found for all (B) isomers tested in this study might be influenced by a 
competitive binding of the substances to the receptor and the ecto-nucleotidase. However, if 
the experimental design of the measurements in this study is considered, where we have a 
continuous flow application of the agonists, and the much higher affinity of the P2Y11 
receptor for ATP as compared to the NTPDase 1, competition in binding does certainly not 
affect our analysis. 
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An interesting observation made here is that the ATP-α-B/-S analogues appear to be more 
potent at the P2Y1 receptor than at the P2Y11 receptor. As both receptors, the P2Y1 and P2Y11 
receptor, were expressed in different cell systems, it is difficult to make an absolute 
comparison of the EC50 values. Therefore, the P2Y1-GFP receptor was also stably expressed 
in 1321N1 cells. In these cells, a comparable rank order of potency for the 2-Cl-ATP-α-B and 
ATP-α-S analogues was found as in HEK293 cells. The tendency that the ligands are overall 
more potent at the P2Y1 receptor than at the P2Y11 receptor was also observed. This 
underlines the conclusion that our data definitely show the stereoselectivity and receptor 
subtype selectivity of the compounds tested. 
 Borano-substituted ATP derivatives are suitable to distinguish the functional 
contribution of the two ATP-activated P2Y receptors 
The (A) isomer of the 2-MeS-ATP-α-B derivatives is the most selective of all the 
analogues tested here, being more active at the P2Y1 receptor. This substantial receptor-
subtype selectivity is due to the combination of modifications on both C2 and the phosphate 
chain of the ATP scaffold. In addition, our previous report showed the lack of any activity of 
the 2-MeS-ATP-α-B diastereoisomers at the P2Y2 receptor (Tulapurkar et al., 2004). This 
suggests the possibility of a selective activation of the P2Y1 receptor by the (A) isomer of 
these compounds in cells/organs, which also express P2Y11 and P2Y2 receptor. Moreover, the 
ATP-α-B derivatives that had no activity at the P2Y2 receptor are compounds suitable to 
distinguish the functional contribution of the two ATP-activated P2Y receptors, the P2Y2 and 
P2Y11 receptor, in physiological or pathophysiological responses of cells to ATP. 
4.2 Ligand binding site characteristics of the P2Y11 receptor deduced from 
mutational analysis 
The amino acid residues [Arg 106 (TM3), Phe109 (TM3), Glu186 (EL2), Arg268 (TM6) and 
Arg307 (TM7)] putatively involved in ligand recognition at the P2Y11 receptor were mutated 
to test our binding mode hypothesis. 1321N1 cells were used to stably express the wild type 
and the mutant receptors, respectively, both as GFP fusion proteins. The expression level of 
the receptors was analyzed by flow cytometry. Wild type and mutant receptors displayed 
comparable fluorescence intensities.  
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The subcellular localization of the mutant receptors was found to be comparable to that of 
the unmutated receptor for the Glu186Ala, Arg268Ala, Arg268Gln, Ala313Asn mutant 
receptors. Although the Phe109Ile mutant receptor was only partially located at the plasma 
membrane, it still exhibited a significant potency for ATP. Similar observations were made in 
a different mutagenesis approach, where a 90% reduction in surface expression levels of the 
wild type P2Y1 receptor had no significant influence on the EC50 values of the investigated 
agonist (Hoffmann et al., 1999). Therefore, the potency of ATP found at the Phe109Ile mutant 
as well as the potency at the mutants with a similar subcellular localization (Arg106Ala, 
Tyr261Ala, and Arg307Ala) likely reflects the intrinsic activity of these constructs. 
Functional activity of the mutated receptors was determined in stably transfected cells by 
monitoring the intracellular [Ca2+]i rise induced by agonist stimulation.  
 Three arginine residues in TM3, 6 and 7 are involved in the recognition of ATP  
The arginine residues in TM3 (Arg106, 3.29) and TM7 (Arg307, 7.39) were found to be 
most critical for P2Y11 receptor activation. The arginine at position 7.39 is believed to take 
part in an H-bond through its backbone carbonyl with the N6 of the ATP molecule. Besides 
this interaction, Arg7.39 is also thought to stabilize the bound ATP through electrostatic 
interaction with ATP-Pα and Pγ of the phosphate moiety together with the Arg3.29. These 
hypothesis were confirmed by detecting a loss-of-function after mutation of these arginine 
residues in the P2Y11 receptor. The corresponding residues in the human P2Y1 receptor 
(Arg128, Arg310) are similarly essential for ligand recognition. Their mutation resulted in 
functionally inactive receptors (Jiang et al., 1997). A model of the human P2Y6 receptor 
showed the involvement of these conserved arginine residues in binding of the phosphate 
moiety of the nucleotide to the receptor (Costanzi et al., 2005). Surprisingly, at the human 
P2Y2 receptor only the mutation of the corresponding arginine in TM7 (Arg292, 7.39) 
resulted in loss of function of the receptor, but mutation of the arginine in TM3 (Arg110, 
3.29) to leucine had little effect on the potency of the agonists (Erb et al., 1995). The arginine 
in TM7 is part of a conserved motif (Q/KxxR) within the Gq-coupled subgroup of P2Y 
receptors. This motif is thought to be important for receptor activation.  
Another cationic residue (Arg268, 6.55) that was thought to be involved in ATP-Pα,β 
recognition is also part of a conserved motif. For members belonging to the Gq-coupled 
subgroup of P2Y receptors the motif is HxxR/K, the Gi-coupled receptors have all arginine 
and not lysine. P1 receptors lack these arginine/ lysine residues, indicating the role of the 
positively charged amino acids in coordination of the phosphate moiety. 
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The Arg268Ala mutant receptor displayed a clearly reduced potency for ATP, compared 
to the wild type receptor, indicating the significance of an intact motif in TM6. When this 
arginine was substituted by glutamine, the potency of ATP could be partially rescued. These 
findings are consistent with the interpretation of a partial recovery of the Arg268 interaction 
with the phosphate moiety of ATP, which results in the partially restored activity. However, 
one cannot ignore the importance of a conserved pattern in TM6. Indeed, it has been 
suggested that at least one mechanism of GPCR activation originates in TM6, being the 
"aromatic zipper" (Rosenkilde et al., 2007). Although in cases where that mechanism of 
activation is clearly missing, the existence of alternative mechanisms, which could involve 
Arg268 cannot be ruled out.  
For ATPγS the loss in potency was not as drastic as for ATP at the Arg268 receptor 
mutants compared to the wild type receptor. This indicates that there is a favorable interaction 
with Pγ-S, as compared to Pγ-O, that still remains in the mutant which might be due to a 
tighter fit of the larger Pγ-S moiety.  
The corresponding residues in the P2Y1 receptor (Lys280, 6.55) and the P2Y2-R (Arg265, 
6.55) were also found to be essential for activation at low ATP concentrations, because a clear 
decrease in potency was found by substitution of Lys280 or Arg265 by uncharged amino 
acids (Erb et al., 1995; Jiang et al., 1997). In the P2Y6-R model this position (Lys259, 6.55) 
was part of a positively charged subpocket that bound the phosphate moiety of docked UDP, 
again highlighting the importance of this residue (Costanzi et al., 2005). For a member of the 
Gi-coupled subgroup of P2Y receptors the P2Y12-R, the significance of this arginine residue 
(Arg256, 6.55) in TM6 was also confirmed (Cattaneo et al., 2003; Hoffmann, 2006).  
 A tyrosine residue in TM6 seems to be important for receptor activation  
The importance of an aromatic residue in TM6 (Tyr261) for ligand recognition was 
investigated. The Tyr261Ala mutant P2Y11 receptor was incapable of being activated by ATP 
at concentrations up to 10 mM. Tyr261 (6.48) was not found to be directly interacting with 
the ATP molecule docked in the proposed P2Y11-R model. However, it has been shown that a 
comparable residue (Tyr273) in the P2Y1 receptor located at the same position (6.48) seems 
to act as a molecular switch for receptor activation (Costanzi et al., 2004). A Tyr273Ala 
mutation led to a functionally inactive receptor that was still able to bind agonist/antagonist 
with the same affinity as the wild type receptor. This is in accordance with the "aromatic 
zipper" theory proposing a probable mechanism of activation.  
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It can be assumed that Tyr261 is also solely involved in P2Y11 receptor activation, since it 
was not found to significantly take part in the binding of ATP in the computed model. Due to 
the lack of a selective radioligand at the P2Y11 receptor it was not possible to prove directly 
this hypothesis. 
 The EL2 is involved in ligand recognition whereas interactions of the P2Y11 
receptor with the adenine ring of ATP are only weak 
Besides the TM regions a role of the ELs for nucleotide binding by P2Y receptors has 
been suggested before (Hoffmann et al., 1999), and the importance of the EL2 Asp204 
residue in ligand recognition has been already shown for the P2Y1 receptor (Hoffmann et al., 
1999; Costanzi et al., 2004; Major and Fischer, 2004). For the P2Y11 receptor the residue 
Glu186 in the EL2 was also predicted to be involved in ligand recognition. Mutation of this 
glutamate to alanine resulted in a decreased potency of ATP at the receptor, consistent with 
the finding at the P2Y1 receptor. However, for the more potent P2Y11 receptor agonist ATPγS 
the shift in potency was not as pronounced. This implies that Glu186 interacts with 
phosphates Pα,β of the triphosphate moiety because the tight fit of the Pγ−S is less affected at 
the receptor mutant. Interaction of the glutamate with the phosphate chain occurs probably 
also via coordination of a Mg2+ ion, as proposed for the corresponding residue in the P2Y1 
receptor (Major and Fischer, 2004). The relatively small shift in potency for agonists at the 
Glu186 mutant implies a modulatory function of this residue in receptor functionality, similar 
to the observations at the P2Y1 receptor (Hoffmann et al., 1999; Moro et al., 1999).  
The involvement of the Phe109 residue that was proposed to interact with bound ATP in 
the P2Y11-R model could not be confirmed. The aromatic amino acid in TM3 (Phe109, 3.32) 
seems to be not very critical for agonist recognition. There was no major effect on the potency 
of ATP at the receptor after substitution of this phenylalanine by isoleucine. However, this 
phenylalanine is highly conserved throughout the P2Y receptor family (Fig. 4A). In the P2Y1 
receptor, mutation of this residue to alanine caused a loss in potency for 2-MeS-ADP of about 
one order of magnitude but was still less critical for ligand recognition than other sites of the 
receptor (Jiang et al., 1997; Moro et al., 1998). Moreover, in a molecular model of the P2Y6 
receptor this phenylalanine (3.32) is possibly involved in hydrophobic interactions with the 
uracil ring of docked UDP (Costanzi et al., 2005).  
The mutation of Phe109 to isoleucine in the P2Y11 receptor did probably not much disturb 
the recognition of ATP at the receptor, since isoleucine is also a bulky, hydrophobic amino 
acid and therefore the loss in potency was only 4-fold. Thus, the prediction of π-stacking 
between the adenine and the phenyl ring could not be verified experimentally. 
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 Arg268 in TM6 plays an important role in the determination of the 
diastereoselectivity of the P2Y11 receptor 
Two of the residues (Glu186, Arg268) discussed here as being possibly involved in ligand 
recognition at the P2Y11 receptor were also shown to influence the diastereoselectivity of the 
receptor. The glutamate in EL2 seems to be important for the activity of the ATP-α-S (A) 
isomers. Substitution of Glu186 by an uncharged, nonpolar amino acid (alanine) clearly 
reduced the potency of the (A) isomer, whereas the potency of the (B) isomers was more or 
less conserved. Therefore, the difference in potency between both ATP-α-S diastereoisomers 
was increased at the Glu186Ala receptor mutant as compared to the wild type P2Y11 receptor.  
The corresponding amino acid in the EL2 of the P2Y1 receptor (Asp204) is believed to be 
responsible for the preference of the (A) isomers of the Pα borane/sulfur substituted ATP 
derivatives. Computational docking studies showed that Asp204 coordinates a Mg2+ ion 
which in turn interacts with the phosphate chain of a docked ATP molecule. In this process, 
the (A) isomers of the ATP-α-B,S analogues show the greatest interaction energies with the 
Mg2+ ion, clearly demonstrating the chiral discrimination of the P2Y1 receptor (Major et al., 
2004). If this is considered, the corresponding residue in the P2Y11 receptor might play a 
similar role. The fact that the (A) isomer shows a reduced potency at the Glu186Ala receptor 
mutant seems to confirm this hypothesis. However, the EL2 of the P2Y11 receptor is much 
longer than that of the P2Y1 receptor (35 aa vs. 25 aa, resp.). Therefore, different mechanisms 
may account for the observed differences in potency. 
The other residue influencing the diastereoselectivity of the P2Y11 receptor is an arginine 
in TM6 (Arg268, 6.55). Mutation of this basic residue to alanine or glutamine resulted in a 
loss of the chiral discrimination at the receptor. The ATP-α-S (A) and (B) isomers were found 
to be equipotent at these mutant receptors. This was mainly caused by a severe loss of 
potency of the (B) isomers at the receptor whereas the activity of the (A) isomer was less 
affected. Thus, the arginine at position 6.55 seems to be essential for a preferred recognition 
of the (B) isomers at the P2Y11 receptor. Interestingly, this arginine is also necessary for the 
preference of adenosine triphosphate over diphosphate at the receptor. The canine P2Y11 
receptor displays a glutamine at position 6.55 and is activated more potently by ADP than 
ATP (Qi et al., 2001) which could be confirmed in our study (data not shown). In addition, 
this residue (Arg268) is also involved in the stereoselective preference of the ATP-α-S (B) 
isomer at the P2Y11 receptor, indicating the necessity of a basic residue at this position for 
proper chiral discrimination.  
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The positive charge of the Arg268 residue and its ability to contribute to H-bonds might 
induce a more tight interaction with the oxygen at Pα than the sulfur, thereby leading to the 
preference of one diastereoisomer at the receptor. Sulfur forms relatively weak H-bonds and 
has a lower potential in participating in electrostatic interactions than oxygen (Major et al., 
2004). 
 Minor role of Ala313 in the recognition of 2-alkythio-ATP analogues 
Another characteristic of the P2Y11 receptor besides its stereoselectivity is the weak 
potency of ATP derivatives carrying a substituent at the C2 position. To decipher the 
molecular basis of this property the unique alanine residue in TM7 (7.45) was mutated to 
asparagine as found in all the other P2Y receptors (Fig. 4A). This Ala313 (7.45) is situated at 
the entrance to a hydrophobic pocket located in the vicinity of the ATP C2 position in the 
P2Y11-R model. The potency of ATP remained nearly unaffected at the Ala313Asn receptor 
mutant whereas 2-MeS-ATP showed a slight gain in function. This finding could support the 
hypothesis of this residue being a key player in the interactions involving ATP-C2 
substitutions. However, 2-neopentylS-ATP with a bulkier substituent at C2 of the ATP 
molecule did not show a gain in function at the Ala313Asn receptor mutant. Therefore, it 
cannot be concluded that the unique alanine in TM7 of the P2Y11 receptor is a true element in 
the determination of the weak potency of C2-substituted ATP analogues, but rather appears to 
be a ‘supporting actor’. 
4.3 Crosstalk between two P2Y receptors: the P2Y1 and P2Y11 receptor 
The present study provides convincing evidence for a physical and functional interaction of 
the P2Y1 and P2Y11 receptor. The existence of GPCR homo- or heterooligomers is now 
largely accepted. Their formation as either constitutive or ligand-dependent complexes is still 
discussed and data are published for both variants (Terrillon and Bouvier, 2004). The 
functional relevance of GPCR oligomers includes modulation of internalization processes or 
alteration of their agonists/antagonists potency, which has to be considered regarding drug 
development (Milligan, 2006).  
Interaction of two members of the P2Y receptor family has been investigated in the 
current study. The P2Y1 and P2Y11 receptor are found to be very close homologues in their 
receptor family. So far a crosstalk between both receptors has not been hypothesized. For the 
P2Y1 receptor the ability to interact with other GPCRs became obvious in a study exploring 
the hetero-dimerization of the receptor with the A1 adenosine receptor (Yoshioka et al., 2001).  
Discussion 
 96
The A1 receptor was also found to interact with the P2Y2 receptor (Suzuki et al., 2006) 
showing that the process of hetero-oligomerization was not only restricted to one subtype of 
the P2Y receptor family.  
 The P2Y1 and P2Y11 receptor associate physically thereby mediating the agonist-
induced endocytosis of the P2Y11 receptor 
In the current study the P2Y1 and P2Y11 receptor were discovered to show a strong 
physical interaction. This was determined by co-pulldown or co-immunoprecipitation 
experiments. The signal for the P2Y1mycHis receptor could be clearly detected in the 
pulldown fraction of the P2Y11GST receptor on GSH beads. There, the signal was much 
stronger than in the lane of the 10 % input (Fig. 28A, lane 5 and 1 respectively) indicating a 
robust complexation of both receptors. Precipitation of the P2Y1mycHis receptor by an anti-
myc antibody and detection of the P2Y11GST receptor in a western blot of the precipitate 
further proved this fact. Moreover, this interaction of the receptors was not due to their 
presence in small membrane patches as the P2Y1mycHis receptor could also be found in the 
pulldown fraction of the P2Y11GST receptor from cellular extracts.  
The hetero-oligomerization of the P2Y1 receptor with the P2Y11 receptor apparently has a 
great impact on the desensitization of the P2Y11 receptor. When expressed alone, the P2Y11 
receptor does not internalize upon stimulation, as shown in this study. The P2Y6 receptor 
behaves similarly and shows only slight reduction in cell surface expression after long-time 
exposure to agonists (Brinson and Harden, 2001). In contrast, the other members of the Gq-
coupled P2Y receptor subgroup are able to undergo agonist-induced internalization as shown 
in studies concerning the P2Y1 receptor (Tulapurkar et al., 2006), the P2Y2 receptor 
(Tulapurkar et al., 2005), or the P2Y4 receptor (Brinson and Harden, 2001).  
In the present study, we show that the endocytosis of the P2Y11 receptor is clearly 
dependent on the presence of its interaction with the partner, the P2Y1 receptor, as shown in 
the current study. Knock-down of the endogenous P2Y1 receptor in HEK293 cells by specific 
siRNA significantly diminished the agonist-induced internalization of the P2Y11GFP receptor. 
The extent of reduction in P2Y1 receptor mRNA transcripts correlated with the reduction of 
endocytosed P2Y11 receptor.  
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Moreover, the P2Y11GFP receptor stably expressed in 1321N1 cells could not be 
internalized by its natural agonist ATP. These cells, opposed to HEK293 cells which are 
known to express several endogenous P2Y receptors including the P2Y1, P2Y2 and P2Y4 
receptor (Schafer et al., 2003), do not express any P2Y receptor endogenously (Lazarowski et 
al., 1995). Interestingly, when the P2Y1mycHis receptor was co-expressed with the 
P2Y11GFP receptor in 1321N1 cells, clear signs of endocytosis of the P2Y11 receptor were 
found. The endocytosed P2Y11 receptor co-localized with the immunostaining of the 
P2Y1mycHis receptor. 
This functional interaction with the P2Y11 receptor was specific for the P2Y1 receptor. 
Agonists or antagonists of the P2Y1 receptor were able to induce or block the endocytosis of 
the P2Y11GFP receptor in HEK293 cells, respectively. In contrast, stimulation of the P2Y2 
receptor with UTP or the non-related PAR-2 receptor with trypsin or PAR2-AP did not lead 
to internalization of the P2Y11 receptor. As the PAR2-HA receptor did also not physically 
interact with the P2Y11GST receptor, as determined by co-pulldown experiments, it is obvious 
that the physical interaction is the prerequisite for a functional interaction. 
However, the endocytosis of the P2Y11 receptor is not only dependent on the interaction 
with the P2Y1 receptor but also on a normal P2Y11 receptor functioning. The A268P2Y11 
receptor mutant that was unresponsive to ATP concentrations up to 100 µM showed 
endocytosis-resistance, when expressed in HEK293 cells. This was not due to a loss of 
interaction with the P2Y1 receptor in HEK293 cells as shown by co-pulldown experiments. A 
difference in P2Y receptor expression profile of the HEKP2Y11GFP or HEKA268P2Y11GFP 
cells did also not account for this observation. This was analyzed by RT-PCR. Thus, the 
R268A mutation of the P2Y11 receptor seems to disrupt the ATP-induced functional 
interaction with the P2Y1 receptor if co-internalization is considered. 
The phenomenon of co-internalization may be a general and important functional 
consequence of hetero-oligomerization to control desensitization and resensitization of 
GPCRs (Prinster et al., 2005). Hetero-oligomerization among GPCRs can induce 
internalization of receptors previously considered endocytosis-reluctant. The somatostatin 
receptor (SSTR) SSTR1 failed to internalize upon agonist stimulation in several cell lines. 
However, the SSTR1 present in a hetero-dimer with the SSTR5 was found to display 
sufficient agonist-induced internalization (Rocheville et al., 2000).  
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Similar findings are presented here for the P2Y1 and P2Y11 receptor. The P2Y11 receptor 
expressed alone lacks any desensitization, as shown here and reported previously by others 
(Communi et al., 1999). This property seems to be important for normal receptor function in 
the maturation process of dendritic cells (DC). These antigen-presenting cells are attracted by 
low concentrations of ATP to migrate to the site of inflammation. Once in the epicenter of 
inflammation, activation of the P2Y11 receptor by high ATP concentrations leads to arrest in 
cell movement to prolong exposure to maturation-inducing factors (Schnurr et al., 2003). 
Thereby, the inability of the P2Y11 receptor to desensitize seems to be important in overriding 
the chemotactic effects of nucleotides acting on other P2Y receptors. However, distinct DC 
subsets respond differently to ATP in terms of migration. DCs directly isolated from human 
blood show no arrest in migration in response to ATP treatment (Schnurr et al., 2003). 
Interestingly, these DC subpopulations display significant mRNA expression levels for the 
P2Y1 receptor opposed to a negligible PCR signal in DCs (Langerhans cells, monocyte-
derived DCs) which do not migrate in the presence of high ATP concentrations. It can be 
hypothesized that the presence of the P2Y1 receptor in DCs isolated from human blood 
enables the desensitization of the P2Y11 receptor in response to ATP, thereby controlling the 
chemotactic behavior and maturation of the cells. After all, distinct DC subsets were found to 
differentially regulate T cell responses in vivo (Pulendran et al., 2000). Therefore, a changed 
function of the P2Y11 receptor by hetero-oligomerization with the P2Y1 receptor might 
contribute to the differences observed in initiating T cell immunity by distinct DC 
subpopulations. 
 The P2Y1-P2Y11 receptor hetero-oligomer shows a pharmacology different to 
that of the receptor monomers  
Hetero-oligomerization of the P2Y11 receptor with the endogenous P2Y1 receptor in 
HEK293 cells has an impact on the receptor pharmacology. So far there is evidence that 
formation of hetero-oligomers can result in a distinct pharmacology of GPCRs (Carrillo et al., 
2003). The A1-P2Y1 receptor hetero-dimer was found to have no affinity for MRS2179, a 
specific P2Y1 receptor antagonist, whereas A1 receptor antagonists could still bind. In 
contrast, the modified ligand binding pocket in the hetero-dimer appears to fit well to a P2Y1 
receptor agonist (ADPβS) but slightly less well to A1 receptor ligands (Yoshioka et al., 2001). 
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In case of the P2Y1-P2Y11 receptor oligomer, the P2Y1 receptor antagonist MRS2179 still 
showed an affinity for the hetero-oligomer, whereas the specific P2Y11 receptor antagonist 
NF157 did not. MRS2179 was able to interfere with the BzATP-stimulated [Ca2+]i rise and 
the ATP-induced internalization of the P2Y11GFP receptor, whereas NF157 was not able to 
inhibit any of these effects. BzATP shows normally no activity at the P2Y1 receptor (von 
Kugelgen, 2006). Therefore, it can be concluded that BzATP and MRS2179 both bind to the 
hetero-dimer. However, there are some discrepancies regarding the activity of BzATP. This 
ligand could induce a [Ca2+]i increase in HEKP2Y11GFP cells but was not able to stimulate 
receptor endocytosis. Such inconsistencies in the action of BzATP have also been found by 
other groups (Feng et al., 2004; Lee et al., 2005). Taken together, this indicates that BzATP 
can only induce specific receptor conformations in accordance with the probabilistic model of 
GPCR function. Different conformations of GPCRs are defined in the probabilistic model, 
where the pharmacological activity of a ligand is defined by the quantity and type of receptor 
conformations that are stabilized by the ligand (Kenakin, 2004). 
Another interesting observation in HEKP2Y11GFP cells is that UDP induced a drastic 
increase in [Ca2+]i. UDP is known to activate the P2Y6 receptor but this receptor was not 
expressed in our HEK293 cells, as analyzed by RT-PCR. The lack of P2Y6 receptor 
expression in HEK293 cells was further confirmed by an unresponsiveness of mock-
transfected cells to UDP. Moreover, the effect of UDP in the HEKP2Y11GFP cells could be 
prevented by preincubation with MRS2179. This indicates an action of UDP at the P2Y1-
P2Y11 receptor hetero-dimer that would have far-reaching consequences. Physiological effects 
of UDP that were assigned to the action at the P2Y6 receptor would have to be reconsidered.  
However, as the action of UDP in the HEKP2Y11GFP cells could also be partially 
blocked by the P2Y11 receptor antagonist NF157 some other reasons than affinity at the 
hetero-dimer have to be considered. NF157 was shown here in the endocytosis experiments 
and the BzATP-induced calcium responses to have no affinity at the P2Y1-P2Y11 receptor 
hetero-dimer. 
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The influence of lack of P2Y11 receptor activity on its endocytosis was discussed above 
for the R268A receptor mutant. This mutation also influenced the pharmacology of the P2Y1-
P2Y11 receptor hetero-oligomer. Heterologous expression of the A268P2Y11GFP receptor in 
HEK293 cells abolished the calcium response to UDP. Moreover, MRS2179 also lost its 
activity. This was not due to a loss of interaction with the P2Y1 receptor in HEK293 cells as 
shown by co-pulldown experiments. A different mRNA expression profile for endogenous 
P2Y receptors in the differently transfected cells was also not the reason. Thus, the ligand 
selectivity of the P2Y1-A268P2Y11 receptor hetero-oligomer was apparently different from that 
of the P2Y1-P2Y11 receptor hetero-dimer. Therefore, the R268 arginine seems to be a critical 
residue in the nucleotide binding pocket of the hetero-oligomer. 
Two theories are currently discussed as to how GPCR oligomers are formed. One is the 
‚contact dimerization’ and the other is the ‚domain swapping’ theory (Fig. 5b) (Kroeger et al., 
2003). In the case of the P2Y1-P2Y11 receptor heterodimer our indications suggest that it is 
formed as a ‚domain swapped’ dimer because the pharmacological profile of P2Y receptor 
ligands implies the creation of a newly formed binding pocket.  
Interestingly, investigations of [cAMP] increase in HEKP2Y11GFP cells revealed the 
pharmacology profile known for the P2Y11 receptor. Hetero-oligomerization of GPCRs is 
known to promote changes in the selectivity of the receptors to certain G proteins. A loss of 
coupling to Gi proteins has been reported following co-expression of µ- and δ-opioid 
receptors (Terrillon and Bouvier, 2004). We cannot be sure that the P2Y1-P2Y11 receptor 
hetero-dimer was unable to couple to Gs proteins, as we only investigated the pharmacology 
of cAMP elevation. However, it can be assumed that the coupling to activation of adenylyl 
cyclase was only possible for the non-oligomerized portion of the heterologously expressed 
P2Y11GFP receptor. Therefore, the ligand selectivities resembled a profile that was 
representative for the P2Y11 receptor monomer. 
 P2Y receptors can be pooled in cellular microdomains 
The importance of GPCR oligomerization becomes apparent when the relation between 
organization and signaling is considered. Organization of receptors and elements of the signal 
transduction pathway clearly affects cellular communication processes (Woolf and 
Linderman, 2004). The homo- or hetero-dimerization of GPCRs thereby allows fine tuning in 
the response to extracellular signals.  
Discussion 
 101
Functional compartmentation of P2Y receptors into cholesterol-rich signaling 
microdomains has been described for endothelial cells of the aorta. These endothelial cells 
may recruit different nucleotide receptors into different signaling domains in order to 
distinguish stimuli and regulate signal transduction (Kaiser et al., 2002). Such cholesterol-rich 
microdomains are also found in HEK293 cells and cholesterol depletion was found to affect 
the agonist-induced internalization of the P2Y2 receptor heterologously expressed in these 
cells (Tulapurkar et al., 2005). In the present study some indication was gained as to suggest 
that P2Y receptors are pooled in these microdomains. The P2Y1mycHis as well as the 
P2Y4HA receptor could be found in the pulldown fraction of the P2Y11GST receptor by 
western blot. The organization of the receptors in such microdomains seems to enable 
sufficient interaction to form oligomers and might be important for the integration of 
nucleotide signals.  
Importantly, the hetero-oligomerization of the P2Y1 or P2Y2 receptor with the A1 receptor 
was also found to take place in HEK293 cells (Yoshioka et al., 2001; Suzuki et al., 2006). The 
spatial organization of the whole purinergic signaling machinery might be an advantage for 
the cells to respond to extracellular nucleotides in a controlled manner.  
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5 ZUSAMMENFASSUNG 
Die Signalübertragung durch extrazelluläre Nukleotide und Nukleoside ist ein weit 
verbreitetes System zur Anpassung an physiologische oder pathophysiologische Zustände in 
den unterschiedlichsten Geweben oder Organen. Die ‚Signalempfänger’ auf zellulärer Ebene 
können, sowohl ionotrope Rezeptoren, als auch G-Protein-gekoppelte Rezeptoren sein und 
werden als purinerge Rezeptoren zusammengefasst. Die metabotropen Rezeptoren gliedern 
sich weiterhin in die Nukleosid-Rezeptoren (P1-Rezeptoren) und die Nukleotid-Rezeptoren 
(P2-Rezeptoren). Die Familie der G-Protein-gekoppelten Nukleotid-Rezeptoren (P2Y) ist sehr 
komplex. Bisher wurden acht verschiedene Rezeptor-Subtypen identifiziert, welche diverse 
Funktionen im menschlichen Körper übernehmen. Die gezielte Aktivierung oder Inhibition 
einzelner Rezeptor-Subtypen im Zuge einer therapeutischen Intervention benötigt daher 
spezifische Agonisten bzw. Antagonisten. Die Selektivität der P2Y-Rezeptor Subtypen für 
einzelne Nukleotide ist teilweise sehr divers, kann sich andererseits aber auch nur geringfügig 
unterscheiden. Die P2Y1- und P2Y11-Rezeptoren bevorzugen beide Adenin-Nukleotide, wobei 
der P2Y1-Rezeptor stärker durch Diphosphate (ADP) und der P2Y11-Rezeptor mehr durch 
Triphosphate (ATP) aktiviert wird. Zahlreiche Studien und die daraus resultierenden 
Erkenntnisse haben bereits zur Entwicklung von P2Y1-Rezeptor-spezifischen Liganden 
geführt, welche keine Affinität am P2Y11-Rezeptor oder an anderen Subtypen haben. 
Allerdings konnten für den P2Y11-Rezeptor bisher keine selektiven Liganden entwickelt 
werden, da sich die Strukturmerkmale der bekannten Agonisten an diesem Rezeptor meist mit 
denen der P2Y1-Rezeptor-Agonisten decken. 
In der Absicht feinste Unterschiede in der Ligandenerkennung zwischen dem P2Y1- und 
P2Y11-Rezeptor aufzudecken, untersuchten wir die Stereoselektivität des Letzteren. Die 
bereits beschriebene stereoselektive Präferenz des P2Y1-Rezeptors wurde nun in dieser Arbeit 
mit der Präferenz des P2Y11-Rezeptors verglichen. Dafür haben wir den P2Y11-Rezeptor als 
GFP Fusionsprotein stabil in 1321N1 Astrozytomzellen exprimiert, welche endogen keine 
funktionellen P2-Rezeptoren aufweisen. In Einzelzell-Kalziummessungen wurden die Zellen 
mit ATP Analoga, bei denen ein Sauerstoffatom am Pα durch Bor (ATP-α-B) oder Schwefel 
(ATP-α-S) substituiert war, stimuliert. Die Substitution am Pα schafft ein neues chirales 
Zentrum im Molekül. Die beiden resultierenden Diastereoisomere (A- und B-Isomere) 
testeten wir auf Aktivität am P2Y11-Rezeptor. Wir identifizierten die Stereoselektivität des 
P2Y11-Rezeptors und stellten fest, dass der Rezeptor die B-Isomere der jeweiligen ATP-α-B/S 
Derivate bevorzugt.  
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Dieses Ergebnis steht im Kontrast zu der bereits bekannten Stereoselektivität des P2Y1 
Rezeptors, welcher die A-Isomere bevorzugt. Weiterhin fanden wir heraus, dass die 
Substitution am Pα zu einem klaren Potenzgewinn der ATP Derivate am P2Y11-Rezeptor 
führt. Da die getesteten ATP-α-B/S Analoga nahezu keine Aktivität am P2Y2-Rezeptor (ein 
weiterer ‘ATP-Rezeptor’) aufweisen, stellen die B-Isomere wichtige Leitstrukturen für die 
Entwicklung eines selektiven P2Y11 Rezeptor Agonisten dar. Diese könnten dann zum 
Beispiel als Adjuvantien in Impfstoffen eingesetzt werden, um deren Effizienz zu verbessern.  
Das rationale Ligandendesign verwendet heutzutage computergestützte Modelle der 
therapeutischen Targets (z.B. Rezeptorproteine). Die berechneten Modelle sind allerdings 
ohne zusätzliche Information aus Mutagenese-Studien nicht genügend validiert. Wir haben 
die Ligandenbindungstasche des P2Y11-Rezeptors mittels Computer-Modelling (in 
Kooperation mit der Bar-Ilan Universität, Israel) und zielgerichteter Mutagenese 
charakterisiert. Wie erwartet, ähneln sich die Nukleotidbindungstaschen des P2Y11- und 
P2Y1-Rezeptors sehr. Drei positiv geladene Aminosäuren im P2Y11-Rezeptor (Arg106, 
Arg268, Arg307) koordinieren die Phosphatkette eines gebundenen ATP Moleküls und sind 
somit für die Nukleotidbindung essentiell. Die zweite extrazelluläre Schleife (EL2) ist auch 
beim P2Y11-Rezeptor wie beim P2Y1-Rezeptor an der Ligandenerkennung beteiligt. Wir 
entdeckten in der EL2 des P2Y11 Rezeptors einen Glutamatrest (Glu186), welcher die Potenz 
von ATP am Rezeptor deutlich mitbestimmt. Die Interaktion des Adeninrings mit der 
aromatischen Aminosäure Phe109 scheint nur eine schwache Wechselwirkung zu sein. Uns 
wurde klar, dass im Gegensatz zum P2Y1-Rezeptor der P2Y11-Rezeptor nur geringfügige 
Interaktionen mit dem Adeninring von gebundenem ATP zeigt. Weiterhin erhielten wir bei 
der Analyse der Mutanten erste Hinweise auf die mögliche molekulare Ursache der 
Diastereoselektivität des Rezeptors. Nach Mutation des Arginins Arg268 in der 
Transmembrandomäne 6 zu Alanin verloren die B-Isomere der ATP-α-S Analoga ihre 
verstärkte Potenz gegenüber den A-Isomeren.  
Der Einsatz von P2Y11-Rezeptor selektiven Agonisten zu therapeutischen Zwecken 
verlangt ausreichend Kenntnis über die Desensitisierung des Rezeptors und eine sich daraus 
möglicherweise entwickelnde Toleranz gegenüber dem Therapeutikum. Daher haben wir die 
Agonist-induzierte Internalisierung des P2Y11GFP Rezeptors untersucht. Bei diesen 
Experimenten wurde deutlich, dass der P2Y11-Rezeptor allein nicht zur Endozytose fähig ist. 
Interessanterweise war die Internalisierung des Rezeptors eindeutig abhängig von der Präsenz 
des P2Y1-Rezeptors. In weiteren Experimenten stellte wir fest, dass beide Rezeptoren 
interagieren und in den Zellen ein Hetero-Oligomer bilden.  
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Die Hetero-Oligomerisierung der P2Y1- und P2Y11-Rezeptoren wurde durch ‘Pulldown’-
Experimente und Immunopräzipitation nachgewiesen. Wir zeigten, dass die Interaktion mit 
dem P2Y1-Rezeptor nicht nur Einfluß auf die Desensitisierung des P2Y11-Rezeptors, sondern 
auch auf dessen Pharmakologie hat. Der spezifische P2Y11-Rezeptor-Antagonist NF157 
zeigte keinerlei Affinität am Hetero-Oligomer. Dagegen war der P2Y1-Rezeptor-Antagonist 
MRS2179 in der Lage sowohl die Internalisierung des P2Y11-Rezeptors, als auch die 
rezeptor-vermittelte Calcium-Antwort zu inhibieren. 
Letztendlich läßt sich sagen, dass die Erkenntnisse des gesamten Projektes sowohl 
Einblicke in die Stereoselektivität, als auch die Struktur des P2Y11-Rezeptors geben und die 
Existenz von P2Y1-P2Y11-Rezeptor Oligomeren eindeutig nachweisen. 
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6 ABSTRACT 
Purinergic signaling represents a primitive signaling system that employs widespread 
receptors which serve many different tissues. The purinergic receptor family consists of two 
different subgroups, the nucleoside (P1) and nucleotide (P2) receptors. The P2 receptors are 
further divided into ionotropic (P2X) and metabotropic (P2Y) receptors and till date seven 
P2X subtypes and eight human P2Y receptor subtypes have been discovered. Among the P2Y 
receptor subtypes, the P2Y1 and P2Y11 receptor are closely related. Agonists acting at the 
P2Y11 receptor are also capable of activating the P2Y1 receptor whereas the P2Y1 receptor 
already responds to very low concentrations of these nucleotides. Therefore, it is important to 
identify mechanisms, which can regulate activation of one or the other receptor in tissues or 
cells where both are expressed. Pharmacological intervention provides one alternative to 
regulate the activation of individual P2Y receptors. For this, chemically modified agonists 
have to be studied to characterize agonist preferences of different receptor subtypes.  
The focus of the present study was to elucidate differences in the ligand recognition 
between the less explored P2Y11 receptor and the more widely studied P2Y1 receptor. 
Therefore, we first investigated the diastereoselectivity of the P2Y11 receptor stably expressed 
as GFP fusion protein in 1321N1 cells. These cells lack any functional expression of 
endogenous P2 receptors. Different diastereoisomers were tested at the stably expressed 
P2Y11 receptor. These isomers show substitution of one of the non-bridging oxygen atoms of 
Pα by borane or sulfur (ATP-α-B/S). Thereby, a new chiral centre in the ATP molecule is 
introduced. In summary, a diastereoselective activity of ATP-α-B and ATP-α-S 
diastereoisomers with a preference for the (B) isomers was found at the P2Y11 receptor. This 
diastereoselectivity is opposite to that of the P2Y1 receptor which prefers the (A) isomers of 
these compounds. This shows that both receptors prefer different diastereoisomers of the 
chiral ATP analogues, in spite of being close homologues in the P2Y receptor family, sharing 
>50% of the amino acid residues involved in ligand recognition. These findings add to the 
understanding of the structural and conformational determinants of nucleotides which activate 
different P2Y receptors. The difference in diastereoselectivity allows a more detailed insight 
into the structure-activity relationships of these P2Y receptors.  
Such a detailed insight can be realized by studying the binding mode of nucleotides at the 
P2Y receptors using mutagenesis analysis in combination with molecular modeling. As a next 
step in the thesis study, we analyzed amino acid residues putatively involved in ligand 
recognition at the P2Y11 receptor.  
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During the course of this study, it became obvious that the nucleotide binding pockets of 
the P2Y1 and P2Y11 receptors are very similar, as expected. Three cationic amino acid 
residues in the TM regions of the P2Y11 receptor (Arg106, Arg268, Arg307) coordinate the 
phosphate chain of a bound ATP molecule. Interaction with the adenine ring via the aromatic 
amino acid Phe109 seems to be a minor interaction. A glutamate (Glu186) in the EL2 of the 
P2Y11 receptor also proved significant for ligand recognition. Moreover, further analysis of 
the mutant receptors gave the first indications about the molecular determinants of the 
stereoselective preference of ATP derivatives at the P2Y11 receptor. Upon mutation of the 
arginine residue Arg268 in TM6 the preference of the (B)-isomers of ATP-α-S analogues at 
the receptor was lost. This finding is of considerable importance, particularly for the 
development of subtype-specific agonists or antagonists at the P2Y11 receptor as potentially 
attractive drug candidates. 
The use of such drugs for therapeutic intervention requires information on the 
desensitization of the P2Y11 receptor induced by agonists. Therefore, we studied the agonist-
induced endocytosis of the receptor in living cells. To our surprise we found that the 
internalization of the P2Y11 receptor was clearly dependent on the presence of the P2Y1 
receptor. Further experiments using pulldown and immunoprecipitation techniques showed 
that both receptors associate physically in HEK293 cells to form a hetero-oligomer. These 
hetero-oligomers showed a distinct pharmacology. The specific P2Y11 receptor antagonist had 
no affinity at the P2Y1-P2Y11 receptor hetero-oligomer whereas the P2Y1 receptor antagonist 
MRS2179 could still interfere with signaling. The importance of GPCR oligomerization 
becomes apparent when the spatial organization of purinergic receptors and signaling are 
considered. The receptor oligomerization might be an advantage for the cell to respond to 
extracellular nucleotides in a well-regulated manner. 
Taken together, the present thesis study has provided new insights into the structural 
determinants of ligands acting at the P2Y11 receptor and insights into the ligand binding mode 
of the receptor. The study gives also convincing evidence for the existence of P2Y receptor 
hetero-oligomers. 
References 
 107
7 REFERENCES 
Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight 
GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA (2006) International Union 
of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: 
from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 58:281-
341. 
Amisten S, Melander O, Wihlborg AK, Berglund G, Erlinge D (2007) Increased risk of acute 
myocardial infarction and elevated levels of C-reactive protein in carriers of the Thr-
87 variant of the ATP receptor P2Y11. Eur Heart J 28:13-18. 
Balogh J, Wihlborg AK, Isackson H, Joshi BV, Jacobson KA, Arner A, Erlinge D (2005) 
Phospholipase C and cAMP-dependent positive inotropic effects of ATP in mouse 
cardiomyocytes via P2Y11-like receptors. J Mol Cell Cardiol 39:223-230. 
Berchtold S, Ogilvie AL, Bogdan C, Muhl-Zurbes P, Ogilvie A, Schuler G, Steinkasserer A 
(1999) Human monocyte derived dendritic cells express functional P2X and P2Y 
receptors as well as ecto-nucleotidases. FEBS Lett 458:424-428. 
Besada P, Shin DH, Costanzi S, Ko H, Mathe C, Gagneron J, Gosselin G, Maddileti S, 
Harden TK, Jacobson KA (2006) Structure-activity relationships of uridine 5'-
diphosphate analogues at the human P2Y6 receptor. J Med Chem 49:5532-5543. 
Bourdon DM, Mahanty SK, Jacobson KA, Boyer JL, Harden TK (2006) (N)-methanocarba-
2MeSADP (MRS2365) is a subtype-specific agonist that induces rapid desensitization 
of the P2Y1 receptor of human platelets. J Thromb Haemost 4:861-868. 
Brinson AE, Harden TK (2001) Differential regulation of the uridine nucleotide-activated 
P2Y4 and P2Y6 receptors. SER-333 and SER-334 in the carboxyl terminus are 
involved in agonist-dependent phosphorylation desensitization and internalization of 
the P2Y4 receptor. J Biol Chem 276:11939-11948. 
Bulenger S, Marullo S, Bouvier M (2005) Emerging role of homo- and heterodimerization in 
G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 
26:131-137. 
Burnstock G (1971) Neural nomenclature. Nature 229:282-283. 
Burnstock G (1976) Do some nerve cells release more than one transmitter? Neuroscience 
1:239-248. 
Burnstock G (2006) Purinergic P2 receptors as targets for novel analgesics. Pharmacol Ther 
110:433-454. 
Burnstock G, Kennedy C (1985) Is there a basis for distinguishing two types of P2-
purinoceptor? Gen Pharmacol 16:433-440. 
Burnstock G, Knight GE (2004) Cellular distribution and functions of P2 receptor subtypes in 
different systems. Int Rev Cytol 240:31-304. 
Buscher R, Hoerning A, Patel HH, Zhang S, Arthur DB, Grasemann H, Ratjen F, Insel PA 
(2006) P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their 
impact on Ca2+ influx. Pharmacogenet Genomics 16:199-205. 
Buvinic S, Poblete MI, Donoso MV, Delpiano AM, Briones R, Miranda R, Huidobro-Toro JP 
(2006) P2Y1 and P2Y2 receptor distribution varies along the human placental vascular 
tree: role of nucleotides in vascular tone regulation. J Physiol 573:427-443. 
Carrillo JJ, Pediani J, Milligan G (2003) Dimers of class A G protein-coupled receptors 
function via agonist-mediated trans-activation of associated G proteins. J Biol Chem 
278:42578-42587. 
 
 
 
References 
 108
Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri 
ZM (2003) Molecular bases of defective signal transduction in the platelet P2Y12 
receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A 100:1978-
1983. 
Chhatriwala M, Ravi RG, Patel RI, Boyer JL, Jacobson KA, Harden TK (2004) Induction of 
novel agonist selectivity for the ADP-activated P2Y1 receptor versus the ADP-
activated P2Y12 and P2Y13 receptors by conformational constraint of an ADP analog. J 
Pharmacol Exp Ther 311:1038-1043. 
Colquhoun D (2006) The quantitative analysis of drug-receptor interactions: a short history. 
Trends Pharmacol Sci 27:149-157. 
Communi D, Robaye B, Boeynaems JM (1999) Pharmacological characterization of the 
human P2Y11 receptor. Br J Pharmacol 128:1199-1206. 
Communi D, Govaerts C, Parmentier M, Boeynaems JM (1997) Cloning of a human 
purinergic P2Y receptor coupled to phospholipase C and adenylyl cyclase. J Biol 
Chem 272:31969-31973. 
Conigrave AD, Fernando KC, Gu B, Tasevski V, Zhang W, Luttrell BM, Wiley JS (2001) 
P2Y(11) receptor expression by human lymphocytes: evidence for two cAMP-linked 
purinoceptors. Eur J Pharmacol 426:157-163. 
Cooper DR, Lewis GP, Lieberman GE, Webb H, Westwick J (1979) ADP metabolism in 
vascular tissue, a possible thrombo-regulatory mechanism. Thromb Res 14:901-914. 
Costanzi S, Mamedova L, Gao ZG, Jacobson KA (2004) Architecture of P2Y nucleotide 
receptors: structural comparison based on sequence analysis, mutagenesis, and 
homology modeling. J Med Chem 47:5393-5404. 
Costanzi S, Joshi BV, Maddileti S, Mamedova L, Gonzalez-Moa MJ, Marquez VE, Harden 
TK, Jacobson KA (2005) Human P2Y(6) receptor: molecular modeling leads to the 
rational design of a novel agonist based on a unique conformational preference. J Med 
Chem 48:8108-8111. 
Cusack NJ, Hourani SM (1982) Adenosine 5-diphosphate antagonists and human platelets: no 
evidence that aggregation and inhibition of stimulated adenylate cyclase are mediated 
by different receptors. Br J Pharmacol 76:221-227. 
Cusack NJ, Pearson JD, Gordon JL (1983) Stereoselectivity of ectonucleotidases on vascular 
endothelial cells. Biochem J 214:975-981. 
Erb L, Garrad R, Wang Y, Quinn T, Turner JT, Weisman GA (1995) Site-directed 
mutagenesis of P2U purinoceptors. Positively charged amino acids in transmembrane 
helices 6 and 7 affect agonist potency and specificity. J Biol Chem 270:4185-4188. 
Evans RJ, Lewis C, Virginio C, Lundstrom K, Buell G, Surprenant A, North RA (1996) Ionic 
permeability of, and divalent cation effects on, two ATP-gated cation channels (P2X 
receptors) expressed in mammalian cells. J Physiol 497 (Pt 2):413-422. 
Feng C, Mery AG, Beller EM, Favot C, Boyce JA (2004) Adenine nucleotides inhibit 
cytokine generation by human mast cells through a Gs-coupled receptor. J Immunol 
173:7539-7547. 
Ferre S, Fredholm BB, Morelli M, Popoli P, Fuxe K (1997) Adenosine-dopamine receptor-
receptor interactions as an integrative mechanism in the basal ganglia. Trends 
Neurosci 20:482-487. 
Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, Palczewski K (2003) Atomic-force 
microscopy: Rhodopsin dimers in native disc membranes. Nature 421:127-128. 
Gallagher JA (2004) ATP P2 receptors and regulation of bone effector cells. J Musculoskelet 
Neuronal Interact 4:125-127. 
Gallego D, Hernandez P, Clave P, Jimenez M (2006) P2Y1 receptors mediate inhibitory 
purinergic neuromuscular transmission in the human colon. Am J Physiol Gastrointest 
Liver Physiol 291:G584-594. 
References 
 109
Gendron FP, Neary JT, Theiss PM, Sun GY, Gonzalez FA, Weisman GA (2003) Mechanisms 
of P2X7 receptor-mediated ERK1/2 phosphorylation in human astrocytoma cells. Am 
J Physiol Cell Physiol 284:C571-581. 
Gever JR, Cockayne DA, Dillon MP, Burnstock G, Ford AP (2006) Pharmacology of P2X 
channels. Pflugers Arch 452:513-537. 
Granstein RD, Ding W, Huang J, Holzer A, Gallo RL, Di Nardo A, Wagner JA (2005) 
Augmentation of cutaneous immune responses by ATP gamma S: purinergic agonists 
define a novel class of immunologic adjuvants. J Immunol 174:7725-7731. 
Hansen JL, Sheikh SP (2004) Functional consequences of 7TM receptor dimerization. Eur J 
Pharm Sci 23:301-317. 
Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, Jacobson KA, Gachet C 
(2006) MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-
bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor 
with strong antithrombotic activity in mice. J Pharmacol Exp Ther 316:556-563. 
Hoffmann C, Moro S, Nicholas RA, Harden TK, Jacobson KA (1999) The role of amino 
acids in extracellular loops of the human P2Y1 receptor in surface expression and 
activation processes. J Biol Chem 274:14639-14647. 
Hoffmann KA, I. von Kugelgen, I. (2006) Evidence for the involvement of basic amino acid 
residues in transmembrane regions 6 and 7 of the human platelet P2Y12-receptor in 
ligand recognition. Purinergic Signalling 2:199-200. 
Horckmans M, Marcet B, Marteau F, Bulte F, Maho A, Parmentier M, Boeynaems JM, 
Communi D (2006) Extracellular adenine nucleotides inhibit the release of major 
monocyte recruiters by human monocyte-derived dendritic cells. FEBS Lett 580:747-
754. 
Ivanov AA, Costanzi S, Jacobson KA (2006) Defining the nucleotide binding sites of P2Y 
receptors using rhodopsin-based homology modeling. J Comput Aided Mol Des 
20:417-426. 
Jacobson KA, Costanzi S, Ohno M, Joshi BV, Besada P, Xu B, Tchilibon S (2004) Molecular 
recognition at purine and pyrimidine nucleotide (P2) receptors. Curr Top Med Chem 
4:805-819. 
Jacobson KA, Costanzi S, Ivanov AA, Tchilibon S, Besada P, Gao ZG, Maddileti S, Harden 
TK (2006) Structure activity and molecular modeling analyses of ribose- and base-
modified uridine 5'-triphosphate analogues at the human P2Y2 and P2Y4 receptors. 
Biochem Pharmacol 71:540-549. 
Jenner P (2005) Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of 
Parkinson's disease. Expert Opin Investig Drugs 14:729-738. 
Jiang Q, Guo D, Lee BX, Van Rhee AM, Kim YC, Nicholas RA, Schachter JB, Harden TK, 
Jacobson KA (1997) A mutational analysis of residues essential for ligand recognition 
at the human P2Y1 receptor. Mol Pharmacol 52:499-507. 
Kaiser RA, Oxhorn BC, Andrews G, Buxton IL (2002) Functional compartmentation of 
endothelial P2Y receptor signaling. Circ Res 91:292-299. 
Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-
192. 
Kenakin T, Onaran O (2002) The ligand paradox between affinity and efficacy: can you be 
there and not make a difference? Trends Pharmacol Sci 23:275-280. 
Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. 
Nature 442:527-532. 
Khakh BS, Burnstock G, Kennedy C, King BF, North RA, Seguela P, Voigt M, Humphrey PP 
(2001) International union of pharmacology. XXIV. Current status of the 
nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev 
53:107-118. 
References 
 110
Kim HS, Ravi RG, Marquez VE, Maddileti S, Wihlborg AK, Erlinge D, Malmsjo M, Boyer 
JL, Harden TK, Jacobson KA (2002) Methanocarba modification of uracil and 
adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, 
P2Y4, and P2Y11 but not P2Y6 receptors. J Med Chem 45:208-218. 
Korcok J, Raimundo LN, Du X, Sims SM, Dixon SJ (2005) P2Y6 nucleotide receptors 
activate NF-kappaB and increase survival of osteoclasts. J Biol Chem 280:16909-
16915. 
Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation 
within the superfamily of G-protein-coupled receptors: molecular modeling and 
mutagenesis approaches to receptor structure and function. Pharmacol Ther 103:21-
80. 
Kroeger KM, Pfleger KD, Eidne KA (2003) G-protein coupled receptor oligomerization in 
neuroendocrine pathways. Front Neuroendocrinol 24:254-278. 
Lazarowski ER, Homolya L, Boucher RC, Harden TK (1997) Identification of an ecto-
nucleoside diphosphokinase and its contribution to interconversion of P2 receptor 
agonists. J Biol Chem 272:20402-20407. 
Lazarowski ER, Watt WC, Stutts MJ, Boucher RC, Harden TK (1995) Pharmacological 
selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine 
tetraphosphate. Br J Pharmacol 116:1619-1627. 
Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski 
D, Olson DP, Hancock J, Choi PS, Haber DA, Luster AD, Scadden DT (2003) P2Y-
like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow 
hematopoietic stem cells. Genes Dev 17:1592-1604. 
Lee H, Jun DJ, Suh BC, Choi BH, Lee JH, Do MS, Suh BS, Ha H, Kim KT (2005) Dual roles 
of P2 purinergic receptors in insulin-stimulated leptin production and lipolysis in 
differentiated rat white adipocytes. J Biol Chem 280:28556-28563. 
Limbird LE (2004) The receptor concept: a continuing evolution. Mol Interv 4:326-336. 
Luo W, Wang Y, Reiser G (2005) Two types of protease-activated receptors (PAR-1 and 
PAR-2) mediate calcium signaling in rat retinal ganglion cells RGC-5. Brain Res 
1047:159-167. 
Luo W, Wang Y, Hanck T, Stricker R, Reiser G (2006) Jab1, a novel protease-activated 
receptor-2 (PAR-2)-interacting protein, is involved in PAR-2-induced activation of 
activator protein-1. J Biol Chem 281:7927-7936. 
Major DT, Fischer B (2004) Molecular recognition in purinergic receptors. 1. A 
comprehensive computational study of the h-P2Y1-receptor. J Med Chem 47:4391-
4404. 
Major DT, Nahum V, Wang Y, Reiser G, Fischer B (2004) Molecular recognition in 
purinergic receptors. 2. Diastereoselectivity of the h-P2Y1-receptor. J Med Chem 
47:4405-4416. 
Marshall FH, Jones KA, Kaupmann K, Bettler B (1999) GABAB receptors - the first 7TM 
heterodimers. Trends Pharmacol Sci 20:396-399. 
Marteau F, Communi D, Boeynaems JM, Suarez Gonzalez N (2004) Involvement of multiple 
P2Y receptors and signaling pathways in the action of adenine nucleotides 
diphosphates on human monocyte-derived dendritic cells. J Leukoc Biol 76:796-803. 
Marteau F, Gonzalez NS, Communi D, Goldman M, Boeynaems JM, Communi D (2005) 
Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular 
ATP in human dendritic cells. Blood 106:3860-3866. 
Matos JE, Robaye B, Boeynaems JM, Beauwens R, Leipziger J (2005) K+ secretion activated 
by luminal P2Y2 and P2Y4 receptors in mouse colon. J Physiol 564:269-279. 
Milligan G (2006) G-protein-coupled receptor heterodimers: pharmacology, function and 
relevance to drug discovery. Drug Discov Today 11:541-549. 
References 
 111
Moore D, Chambers J, Waldvogel H, Faull R, Emson P (2000) Regional and cellular 
distribution of the P2Y(1) purinergic receptor in the human brain: striking neuronal 
localisation. J Comp Neurol 421:374-384. 
Moore DJ, Chambers JK, Wahlin JP, Tan KB, Moore GB, Jenkins O, Emson PC, Murdock 
PR (2001) Expression pattern of human P2Y receptor subtypes: a quantitative reverse 
transcription-polymerase chain reaction study. Biochim Biophys Acta 1521:107-119. 
Moreschi I, Bruzzone S, Nicholas RA, Fruscione F, Sturla L, Benvenuto F, Usai C, Meis S, 
Kassack MU, Zocchi E, De Flora A (2006) Extracellular NAD+ is an agonist of the 
human P2Y11 purinergic receptor in human granulocytes. J Biol Chem 281:31419-
31429. 
Moro S, Hoffmann C, Jacobson KA (1999) Role of the extracellular loops of G protein-
coupled receptors in ligand recognition: a molecular modeling study of the human 
P2Y1 receptor. Biochemistry 38:3498-3507. 
Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA (1998) Human P2Y1 
receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist 
and antagonist recognition sites. J Med Chem 41:1456-1466. 
Nahum V, Zundorf G, Levesque SA, Beaudoin AR, Reiser G, Fischer B (2002) Adenosine 5'-
O-(1-boranotriphosphate) derivatives as novel P2Y(1) receptor agonists. J Med Chem 
45:5384-5396. 
Nicholas RA, Watt WC, Lazarowski ER, Li Q, Harden K (1996) Uridine nucleotide 
selectivity of three phospholipase C-activating P2 receptors: identification of a UDP-
selective, a UTP-selective, and an ATP- and UTP-specific receptor. Mol Pharmacol 
50:224-229. 
Oury C, Toth-Zsamboki E, Vermylen J, Hoylaerts MF (2006) The platelet ATP and ADP 
receptors. Curr Pharm Des 12:859-875. 
Palmer RK, Boyer JL, Schachter JB, Nicholas RA, Harden TK (1998) Agonist action of 
adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol 54:1118-1123. 
Pearson JD, Carleton JS, Gordon JL (1980) Metabolism of adenine nucleotides by 
ectoenzymes of vascular endothelial and smooth-muscle cells in culture. Biochem J 
190:421-429. 
Prinster SC, Hague C, Hall RA (2005) Heterodimerization of g protein-coupled receptors: 
specificity and functional significance. Pharmacol Rev 57:289-298. 
Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, 
Maliszewski C, Davoust J, Fay J, Palucka K (2000) Flt3-ligand and granulocyte 
colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J 
Immunol 165:566-572. 
Qi AD, Zambon AC, Insel PA, Nicholas RA (2001) An arginine/glutamine difference at the 
juxtaposition of transmembrane domain 6 and the third extracellular loop contributes 
to the markedly different nucleotide selectivities of human and canine P2Y11 
receptors. Mol Pharmacol 60:1375-1382. 
Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 
50:413-492. 
Rang H, Dale MM, Ritter JM, Moore PK (2003) Pharmacology, Section One, How drugs act: 
General Principles: Churchill-Livingstone. 
Ravi RG, Kim HS, Servos J, Zimmermann H, Lee K, Maddileti S, Boyer JL, Harden TK, 
Jacobson KA (2002) Adenine nucleotide analogues locked in a Northern 
methanocarba conformation: enhanced stability and potency as P2Y(1) receptor 
agonists. J Med Chem 45:2090-2100. 
Robaye B, Ghanem E, Wilkin F, Fokan D, Van Driessche W, Schurmans S, Boeynaems JM, 
Beauwens R (2003) Loss of nucleotide regulation of epithelial chloride transport in the 
jejunum of P2Y4-null mice. Mol Pharmacol 63:777-783. 
References 
 112
Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC (2000) Subtypes of the 
somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 
275:7862-7869. 
Rodrigues RJ, Almeida T, Richardson PJ, Oliveira CR, Cunha RA (2005) Dual presynaptic 
control by ATP of glutamate release via facilitatory P2X1, P2X2/3, and P2X3 and 
inhibitory P2Y1, P2Y2, and/or P2Y4 receptors in the rat hippocampus. J Neurosci 
25:6286-6295. 
Rosenkilde MM, Andersen MB, Nygaard R, Frimurer TM, Schwartz TW (2007) Activation 
of the CXCR3 chemokine receptor through anchoring of a small molecule chelator 
ligand between TM-III, -IV, and -VI. Mol Pharmacol 71:930-941. 
Schachter JB, Li Q, Boyer JL, Nicholas RA, Harden TK (1996) Second messenger cascade 
specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J 
Pharmacol 118:167-173. 
Schafer R, Sedehizade F, Welte T, Reiser G (2003) ATP- and UTP-activated P2Y receptors 
differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol 
Lung Cell Mol Physiol 285:L376-385. 
Schnurr M, Toy T, Stoitzner P, Cameron P, Shin A, Beecroft T, Davis ID, Cebon J, 
Maraskovsky E (2003) ATP gradients inhibit the migratory capacity of specific human 
dendritic cell types: implications for P2Y11 receptor signaling. Blood 102:613-620. 
Suzuki T, Namba K, Tsuga H, Nakata H (2006) Regulation of pharmacology by hetero-
oligomerization between A1 adenosine receptor and P2Y2 receptor. Biochem Biophys 
Res Commun 351:559-565. 
Terrillon S, Bouvier M (2004) Roles of G-protein-coupled receptor dimerization. EMBO Rep 
5:30-34. 
Tsim KW, Barnard EA (2002) The signaling pathways mediated by P2Y nucleotide receptors 
in the formation and maintenance of the skeletal neuromuscular junction. 
Neurosignals 11:58-64. 
Tulapurkar ME, Zundorf G, Reiser G (2006) Internalization and desensitization of a green 
fluorescent protein-tagged P2Y nucleotide receptor are differently controlled by 
inhibition of calmodulin-dependent protein kinase II. J Neurochem 96:624-634. 
Tulapurkar ME, Laubinger W, Nahum V, Fischer B, Reiser G (2004) Subtype specific 
internalization of P2Y1 and P2Y2 receptors induced by novel adenosine 5'-O-(1-
boranotriphosphate) derivatives. Br J Pharmacol 142:869-878. 
Tulapurkar ME, Schafer R, Hanck T, Flores RV, Weisman GA, Gonzalez FA, Reiser G 
(2005) Endocytosis mechanism of P2Y2 nucleotide receptor tagged with green 
fluorescent protein: clathrin and actin cytoskeleton dependence. Cell Mol Life Sci 
62:1388-1399. 
Ubl JJ, Vöhringer C, Reiser G (1998) Co-existence of two types of [Ca2+]i-inducing protease-
activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells. 
Neuroscience 86:597-609. 
Ullmann H, Meis S, Hongwiset D, Marzian C, Wiese M, Nickel P, Communi D, Boeynaems 
JM, Wolf C, Hausmann R, Schmalzing G, Kassack MU (2005) Synthesis and 
structure-activity relationships of suramin-derived P2Y11 receptor antagonists with 
nanomolar potency. J Med Chem 48:7040-7048. 
Vigne P, Hechler B, Gachet C, Breittmayer JP, Frelin C (1999) Benzoyl ATP is an antagonist 
of rat and human P2Y1 receptors and of platelet aggregation. Biochem Biophys Res 
Commun 256:94-97. 
Vöhringer C, Schäfer R, Reiser G (2000) A chimeric rat brain P2Y1 receptor tagged with 
green-fluorescent protein: high-affinity ligand recognition of adenosine diphosphates 
and triphosphates and selectivity identical to that of the wild-type receptor. Biochem 
Pharmacol 59:791-800. 
References 
 113
von Kugelgen I (2006) Pharmacological profiles of cloned mammalian P2Y-receptor 
subtypes. Pharmacol Ther 110:415-432. 
Vonend O, Grote T, Oberhauser V, Von Kugelgen I, Rump LC (2003) P2Y-receptors 
stimulating the proliferation of human mesangial cells through the MAPK42/44 
pathway. Br J Pharmacol 139:1119-1126. 
Wang L, Olivecrona G, Gotberg M, Olsson ML, Winzell MS, Erlinge D (2005) ADP acting 
on P2Y13 receptors is a negative feedback pathway for ATP release from human red 
blood cells. Circ Res 96:189-196. 
White PJ, Webb TE, Boarder MR (2003) Characterization of a Ca2+ response to both UTP 
and ATP at human P2Y11 receptors: evidence for agonist-specific signaling. Mol 
Pharmacol 63:1356-1363. 
Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B (2001) The 
P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived 
dendritic cells. J Immunol 166:7172-7177. 
Woolf PJ, Linderman JJ (2004) An algebra of dimerization and its implications for G-protein 
coupled receptor signaling. J Theor Biol 229:157-168. 
Yoshioka K, Saitoh O, Nakata H (2001) Heteromeric association creates a P2Y-like 
adenosine receptor. Proc Natl Acad Sci U S A 98:7617-7622. 
Yoshioka K, Saitoh O, Nakata H (2002) Agonist-promoted heteromeric oligomerization 
between adenosine A(1) and P2Y(1) receptors in living cells. FEBS Lett 523:147-151. 
Yoshioka K, Hosoda R, Kuroda Y, Nakata H (2002) Hetero-oligomerization of adenosine A1 
receptors with P2Y1 receptors in rat brains. FEBS Lett 531:299-303. 
Zylberg J, Ecke D, Fischer B, Reiser G (2007) Structure and ligand binding site 
characteristics of the human P2Y11 nucleotide receptor deduced from computational 
modelling and mutational analysis. Biochem J. 
 
 
Abbreviations 
 114
8 ABBREVIATIONS 
2-Cl-ATP-α-B 2-chloro-adenosine-5’-(1-boranotriphosphate) 
2-MeSADP 2-methylthio-adenosine-5’-diphosphate 
2-MeSATP 2-methylthio-adenosine-5’-triphosphate 
2-MeS-ATP-α-B 2-methylthio-adenosine-5’-(1-boranotriphosphate) 
2-MeS-ATP-α-S 2-methylthio-adenosine-5’-(1-thiotriphosphate) 
2-neopentyl-thio-ATP 2-neopentylthio-adenosine-5’-triphosphate 
5-Br-UDP 5-bromo-uridine-5’-diphosphate 
ADP adenosine-5’-diphosphate 
ADPRC ADP-ribosylcyclase 
ADPβS adenosine-5’-(2-thiodiphosphate) 
AMP adenosine-5’-monophosphate 
Ap4A diadenosine 5’,5’’’-P1,P4-tetraphosphate 
ARC67085 2-propylthio-β, γ-dichloromethylene-D-ATP 
ATP adenosine-5’-triphosphate 
ATP-α-B adenosine-5’-(1-boranotriphosphate) 
ATPβS adenosine-5’-(2-thiotriphosphate) 
ATPγS adenosine-5’-(3-thiotriphosphate) 
B2AR β2 adrenergic receptor 
BRET Bioluminescence Resonance Energy Transfer 
BRHO bovine rhodopsin 
BzATP 2'-and 3'-O-(4-benzoyl-benzoyl)adenosine 5'-triphosphate 
CaCl2 calcium chloride 
cADPR cyclic adenosine diphosphate ribose 
cAMP cyclic Adenosinemonophosphate 
CF Cystic Fibrosis 
CGS21680 2-[p-(2-carboxyethyl)phenylethylamino]-5'-N-ethyl-
carboxamidoadenosine 
CPA N6-cyclopentyladenosine 
C-terminus carboxyl terminus 
D2 D2 dopamine receptor 
DC dendritic cells 
DMEM Dulbecco's Modified Eagle Medium 
DMSO dimethylsulfoxide 
DNA desoxyribonucleic acid 
DPCPX 1,3-dipropyl-8-cyclopentylxanthine 
D-receptor dopamine receptor 
DTT dithiothreitol 
ECL enhanced chemiluminescence 
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EDTA ethylene-diamine-tetra-acetic acid 
EIA enzyme-linked immuno assay 
ER endoplasmic reticulum 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
G418 Sulphate geneticin disulfate 
GAPDH glycerinaldehyde-3-phosphate-dehydrogenase 
GFP green fluorescent protein 
GPCR G protein-coupled receptor 
G protein guanine nucleotide-binding protein 
GSH glutathione sepharose 
HBSS Hank’s Buffered Salt Solution 
HEPES N- (2-Hydroxyethyl)-piperazin-N’-2- ethansulfonic acid 
IB-MECA N6-(3-iodo-benzyl)-5’-(N-methylcarbamoyl)adenosine 
IBMX 3-Isobutyl-1-methylxanthine 
INS37217 denufosol tetrasodium 
KCl potassium chloride 
kDA kilo Dalton 
KF17837 1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine 
KH2PO4 potassium dihydrogenphosphate 
L-DOPA L-3,4-Dihydroxyphenylalanin 
MATra Magnet Assisted Transfection 
MgCl2 magnesium chloride 
MgSO4 magnesium sulphate 
MRS1067 3,6-dichloro-2’-isopropyloxy-4’-isopropylflavone 
MRS2179 N6-methyl-2'-deoxyadenosine-3',5'-bisphosphate 
MRS2365 (N)-Methanocarba-2-MeS-ADP 
MRS2500 2-iodo-N
6
-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-
bisphosphate 
MRS2567 1,2-di-(4-isothiocyanatophenyl)ethane 
Na2HPO4*2H2O sodium hydrogenphosphate-Dihydrate 
NaCl sodium chloride 
NaF sodium fluoride 
NaHCO3 sodium hydrogencarbonate 
NC nitrocellulose 
NECA 5'-N-ethyl-carboxamidoadenosine 
NF157 8,8’-[Carbonylbis[imino-3,1-phenylenecarbonylimino  (4-fluoro-3,1-phenylene)carbonylimino]]bis-1,3,5-naphtalenetrisulfonic acid 
NK1 tachykinin receptor 
NO Nitrogenmonooxide 
N-terminus amino-terminus 
P1 Purinergic receptor family 1 
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P2 Purinergic receptor family 2 
P2X ionotropic P2 receptor 
P2Y metabotropic P2 receptor 
PAGE polyacrylamide gel electrophoresis 
PAR2 protease activated receptor 2 
PAR2-AP PAR2- activating peptide 
PCR polymerase chain reaction 
PEG polyethyleneglycol 
PFA paraformaldehyde 
PPADS pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate 
RBC red blood cells 
RNA ribonucleic acid 
Rp/Sp-ATP-α-S Rp/Sp-adenosine-5’-(1-thiotriphosphate) 
SDS sodiumdodecylsulphate 
siRNA small interfering RNA 
SSTR somatostatin receptor 
TEMED tetramethylethylenediamine 
TM Transmembrane domain 
TNP-ATP 2'(or 3')-O-(2, 4, 6-trinitrophenyl)adenosine 5'-triphosphate 
UDP uridine-5’-diphosphate 
UDPβS uridine-5’-(2-thiodiphosphate) 
UTP uridine-5’-triphosphate 
UTPγS uridine-5’-(3-thiotriphosphate) 
ΗΑ hemagglutinin 
α−receptor α adrenergic receptor 
β-NAD+e extracellular NAD+ (β-form) 
β−receptor β adrenergic receptor 
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